Citation Report
List of articles citing

Association of missense and 5ıısplice-site mutations in tau with the inherited dementia FTDP-17

DOI: 10.1038/31508
Nature, 1998, 393, 702-5.

#	Paper	IF	Citations
2337	Brain Dysfunction Associated with Amyloid Fibrils and Other Aggregated Proteins. 355-382		
2336	Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. **1998**, 1, 355-8		274
2335	Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. **1998**, 5, 832-7		240
2334	Protein precipitation: a common etiology in neurodegenerative disorders?. **1998**, 14, 396-402		134
2333	Assembled tau filaments differ from native paired helical filaments as determined by scanning transmission electron microscopy (STEM). **1998**, 814, 86-98		13
2332	Tau in Alzheimer's disease. **1998**, 8, 425-7		395
2331	Recent work on Alzheimer's disease transgenics. **1998**, 9, 561-4		19
2330	Neuropathology of Dementing Disorders. **1998**, 21, 497-498		
2329	Tau protein pathology in neurodegenerative diseases. **1998**, 21, 428-33		567
2328	Oral or parenteral therapy for B12 deficiency. **1998**, 352, 1721-2		75
2327	New susceptibility gene for Alzheimer's disease on chromosome 12?. **1998**, 352, 1720-1		8
2326	Filamentous nerve cell inclusions in neurodegenerative diseases. **1998**, 8, 619-32		233
2325	Conformational changes and disease--serpins, prions and Alzheimer's. **1998**, 8, 799-809		223
2324	Tau mutations cause frontotemporal dementias. **1998**, 21, 955-8		251
2323	Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. **1998**, 433, 201-4		87
2322	Synthetic filaments assembled from C-terminally truncated alpha-synuclein. **1998**, 436, 309-12		330
2321	Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. **1998**, 437, 207-10		367

2320	Genetic classification of primary neurodegenerative disease. **1998**, 282, 1075-9	244
2319	Potential therapeutic targets for Alzheimer's disease. **1998**, 2, 157-179	5
2318	The 77-kDa echinoderm microtubule-associated protein (EMAP) shares epitopes with the mammalian brain MAPs, MAP-2 and tau. **1998**, 250, 502-5	5
2317	Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. **1998**, 153, 1359-63	233
2316	Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. **1998**, 51, 1546-54	4170
2315	Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. **1998**, 95, 13103-7	465
2314	Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. **1998**, 7, 1825-9	223
2313	Genetic epidemiology of Parkinson's disease. **1998**, 11, 98-106	30
2312	Frontotemporal dementia genetics. **1998**, 11, 55-60	5
2311	Clinical and genetic aspects of progressive supranuclear palsy. **1998**, 11, 107-14	26
2310	Disease genes and chromosomes: disease maps of the human genome. Chromosome 17. **1998**, 2, 357-81	2
2309	Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. **1998**, 95, 7737-41	1300
2308	Molecular genetic characterisation of frontotemporal dementia on chromosome 3. **1999**, 10 Suppl 1, 93-101	34
2307	Sensory symptoms restricted to proximal body parts in small cortical infarction. **1999**, 53, 889-90	4
2306	Adult-onset "infant" botulism: an unusual cause of weakness in the intensive care unit. **1999**, 53, 891	7
2305	Tau mutations in frontotemporal dementia. **1999**, 10 Suppl 1, 88-92	19
2304	The diagnosis of Alzheimer's disease. **1999**, 1, 249-63	4
2303	A novel antineuronal antibody in a motor neuron syndrome associated with breast cancer. **1999**, 53, 852-5	38

2302	Inheritance of frontotemporal dementia. **1999**, 56, 817-22	174
2301	A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). **1999**, 122 (Pt 4), 741-56	192
2300	Specific cognitive deficits in mild frontal variant frontotemporal dementia. **1999**, 122 (Pt 8), 1469-93	327
2299	Impact of headache education program in the workplace. **1999**, 53, 868-71	17
2298	Introduction to Alzheimer's disease. **2000**, 32, 1-21	1
2297	Tau phosphorylation both in vitro and in cells. **2000**, 32, 375-93	1
2296	An extensive list of genes that produce alternative transcripts in the mouse. **1999**, 15, 170-1	6
2295	Clinical and pathological evidence for a frontal variant of Alzheimer disease. **1999**, 56, 1233-9	311
2294	The tangled biology of tau. **1999**, 96, 7120-1	23
2293	Olfactory dysfunction in multiple sclerosis: relation to longitudinal changes in plaque numbers in central olfactory structures. **1999**, 53, 880-2	72
2292	Association of MS with thyroid disorders. **1999**, 53, 883-5	59
2291	Transgenic animals in Alzheimer's disease research. **1999**, 10, 15-24	25
2290	Age and cause of death in mitochondrial diseases. **1999**, 53, 855-7	42
2289	Absent pachymeningeal gadolinium enhancement on cranial MRI despite symptomatic CSF leak. **1999**, 53, 402-4	69
2288	A pilot study of MRI activity before and during interferon beta-1a therapy. **1999**, 53, 874-6	18
2287	Deamidation and isoaspartate formation in smeared tau in paired helical filaments. Unusual properties of the microtubule-binding domain of tau. **1999**, 274, 7368-78	86
2286	Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. **1999**, 96, 8229-34	211
2285	Mutational analysis of the tau gene in progressive supranuclear palsy. **1999**, 53, 1421-4	45

2284	The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. **1999**, 66, 665-7	80
2283	Neurologic complications associated with hepatitis C virus infection. **1999**, 53, 861-4	103
2282	A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. **1999**, 53, 1415-21	100
2281	Tau immunoreactivity detected in human plasma, but no obvious increase in dementia. **1999**, 10, 442-5	25
2280	Isolated trochlear nerve palsy in patients with multiple sclerosis. **1999**, 53, 877-9	43
2279	Brain biopsy in primary angiitis of the central nervous system. **1999**, 53, 858-60	216
2278	Transient elevation in plasma prolactin level in rats with temporal lobe status epilepticus. **1999**, 53, 885-7	7
2277	Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). **1999**, 75, 579-84	27
2276	Clinical and pathological overlap between frontotemporal dementia, primary progressive aphasia and corticobasal degeneration: the Pick complex. **1999**, 10 Suppl 1, 46-9	61
2275	Association of an extended haplotype in the tau gene with progressive supranuclear palsy. **1999**, 8, 711-5	677
2274	5' splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. **1999**, 274, 15134-43	232
2273	The genetics of disorders with synuclein pathology and parkinsonism. **1999**, 8, 1901-5	27
2272	The spatial patterns of Pick bodies, Pick cells and Alzheimer's disease pathology in Pick's disease. **1999**, 19, 64-70	10
2271	Introduction: Pick's disease and frontotemporal dementia. **1999**, 19, 417-421	2
2270	Frontotemporal dementia with tauopathy: A review and preliminary immunohistochemical study of tau kinases and phosphatases. **1999**, 19, 433-440	1
2269	Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. **1999**, 72, 1243-9	249
2268	REVIEW: tau protein pathology in Alzheimer's disease and related disorders. **1999**, 25, 171-87	154
2267	Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. **1999**, 25, 435-58	86

2266	The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. *Nature*, **1999**, 399, 784-8	50.4	606
2265	Tau and synuclein and their role in neuropathology. **1999**, 9, 657-61		65
2264	Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. **1999**, 9, 663-79		209
2263	Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. **1999**, 9, 681-93		267
2262	Fibrillogenesis of tau: insights from tau missense mutations in FTDP-17. **1999**, 9, 695-705		38
2261	Transgenic models of tauopathies and synucleinopathies. **1999**, 9, 733-9		27
2260	Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature*, **1999**, 399, A23-31	50.4	1214
2259	Tau gene mutation in familial progressive subcortical gliosis. **1999**, 5, 454-7		171
2258	Phosphorylation-dependent prolyl isomerization: a novel signaling regulatory mechanism. **1999**, 56, 788-806		109
2257	Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. **1999**, 246 Suppl 2, II6-15		255
2256	Microtubule-associated protein tau, heparan sulphate and alpha-synuclein in several neurodegenerative diseases with dementia. **1999**, 97, 585-94		59
2255	A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. **1999**, 98, 62-77		135
2254	A familial case of Alzheimer's disease without tau pathology may be linked with chromosome 3 markers. **1999**, 105, 32-7		27
2253	Neuropsychiatric aspects of frontotemporal dementias. **1999**, 1, 93-8		11
2252	Tangled areas of Alzheimer brain have upregulated levels of exon 10 containing tau mRNA. **1999**, 831, 301-5		45
2251	Neurodegenerative disease: a different view of diagnosis. **1999**, 5, 514-7		17
2250	Proteolysis by presenilins and the renaissance of tau. **1999**, 9, 241-4		19
2249	Editorial: useful URLs. **1999**, 9, 244		

2248	Mutation in the tau exon 10 splice site region in familial frontotemporal dementia. **1999**, 45, 270-271	39
2247	Immunohistochemical detection of infected neurons as a rapid diagnosis of enterovirus 71 encephalomyelitis. **1999**, 45, 271-2	29
2246	Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. **1999**, 45, 358-68	1360
2245	From genotype to phenotype: a clinical pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation. **1999**, 45, 704-15	118
2244	Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia. **1999**, 46, 243-8	125
2243	Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. **1999**, 46, 325-32	130
2242	Phenotypic variation in hereditary frontotemporal dementia with tau mutations. **1999**, 46, 617-26	198
2241	FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. **1999**, 46, 708-15	160
2240	Neurofibrillary tangle parkinsonian disorders--tau pathology and tau genetics. **1999**, 14, 731-6	34
2239	Molecular basis of the neurodegenerative disorders. **1999**, 340, 1970-80	330
2238	The biochemistry of Alzheimer's disease. **1999**, 14, 437-46	6
2237	Alzheimer's Disease. **1999**,	
2236	Tau protein as a therapeutic target in Alzheimer disease and other neurodegenerative disorders. **1999**, 9, 1359-1370	7
2235	Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. **1999**, 96, 5598-603	448
2234	Toxic neuronal apoptosis and modifications of tau and APP gene and protein expressions. **1999**, 31, 635-47	20
2233	High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. **1999**, 64, 414-21	366
2232	Molecular genetics of familial parkinsonism. **1999**, 5, 145-55	7
2231	Genetics of Parkinson's disease. **1999**, 53, 109-16	26

2230	Neurodegenerative tauopathies: human disease and transgenic mouse models. **1999**, 24, 507-10	95
2229	Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. **1999**, 24, 751-62	510
2228	Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. **1999**, 259, 133-5	142
2227	Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations. **1999**, 260, 193-5	25
2226	Altered conformation of recombinant frontotemporal dementia-17 mutant tau proteins. **1999**, 260, 153-6	40
2225	No genetic association between polymorphisms in the Tau gene and Alzheimer's disease in clinic or population based samples. **1999**, 266, 193-6	46
2224	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. **1999**, 274, 61-5	24
2223	Identification of a novel polymorphism in the promoter region of the tau gene highly associated to progressive supranuclear palsy in humans. **1999**, 275, 183-6	52
2222	Tau gene polymorphisms and apolipoprotein E epsilon4 may interact to increase risk for Alzheimer's disease. **1999**, 277, 29-32	56
2221	Mutation screening of the tau gene in patients with early-onset Alzheimer's disease. **1999**, 277, 137-9	38
2220	Genes and susceptible loci of Alzheimer's disease. **1999**, 48, 121-7	45
2219	Tau protein and the paired helical filament of Alzheimer's disease. **1999**, 50, 469-70	14
2218	Mutations in the Tau gene cause frontotemporal dementia. **1999**, 50, 471-2	8
2217	Recent advances on neuronal caspases in development and neurodegeneration. **1999**, 35, 195-220	97
2216	Discussion. **1999**, 20, 85	18
2215	Phylogenetic diversity of the expression of the microtubule-associated protein tau: implications for neurodegenerative disorders. **1999**, 68, 119-28	76
2214	FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10. **1999**, 443, 93-6	156
2213	Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations. **1999**, 446, 199-202	90

2212	Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. **1999**, 446, 228-32		157
2211	Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. **1999**, 447, 195-9		223
2210	Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. **1999**, 450, 306-11		195
2209	Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease. **1999**, 451, 39-44		62
2208	FTDP-17 tau mutations decrease the susceptibility of tau to calpain I digestion. **1999**, 461, 91-5		36
2207	Pathways to primary neurodegenerative disease. **1999**, 74, 835-7		14
2206	Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. **1999**, 354, 1101-18		143
2205	Elimination of prions by branched polyamines and implications for therapeutics. **1999**, 96, 14529-34		224
2204	New order from neurological disorders. *Nature*, **1999**, 399, A3-5	50.4	61
2203	The tauopathies: toward an experimental animal model. **1999**, 154, 1-6		46
2202	Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. **1999**, 154, 255-70		182
2201	Stable expression in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). **1999**, 154, 1649-56		76
2200	Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. **1999**, 155, 2153-65		356
2199	Ligand-dependent tau filament formation: implications for Alzheimer's disease progression. **1999**, 38, 14851-9		136
2198	The Guam cycad toxin methylazoxymethanol damages neuronal DNA and modulates tau mRNA expression and excitotoxicity. **1999**, 155, 11-21		53
2197	Construction of a detailed physical and transcript map of the FTDP-17 candidate region on chromosome 17q21. **1999**, 60, 129-36		7
2196	Overview of frontotemporal dementias and the consensus applied. **1999**, 10 Suppl 1, 6-9		23
2195	A case of sporadic Pick disease with onset at 27 years. **1999**, 56, 1289-91		11

2194	Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. **1999**, 53, 871-4	308
2193	Interaction of the U1 snRNP with nonconserved intronic sequences affects 5' splice site selection. **1999**, 13, 569-80	93
2192	Classification of the dementias. **1999**, 9, 55-64	9
2191	The molecular basis and genetic determinants of Alzheimer disease. **1999**, 9, 297-304	
2190	The tau mutation (val337met) disrupts cytoskeletal networks of microtubules. **1999**, 10, 993-7	30
2189	A distinct familial presenile dementia with a novel missense mutation in the tau gene. **1999**, 10, 497-501	140
2188	A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration. **1999**, 53, 864-8	88
2187	Tau protein in normal and Alzheimer's disease brain: an update. **1999**, 1, 329-51	86
2186	Neuronal death in Alzheimer's disease. **2000**, 39, 328-30	1
2185	Filamentous tau pathology in nerve cells, astrocytes, and oligodendrocytes of aged baboons. **2000**, 59, 39-52	60
2184	Tau gene mutation K257T causes a tauopathy similar to Pick's disease. **2000**, 59, 990-1001	125
2183	Pro-apoptotic effects of tau mutations in chromosome 17 frontotemporal dementia and parkinsonism. **2000**, 11, 57-60	26
2182	Non-Alzheimer dementias. **2000**, 13, 409-414	0
2181	Tau pathology: a marker of neurodegenerative disorders. **2000**, 13, 371-6	94
2180	Missense point mutations of tau to segregate with FTDP-17 exhibit site-specific effects on microtubule structure in COS cells: a novel action of R406W mutation. **2000**, 60, 380-7	30
2179	Significant association between the tau gene A0/A0 genotype and Parkinson's disease. **2000**, 47, 242-245	111
2178	Association of early-onset Alzheimer's disease with an interleukin-1 gene polymorphism. **2000**, 47, 361-365	317
2177	Association of interleukin-1 gene polymorphisms with Alzheimer's disease. **2000**, 47, 365-368	346

2176	Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. **2000**, 47, 369-373	34
2175	Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. **2000**, 47, 374-377	206
2174	Sensory discrimination capabilities in patients with focal hand dystonia. **2000**, 47, 377-380	137
2173	Very low levels of the mtDNA A3243G mutation associated with mitochondrial dysfunction in vivo. **2000**, 47, 381-384	58
2172	Increased bone turnover in epileptic patients treated with carbamazepine. **2000**, 47, 385-388	76
2171	De novo mutation in the Notch3 gene causing CADASIL. **2000**, 47, 388-391	150
2170	Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. **2000**, 47, 391-395	364
2169	Congenital encephalomyopathy with epilepsy, chorioretinitis, basal ganglia involvement, and muscle minicores. **2000**, 47, 395-399	3
2168	A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease. **2000**, 47, 399-403	94
2167	William Osler: On Chorea: On Charcot. **2000**, 47, 404-407	10
2166	Missing tau mutation identified. **2000**, 47, 417-418	15
2165	A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). **2000**, 47, 422-429	93
2164	Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: Expanding the phenotype. **2000**, 48, 65-71	213
2163	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. **2000**, 48, 77-87	281
2162	Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation. **2000**, 48, 850-858	91
2161	Pick's disease is associated with mutations in the tau gene. **2000**, 48, 859-867	116
2160	Reactivation of human neurotropic JC virus expressing oncogenic protein in a recurrent glioblastoma multiforme. **2000**, 48, 932-936	42
2159	Herpes simplex virus type 1 (HSV-1)-induced retinitis following herpes simplex encephalitis: Indications for brain-to-eye transmission of HSV-1. **2000**, 48, 936-939	22

2158	A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. **2000**, 48, 939-943	124
2157	Therapeutic benefit of polyamine-modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenics. **2000**, 48, 943-947	33
2156	Research goals in progressive supranuclear palsy. **2000**, 15, 446-458	26
2155	Linkage exclusion in French families with probable Parkinson' s disease. **2000**, 15, 1075-83	32
2154	The solution structure of the C-terminal segment of tau protein. **2000**, 6, 550-9	15
2153	Autosomal recessive juvenile parkinsonism: a key to understanding nigral degeneration in sporadic Parkinson's disease. **2000**, 20 Suppl, S85-90	84
2152	Untangling Alzheimer's disease from fibrous lesions of neurofibrillary tangles and senile plaques. **2000**, 20 Suppl, S55-60	8
2151	Late-onset neurodegenerative diseases--the role of protein insolubility. **2000**, 196 (Pt 4), 609-16	57
2150	A new case of frontotemporal dementia and parkinsonism resulting from an intron 10 +3-splice site mutation in the tau gene: clinical and pathological features. **2000**, 26, 368-78	32
2149	Comment: the epidemiology of the genetic liability for schizophrenia. **2000**, 34, S56-S57	
2148	Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. **2000**, 25, 402-5	1092
2147	The molecular genetics of the tauopathies. **2000**, 35, 461-71	44
2146	Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. **2000**, 88, 93-113	133
2145	Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions. **2000**, 853, 5-14	74
2144	Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). **2000**, 2, 0193-0205	24
2143	Fibers of tau fragments, but not full length tau, exhibit a cross beta-structure: implications for the formation of paired helical filaments. **2000**, 9, 2427-35	40
2142	RNA processing and human disease. **2000**, 57, 235-49	95
2141	CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. **2000**, 107, 563-79	194

2140	Familial frontotemporal dementia with ubiquitin inclusion bodies and without motor neuron disease. **2000**, 100, 421-6	28
2139	Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. **2000**, 99, 469-81	303
2138	A double-labeling immunohistochemical study of tau exon 10 in Alzheimer's disease, progressive supranuclear palsy and Pick's disease. **2000**, 100, 235-44	32
2137	The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population. **2000**, 247, 52-5	28
2136	A case of frontotemporal dementia with tau P301L mutation in the Far East. **2000**, 247, 705-7	10
2135	Alzheimer disease: mouse models pave the way for therapeutic opportunities. **2000**, 57, 176-81	44
2134	Ultrastructural Pathology of Neurofibrillary Tangles in Transgenic Mice Carrying Mutant (P301l) Human Tau Gene. **2000**, 6, 584-585	2
2133	Comment: The Epidemiology of the Genetic Liability for Schizophrenia. **2000**, 34, A56-A57	
2132	Corticobasal ganglionic degeneration and/or frontotemporal dementia? A report of two overlap cases and review of literature. **2000**, 68, 304-12	70
2131	Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. **2000**, 97, 5129-34	743
2130	Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. **2000**, 275, 41340-9	253
2129	Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. **2000**, 123 (Pt 5), 880-93	250
2128	Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onset of neurodegenetative disease. **2000**, 275, 38182-9	165
2127	Determinants of 4-repeat tau expression. Coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion. **2000**, 275, 17700-9	102
2126	Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17. **2000**, 20, 4036-48	104
2125	The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture. **2000**, 54, 2045-54	126
2124	Control of hnRNP A1 alternative splicing: an intron element represses use of the common 3' splice site. **2000**, 20, 7353-62	18
2123	The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. **2000**, 55, 1368-75	272

2122	Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. **2000**, 54, 1960-4	151
2121	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 11-2000. A 74-year-old man with memory loss, language impairment, and personality changes. **2000** , 342, 1110-7	4
2120	A stimulating view of human visual cortex. **2000**, 54, 785-6	3
2119	Tau mutations in familial frontotemporal dementia. **2000**, 123 (Pt 5), 857-9	42
2118	Non-Alzheimer dementias. **2000**, 20, 439-46	15
2117	Comment: The Epidemiology of the Genetic Liability for Schizophrenia. **2000**, 34, S56-S57	
2116	Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. **2000**, 55, 800-5	214
2115	Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients. **2000**, 9, 3075-82	44
2114	Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. **2000**, 11, 4093-104	109
2113	Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways. **2000**, 275, 35353-60	79
2112	Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics. **2000**, 28, 710-9	66
2111	Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. **2000**, 59, 133-54	176
2110	Familial frontotemporal dementia with ubiquitin-positive, tau-negative inclusions. **2000**, 54, 818-27	133
2109	Untangling tau-related dementia. **2000**, 9, 979-86	74
2108	Patient mutations in doublecortin define a repeated tubulin-binding domain. **2000**, 275, 34442-50	120
2107	An extended 5'-tau susceptibility haplotype in progressive supranuclear palsy. **2000**, 55, 1364-7	47
2106	Doublecortin mutations cluster in evolutionarily conserved functional domains. **2000**, 9, 703-12	102
2105	In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. **2000**, 39, 6136-44	132

2104	Search for a mutation in the tau gene in a Swiss family with frontotemporal dementia. **2000**, 161, 330-5	9
2103	Amyloid-beta injection in rat amygdala alters tau protein but not mRNA expression. **2000**, 162, 158-70	15
2102	Apolipoprotein E epsilon4 allele has no effect on age at onset or duration of disease in cases of frontotemporal dementia with pick- or microvacuolar-type histology. **2000**, 163, 452-6	33
2101	Abnormal tau-containing filaments in neurodegenerative diseases. **2000**, 130, 271-9	148
2100	Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. **2000**, 7, 87-98	244
2099	Molecular classification of the dementias. **2000**, 355, 626	52
2098	Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. **2000**, 33, 95-130	1420
2097	The splicing determinants of a regulated exon in the axonal MAP tau reside within the exon and in its upstream intron. **2000**, 80, 207-18	17
2096	Tau polymorphisms are not associated with Alzheimer's disease. **2000**, 284, 77-80	34
2095	No association between TAU haplotype and Alzheimer's disease in population or clinic based series or in familial disease. **2000**, 285, 147-9	35
2094	Tau protein in cerebrospinal fluid from semantic dementia patients. **2000**, 294, 155-8	20
2093	Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. **2000**, 21, 503-10	118
2092	Quantitative neurohistological features of frontotemporal degeneration. **2000**, 21, 913-9	59
2091	Age-related progression of tau pathology in brains of baboons. **2000**, 21, 905-12	60
2090	Neurofibrillary tangle-associated collapsin response mediator protein-2 (CRMP-2) is highly phosphorylated on Thr-509, Ser-518, and Ser-522. **2000**, 39, 4267-75	158
2089	New insights into genetic and molecular mechanisms of brain degeneration in tauopathies. **2000**, 20, 225-44	44
2088	Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. **2000**, 1502, 110-21	99
2087	Structure of tau protein and assembly into paired helical filaments. **2000**, 1502, 122-32	114

2086	The epidemiology of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). **2000**, 6, 145-153	13
2085	Diagnosis and differential diagnosis of Parkinson's disease and parkinsonism. **2000**, 7, 63-70	15
2084	Analysis of the molecular heterogeneity of the microtubule-associated protein tau by two-dimensional electrophoresis and RT-PCR. **2000**, 5, 231-42	11
2083	The genetics of Parkinson's disease. **2000**, 10, 292-8	64
2082	Progressive supranuclear palsy in the molecular age. **2000**, 356, 870-1	11
2081	Tau aggregation into fibrillar polymers: taupathies. **2000**, 476, 89-92	57
2080	The natural osmolyte trimethylamine N-oxide (TMAO) restores the ability of mutant tau to promote microtubule assembly. **2000**, 484, 265-70	33
2079	Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. **2000**, 39, 11714-21	279
2078	Frontotemporal dementia. **2000**, 18, 979-92	30
2077	The nosology of dementia. **2000**, 18, 773-88	17
2076	The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. **2000**, 18, 903-22	122
2075	Familial frontotemporal dementia with a P301L tau mutation in Japan. **2000**, 176, 57-64	23
2074	Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. **2000**, 177, 48-59	57
2073	Cognitive change in motor neurone disease/amyotrophic lateral sclerosis (MND/ALS). **2000**, 180, 15-20	155
2072	Neurodegenerative tauopathies. **2001**, 24, 1121-59	2089
2071	Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations. **2001**, 168, 413-8	53
2070	Alternative splicing of amino-terminal Tau mRNA in rat spinal cord during development and following axonal injury. **2001**, 169, 105-13	6
2069	Regulation of alternative splicing of human tau exon 10 by phosphorylation of splicing factors. **2001**, 18, 80-90	93

2068	FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. **2001**, 18, 702-14	176
2067	Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. **2001**, 74, 458-75	168
2066	Proapoptotic effects of tau cleavage product generated by caspase-3. **2001**, 8, 162-72	176
2065	Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. **2001**, 8, 1036-45	125
2064	Presenilin binding protein is associated with neurofibrillary alterations in Alzheimer's disease and stimulates tau phosphorylation. **2001**, 159, 1597-602	28
2063	Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy. **2001**, 158, 235-46	59
2062	Molecular analysis of mutant and wild-type tau deposited in the brain affected by the FTDP-17 R406W mutation. **2001**, 158, 373-9	50
2061	Structural analysis of Pick's disease-derived and in vitro-assembled tau filaments. **2001**, 158, 1481-90	50
2060	The molecular bases of spontaneous immunological mutations in the mouse and their homologous human diseases. **2001**, 101, 113-29	8
2059	Pathological glial tau accumulations in neurodegenerative disease: review and case report. **2001**, 39, 469-79	35
2058	Phenotypic correlations in FTDP-17. **2001**, 22, 89-107	207
2057	The status of "Pick's Disease" and other tauopathies within the frontotemporal dementias. **2001**, 22, 109-11	5
2056	Tau proteins with frontotemporal dementia-17 mutations have both altered expression levels and phosphorylation profiles in differentiated neuroblastoma cells. **2001**, 108, 701-12	26
2055	Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. **2001**, 55, 175-85	359
2054	Alternative RNA splicing in the nervous system. **2001**, 65, 289-308	277
2053	The extended haplotype of the microtubule associated protein tau gene is not associated with Pick's disease. **2001**, 299, 156-8	32
2052	Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy. **2001**, 311, 145-8	46
2051	The microtubule associated protein Tau gene and Alzheimer's disease--an association study and meta-analysis. **2001**, 314, 92-6	50

2050	Genetic risk factors: session V summary and research needs. **2001**, 22, 845-8	
2049	Tau and transgenic animal models. **2001**, 35, 266-86	125
2048	Engineered modeling and the secrets of Parkinson's disease. **2001**, 24, S49-55	12
2047	Engineered modeling and the secrets of Parkinson's disease. **2001**, 24, 49-55	11
2046	Parkinson disease: etiology, pathogenesis and future of gene therapy. **2001**, 41, 5-12	91
2045	Compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family. **2001**, 49, 267-71	67
2044	Familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii peninsula of Japan: Clinical and neuropathological study and tau analysis. **2001**, 49, 501-511	92
2043	Analysis of tauopathies with transgenic mice. **2001**, 7, 467-70	79
2042	Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3beta identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes. **2001**, 493, 40-4	31
2041	Focal degenerative dementia syndromes. **2001**, 17, 303-18	6
2040	An overview of common non-Alzheimer dementias. **2001**, 17, 281-301	20
2039	Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. **2001**, 98, 6923-8	704
2038	The emerging utility of animal models of chronic neurodegenerative diseases. **2001**, 5, 125-32	5
2037	Transgenic mouse models of Alzheimer's disease: phenotype and mechanisms of pathogenesis. **2001**, 67, 195-202	22
2036	Etiology, Genetics, and Pathogenesis of Alzheimer's Disease. **2001**, 333-348	
2035	Tau be or not tau beTauopathien und transgene Tiermodelle. **2001**, 7, 93-102	
2034	Frontotemporal Dementias: From Classification Problems to Pathogenetic Uncertainties. **2001**, 145-154	
2033	The genetic causes of neurodegenerative diseases. **2001**, 3, 109-116	19

2032	Alzheimer's disease: genes, proteins, and therapy. **2001**, 81, 741-66	4885
2031	Rna-binding protein Musashi2: developmentally regulated expression in neural precursor cells and subpopulations of neurons in mammalian CNS. **2001**, 21, 8091-107	186
2030	Tau Phosphorylation. **2001**, 315-332	5
2029	Attenuated neurodegenerative disease phenotype in tau transgenic mouse lacking neurofilaments. **2001**, 21, 6026-35	62
2028	Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice. **2001**, 12, 2007-16	41
2027	Recent advances in the understanding of tau protein and movement disorders. **2001**, 14, 491-7	14
2026	Selective deposition of mutant tau in the FTDP-17 brain affected by the P301L mutation. **2001**, 60, 872-84	39
2025	Therapy and management of frontal lobe dementia patients. **2001**, 56, S41-5	27
2024	Transgenic mouse models of tauopathies: prospects for animal models of Pick's disease. **2001**, 56, S26-30	18
2023	Frontotemporal lobar degeneration. An update on clinical, pathological and genetic findings. **2001**, 47, 1-8	18
2022	Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22. **2001**, 124, 1948-57	118
2021	Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. **2001**, 357, 759-67	70
2020	Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. **2001**, 357, 759-767	91
2019	The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. **2001**, 98, 851-9	146
2018	Frontotemporal dementia: report of a familial case. **2001**, 56, S31-4	0
2017	Molecular Genetics and Transgenic Modeling of the Tauopathies. 71-85	1
2016	Regulation of Four-Repeat tau Expression: Interactions between Exon and Intron Splicing Regulatory Sequences. 87-95	
2015	Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. **2001**, 3, 75-80	437

2014	Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. **2001**, 276, 48165-74	395
2013	Frontal lobe dementia with novel tauopathy: sporadic multiple system tauopathy with dementia. **2001**, 60, 328-41	65
2012	Genetic analysis in patients with familial and sporadic frontotemporal dementia: two tau mutations in only familial cases and no association with apolipoprotein epsilon4. **2001**, 12, 387-92	20
2011	TAU as a susceptibility gene for amyotropic lateral sclerosis-parkinsonism dementia complex of Guam. **2001**, 58, 1871-8	65
2010	A genomic sequence analysis of the mouse and human microtubule-associated protein tau. **2001**, 12, 700-12	54
2009	[Tauopathies--a new class of neurodegenerative diseases]. **2001**, 72, 78-85	5
2008	Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. **2001**, 101, 167-73	145
2007	Familial frontotemporal dementia and parkinsonism with a novel N296H mutation in exon 10 of the tau gene and a widespread tau accumulation in the glial cells. **2001**, 102, 285-92	80
2006	Frontotemporal dementia with ubiquitinated cytoplasmic and intranuclear inclusions. **2001**, 102, 94-102	80
2005	Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia. **2000**, 74, 490-500	68
2004	Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. **2000**, 74, 878-81	81
2003	EFNS Task Force on Molecular Diagnosis of Neurologic Disorders: guidelines for the molecular diagnosis of inherited neurologic diseases. Second of two parts. **2001**, 8, 407-24	16
2002	Genetics of Parkinsonism: a review. **2001**, 65, 111-126	56
2001	Behaviour in frontotemporal dementia, Alzheimer's disease and vascular dementia. **2001**, 103, 367-78	196
2000	Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. **2001**, 13, 2131-40	85
1999	Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy. **2001**, 16, 764-5	26
1998	Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. **2001**, 16, 769-71	107
1997	Bilateral pallidal stimulation for idiopathic segmental axial dystonia advanced from Meige syndrome refractory to bilateral thalamotomy. **2001**, 16, 774-7	126

1996	Case report of pallido-pyramidal disease with supplementary motor area involvement. **2001**, 16, 762-4	7
1995	Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17): PPND family. A longitudinal videotape demonstration. **2001**, 16, 756-60	8
1994	Case of essential palatal tremor: atypical features and remarkable benefit from botulinum toxin injection. **2001**, 16, 779-82	32
1993	Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy. **2001**, 16, 765-7	27
1992	Playing harp, another unusual task-specific dystonia. **2001**, 16, 778-9	15
1991	Abolition of postapoplectic hemichorea by Vo-complex thalamotomy: long-term follow-up study. **2001**, 16, 771-4	14
1990	Truncal and limb apraxia in corticobasal degeneration. **2001**, 16, 760-2	14
1989	Focal myopathy as a cause of anterocollis in Parkinsonism. **2001**, 16, 754-6	34
1988	Acute paroxysmal dystonia induced by fluoxetine. **2001**, 16, 767-9	16
1987	Mutated tau binds less avidly to microtubules than wildtype tau in living cells. **2001**, 63, 268-75	26
1986	Molecular approaches to cerebral laterality: Development and neurodegeneration. **2001**, 101, 370-381	81
1985	Dementia and neurodevelopmental predisposition: cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia. **2001**, 50, 741-6	92
1984	Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis. **2001**, 49, 643-649	61
1983	Late-onset metachromatic leukodystrophy clinically presenting as isolated peripheral neuropathy: Compound heterozygosity for the IVS2+1G->a mutation and a newly identified missense mutation (Thr408Ile) in a Spanish family. **2001**, 50, 108-112	22
1982	Familial frontotemporal dementia and parkinsonism with a novel mutation at an intron 10+11-splice site in the tau gene. **2001**, 50, 117-20	55
1981	Progressive mitochondrial disease resulting from a novel missense mutation in the mitochondrial DNA ND3 gene. **2001**, 50, 104-7	79
1980	Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. **2001**, 50, 112-7	72
1979	Pick's disease associated with the novel Tau gene mutation K369I. **2001**, 50, 503-13	120

1978	Yet another paraneoplastic antibody. **2001**, 49, 141-2	9
1977	Deep brain stimulation for Parkinson's disease. **2001**, 49, 142-3	21
1976	The case of the missing tau, or, why didn't the mRNA bark?. **2001**, 49, 144-5	2
1975	Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. **2001**, 49, 165-75	146
1974	Abnormal activity in the globus pallidus in off-period dystonia. **2001**, 49, 242-5	17
1973	Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. **2001**, 49, 245-9	175
1972	Absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients. **2001**, 49, 249-253	42
1971	Anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus. **2001**, 49, 253-7	47
1970	14-3-3 protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeldt-Jakob disease patients. **2001**, 49, 257-60	29
1969	Propofol in subanesthetic doses terminates status epilepticus in a rodent model. **2001**, 49, 260-263	36
1968	Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene. **2001**, 49, 263-7	165
1967	Laforin is a cell membrane and endoplasmic reticulum□ssociated protein tyrosine phosphatase. **2001**, 49, 271-275	44
1966	The genetics of cognitive processes: candidate genes in humans and animals. **2001**, 31, 511-31	42
1965	Shattuck lecture--neurodegenerative diseases and prions. **2001**, 344, 1516-26	608
1964	Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. **2001**, 9, 659-66	42
1963	The splice of life: alternative splicing and neurological disease. **2001**, 2, 43-50	121
1962	Pathophysiological aspects of frontotemporal dementia--emphasis on cytoskeleton proteins and autoimmunity. **2001**, 122, 1923-35	23
1961	Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. **2001**, 13, 41-8	195

1960	Genetic dissection of neurodegenerative disease. **2001**, 1, 134-141	7
1959	Presenilins, amyloid precursor protein and the molecular basis of Alzheimer's disease. **2001**, 1, 91-103	19
1958	Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease. **2001**, 1, 194-206	18
1957	Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2. **2001**, 276, 2108-14	93
1956	Tau mutations--center tent or sideshow?. **2001**, 58, 351-2	3
1955	Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. **2001**, 286, 2245-50	135
1954	Functional differences of tau isoforms containing 3 or 4 C-terminal repeat regions and the influence of oxidative stress. **2001**, 276, 34288-97	16
1953	Analysis of alpha-synuclein, parkin, tau, and UCH-L1 in a Japanese family with autosomal dominant parkinsonism. **2001**, 46, 20-4	9
1952	Learning and memory in transgenic mice modeling Alzheimer's disease. **2001**, 8, 301-8	187
1951	Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. **2001**, 60, 357-68	99
1950	Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. **2001**, 276, 37967-73	103
1949	Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. **2001**, 58, 383-7	111
1948	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. **2001**, 56, 1702-6	358
1947	Biomedicine. Tauists and beta-aptists united--well almost!. **2001**, 293, 1446-7	45
1946	The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. **2001**, 21, 3888-900	360
1945	Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. **2001**, 276, 42986-93	89
1944	Clinical implications of the genetics of ALS and other motor neuron diseases. **2001**, 57, 9-17	23
1943	The Aetiology of Alzheimer Disease: Diverse Routes into a Common Tau Pathway. **2001**, 97-132	1

1942	Pick's disease: a clinical overview. **2001**, 56, S3-5	30
1941	Behavior and treatment in frontotemporal dementia. **2001**, 56, S46-51	90
1940	Competition for microtubule-binding with dual expression of tau missense and splice isoforms. **2001**, 12, 171-84	94
1939	Complete genomic screen in Parkinson disease: evidence for multiple genes. **2001**, 286, 2239-44	208
1938	Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. **2001**, 56, S21-5	103
1937	Both total and phosphorylated tau are increased in Alzheimer's disease. **2001**, 70, 624-30	154
1936	Senile dementia of the neurofibrillary tangle type: a comparison with Alzheimer's disease. **2001**, 12, 117-26	28
1935	The genetic and pathological classification of familial frontotemporal dementia. **2001**, 58, 1813-6	105
1934	Diagnosis and management of progressive supranuclear palsy. **2001**, 21, 41-8	50
1933	In vitro assembly of Alzheimer-like filaments. How a small cluster of charged residues in Tau and MAP2 controls filament morphology. **2002**, 277, 34755-9	15
1932	Apolipoprotein E polymorphism in German patients with frontotemporal degeneration. **2002**, 72, 639-41	25
1931	tau Exon 10 expression involves a bipartite intron 10 regulatory sequence and weak 5' and 3' splice sites. **2002**, 277, 26587-99	68
1930	Defects in pre-mRNA processing as causes of and predisposition to diseases. **2002**, 21, 803-18	71
1929	Genetics, molecular biology, neuropathology and phenotype of frontal lobe dementia: a case history. **2002**, 180, 455-60	2
1928	Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. **2002**, 99 Suppl 4, 16419-26	246
1927	Gene finding in genetically isolated populations. **2002**, 11, 2507-15	86
1926	Sequence analysis of tau in familial and sporadic progressive supranuclear palsy. **2002**, 72, 388-90	10
1925	Familial Lewy body diseases. **2002**, 15, 217-23	8

1924	Primary Progressive Aphasia: Dissociation of the Loss of Syntax and Semantics in a Biologically Determined Brain Degeneration. **2002**, 149-158	
1923	Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study. **2002**, 125, 44-57	22
1922	Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. **2002**, 125, 732-51	110
1921	Argyrophilic grain disease is a sporadic 4-repeat tauopathy. **2002**, 61, 547-56	200
1920	Frontotemporal dementia. **2002**, 180, 140-3	269
1919	Neuropathobiology in transgenic mice. The case of Alzheimer's disease. **2003**, 209, 333-61	2
1918	Neuropathologic variation in frontotemporal dementia due to the intronic tau 10(+16) mutation. **2002**, 58, 1169-75	48
1917	Chromosome 3 linked frontotemporal dementia (FTD-3). **2002**, 59, 1585-94	95
1916	Mapping the Progress of Alzheimer and Parkinson Disease. **2002**,	2
1915	Functional characterization of FTDP-17 tau gene mutations through their effects on Xenopus oocyte maturation. **2002**, 277, 9199-205	37
1914	Presenile dementia syndromes: an update on taxonomy and diagnosis. **2002**, 72, 691-700	60
1913	SRp30c is a repressor of 3' splice site utilization. **2002**, 22, 4001-10	51
1912	Mouse models of Alzheimer's disease: a quest for plaques and tangles. **2002**, 43, 89-99	41
1911	Corticobasal degeneration and frontotemporal dementia presentations in a kindred with nonspecific histopathology. **2002**, 13, 80-90	21
1910	Neurodegenerative diseases. **2002**, 210-236	3
1909	Aging and dementia: principles, evaluation and diagnosis. **2002**, 237-251	1
1908	Frontotemporal dementia. **2002**, 283-288	
1907	Other extrapyramidal syndromes: parkinsonism-plus and other forms of secondary parkinsonism. **2002**, 490-512	0

1906	Progressive supranuclear palsy: clinical and genetic aspects. **2002**, 15, 429-37	17
1905	New developments in frontotemporal dementia and parkinsonism linked to chromosome 17. **2002**, 15, 423-8	32
1904	Frontotemporal dementia: a review. **2002**, 8, 566-83	116
1903	Association between the extended tau haplotype and frontotemporal dementia. **2002**, 59, 935-9	78
1902	The Ubiquitin/Proteasome Pathway in Neurological Disorders. **2002**, 137-153	
1901	The Neuropathology of Alzheimer's Disease. 223-226	
1900	Neurogenetics of Dementia. 361-375	
1899	Animal Models of Cognitive Disorders. 211-233	
1898	Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau. **2002**, 161, 1711-22	62
1897	Regulation of tau RNA maturation by thyroid hormone is mediated by the neural RNA-binding protein musashi-1. **2002**, 20, 198-210	36
1896	P301L tauopathy: confocal immunofluorescence study of perinuclear aggregation of the mutated protein. **2002**, 200, 85-93	20
1895	Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. **2002**, 13, 112-8	110
1894	Familial frontotemporal dementia associated with a novel presenilin-1 mutation. **2002**, 14, 13-21	51
1893	Genetics of dementia. **2002**, 86, 591-614	19
1892	Inherited dementias. **2002**, 20, 779-808, vii	10
1891	Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. **2002**, 99, 13896-901	234
1890	Molecular cloning and functional characterization of chicken brain tau: isoforms with up to five tandem repeats. **2002**, 41, 15203-11	45
1889	Disordered proteins in dementia. **2002**, 34, 259-71	17

1888	The prevalence of frontotemporal dementia. **2002**, 58, 1615-21	909
1887	Transgenic Mouse. **2002**,	4
1886	Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. **2002**, 515, 151-4	52
1885	Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's Disease. **2002**, 518, 1-4	89
1884	Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. **2002**, 34, 509-19	431
1883	Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. **2002**, 35, 433-46	132
1882	Alzheimer's disease and the amyloid cascade hypothesis: ten years on. **2002**, 2, 87-92	82
1881	Tau gene mutations: dissecting the pathogenesis of FTDP-17. **2002**, 8, 555-62	159
1880	A family with a tau P301L mutation presenting with parkinsonism. **2002**, 9, 121-3	11
1879	Progressive supranuclear palsy and its relation to pacific foci of the parkinsonism-dementia complex and Guadeloupean parkinsonism. **2002**, 9, 39-54	29
1878	Modulation of the membrane-binding projection domain of tau protein: splicing regulation of exon 3. **2002**, 101, 109-21	22
1877	Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. **2002**, 104, 210-9	37
1876	Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. **2002**, 23, 1323-32	111
1875	Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. **2002**, 23, 363-70	62
1874	Parkinson's genetics: molecular insights for the new millennium. **2002**, 23, 503-14	17
1873	Tau neurotoxicity without the lesions: a fly challenges a tangled web. **2002**, 25, 327-9	21
1872	Effects on splicing and protein function of three mutations in codon N296 of tau in vitro. **2002**, 323, 33-6	50
1871	A polymorphism within intron 11 of the tau gene is not increased in frequency in patients with sporadic Alzheimer's disease, nor does it influence the extent of tau pathology in the brain. **2002**, 324, 113-6	18

1870	The cytosolic inclusion bodies that consist of splice variants that lack exon 5 of the presenilin-2 gene differ obviously from Hirano bodies observed in the brain from sporadic cases of Alzheimer's disease patients. **2002**, 328, 198-200	12
1869	The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease. **2002**, 330, 201-3	35
1868	The role of tau in Alzheimer's disease. **2002**, 86, 615-27	50
1867	Frontotemporal dementia. **2002**, 86, 501-18, vi	24
1866	Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. **2002**, 22, 133-41	198
1865	The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons. **2002**, 22, 6394-400	61
1864	The Brain of the Aging Baboon: A Nonhuman Primate Model for Neuronal and Glial Tau Pathology. **2002**, 31, 118-129	3
1863	Verwandte Erkrankungen. **2002**,	
1862	Neurofibrillary pathology leads to synaptic loss and not the other way around in Alzheimer disease. **2002**, 4, 235-8	29
1861	Tau, where are we now?. **2002**, 4, 375-98	70
1860	Pharmacogenomics in Alzheimer's disease. **2002**, 2, 59-84	28
1859	Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. **2002**, 22, 3376-85	243
1858	Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation. **2002**, 4, 399-404	33
1857	Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. **2002**, 22, 9340-51	511
1856	Clinical features of frontotemporal dementia due to the intronic tau 10(+16) mutation. **2002**, 58, 1161-8	76
1855	Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. **2002**, 125, 969-75	76
1854	Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family. **2002**, 59, 943-50	32
1853	Involvement of microtubule integrity in memory impairment caused by colchicine. **2002**, 71, 119-38	53

1852	Splicing regulation as a potential genetic modifier. **2002**, 18, 123-7	182
1851	Complex relationship between Parkin mutations and Parkinson disease. **2002**, 114, 584-91	154
1850	A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. **2002**, 51, 296-301	510
1849	A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease. **2002**, 51, 373-6	77
1848	Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. **2002**, 51, 525-30	130
1847	An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. **2002**, 52, 511-6	170
1846	Is the saitohin gene involved in neurodegenerative diseases?. **2002**, 52, 829-32	33
1845	Alzheimer's disease: beta-Amyloid protein and tau. **2002**, 70, 392-401	80
1844	Transgenic zebrafish model of neurodegeneration. **2002**, 70, 734-45	80
1843	Further extension of the H1 haplotype associated with progressive supranuclear palsy. **2002**, 17, 550-6	47
1842	Genetics of parkinsonism. **2002**, 17, 645-56	87
1841	Familial conformational diseases and dementias. **2002**, 20, 1-14	46
1840	Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. **2002**, 446, 257-66	92
1839	Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. **2002**, 19, 95-9	49
1838	Amyloid peptide toxicity and microtubule-stabilizing drugs. **2002**, 19, 101-5	20
1837	[Neuropsychological disorders in amyotrophic lateral sclerosis]. **2002**, 73, 1144-52	5
1836	Functions and malfunctions of the tau proteins. **2002**, 59, 1668-80	127
1835	A novel presenilin 1 mutation (L174 M) in a large Cuban family with early onset Alzheimer disease. **2002**, 4, 97-104	18

1834	Frontotemporal lobar degeneration--tau as a pied piper?. **2002**, 4, 63-75	40
1833	Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. **2002**, 104, 398-402	74
1832	Evidence for pathological involvement of the spinal cord in motor neuron disease-inclusion dementia. **2002**, 103, 221-7	24
1831	Contrasting genotypes of the tau gene in two phenotypically distinct patients with P301L mutation of frontotemporal dementia and parkinsonism linked to chromosome 17. **2002**, 249, 669-75	17
1830	A large Calabrian kindred segregating frontotemporal dementia. **2002**, 249, 911-22	16
1829	Functional effects of tau gene mutations deltaN296 and N296H. **2002**, 80, 548-51	53
1828	Potential novel targets for Alzheimer pharmacotherapy: I. Secretases. **2002**, 27, 169-83	23
1827	Differential assembly of human tau isoforms in the presence of arachidonic acid. **2000**, 74, 1749-57	123
1826	The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules. **2000**, 74, 2583-9	48
1825	Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. **2000**, 75, 1681-4	66
1824	Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations. **2000**, 75, 2155-62	72
1823	Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. **2002**, 83, 1498-508	111
1822	Polymorphisms in the tau gene in sporadic frontotemporal dementia and other neurodegenerative disorders. **2002**, 9, 485-9	14
1821	Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis. **2002**, 10, 399-405	78
1820	Tau negative frontal lobe dementia at 17q21: significant finemapping of the candidate region to a 4.8 cM interval. **2002**, 7, 1064-74	98
1819	Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome. **2002**, 32, 448-52	215
1818	Modelling neurodegenerative diseases in Drosophila: a fruitful approach?. **2002**, 3, 237-43	119
1817	Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. **2002**, 41, 14885-96	268

1816	Discovery of compounds that will prevent tau pathology. **2002**, 19, 261-6	11
1815	Tau neurofibrillary pathology and microtubule stability. **2002**, 19, 289-93	51
1814	Tau function and dysfunction in neurons: its role in neurodegenerative disorders. **2002**, 25, 213-31	43
1813	Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. **2002**, 1, 1-31	147
1812	Tau and axonopathy in neurodegenerative disorders. **2002**, 2, 131-50	100
1811	Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. **2002**, 2, 151-65	98
1810	Alzheimer neurofibrillary degeneration: therapeutic targets and high-throughput assays. **2003**, 20, 425-9	19
1809	Tau protein in familial and sporadic diseases. **2003**, 4, 37-48	31
1808	Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. **2003**, 32, 1091-105	97
1807	The neuropathological spectrum of neurodegenerative tauopathies. **2003**, 55, 299-305	42
1806	Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. **2003**, 22, 70-7	251
1805	Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. **2003**, 105, 469-76	46
1804	Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic cases. **2003**, 105, 543-8	33
1803	The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy. **2003**, 106, 323-36	76
1802	Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies. **2003**, 106, 419-35	62
1801	Another phenotype of frontotemporal dementia and parkinsonism linked to chromosome-17 (FTDP-17) with a missense mutation of S305N closely resembling Pick's disease. **2003**, 250, 990-2	17
1800	Association of tau gene polymorphism with Parkinson's disease. **2003**, 24, 223-4	11
1799	Genes and parkinsonism. **2003**, 2, 221-8	85

1798	A linkage study of candidate loci in familial Parkinson's Disease. **2003**, 3, 6	14
1797	Predictors of mortality in frontotemporal dementia: a retrospective study of the prognostic influence of pre-diagnostic features. **2003**, 18, 594-601	16
1796	State of the art review: molecular diagnosis of inherited movement disorders. Movement Disorders Society task force on molecular diagnosis. **2003**, 18, 3-18	30
1795	Pseudoathetosis in a patient with leprosy. **2003**, 18, 598-601	6
1794	Phenotypic presentation of frontotemporal dementia with Parkinsonism-chromosome 17 type P301S in a patient of Jewish-Algerian origin. **2003**, 18, 595-8	9
1793	Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease. **2003**, 18, 593-5	27
1792	Parkinson's syndrome associated with neurofibrillary degeneration and tau pathologic findings. **2003**, 18 Suppl 6, S28-33	52
1791	Update on epidemiological aspects of progressive supranuclear palsy. **2003**, 18 Suppl 6, S43-50	114
1790	Pick's complex and FTDP-17. **2003**, 18 Suppl 6, S57-62	22
1789	Extended investigation of tau and mutation screening of other candidate genes on chromosome 17q21 in a Swedish FTDP-17 family. **2003**, 121B, 112-8	13
1788	International approaches to frontotemporal dementia diagnosis: from social cognition to neuropsychology. **2003**, 54 Suppl 5, S7-10	25
1787	How much phenotypic variation can be attributed to parkin genotype?. **2003**, 54, 176-85	224
1786	Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315R. **2003**, 54, 573-81	74
1785	An English kindred with a novel recessive tauopathy and respiratory failure. **2003**, 54, 682-6	56
1784	Genetic epidemiology of amyotrophic lateral sclerosis. **2003**, 63, 83-101	91
1783	Tau phosphorylation and kinase activation in familial tauopathy linked to deln296 mutation. **2003**, 29, 23-34	38
1782	Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. **2003** , 29, 288-302	167
1781	Frontotemporal and motor neurone degeneration with neurofilament inclusion bodies: additional evidence for overlap between FTD and ALS. **2003**, 29, 239-53	71

1780	Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. **2003**, 86, 582-90	541
1779	Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. **2003**, 87, 427-36	52
1778	Senile dementia of the neurofibrillary tangle type (tangle-only dementia): neuropathological criteria and clinical guidelines for diagnosis. **2003**, 23, 311-7	67
1777	NEDD8 protein is involved in ubiquitinated inclusion bodies. **2003**, 199, 259-66	66
1776	Induced HMGA1a expression causes aberrant splicing of Presenilin-2 pre-mRNA in sporadic Alzheimer's disease. **2003**, 10, 698-708	60
1775	Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. **2003**, 8, 343-7	182
1774	Modelling brain diseases in mice: the challenges of design and analysis. **2003**, 4, 296-307	68
1773	Alzheimer's disease and Parkinson's disease. **2003**, 348, 1356-64	929
1772	Initiation and synergistic fibrillization of tau and alpha-synuclein. **2003**, 300, 636-40	666
1771	Pre-mRNA splicing and human disease. **2003**, 17, 419-37	921
1770	Nitration of tau protein is linked to neurodegeneration in tauopathies. **2003**, 163, 1021-31	167
1769	Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. **2003**, 162, 213-8	84
1768	Tau exon 10 +16 mutation FTDP-17 presenting clinically as sporadic young onset PSP. **2003**, 61, 102-4	78
1767	Tau haplotype frequency in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. **2003**, 181, 12-6	30
1766	A novel tau mutation in exon 9 (1260V) causes a four-repeat tauopathy. **2003**, 184, 131-40	49
1765	An N-terminal fragment of ProSAAS (a granin-like neuroendocrine peptide precursor) is associated with tau inclusions in Pick's disease. **2003**, 308, 646-54	20
1764	Prevalence of TAU mutations in an Italian clinical series of familial frontotemporal patients. **2003**, 338, 85-7	34
1763	Mutational study of the nuclear factor kappa B inducing kinase gene in patients with progressive supranuclear palsy. **2003**, 340, 158-60	0

1762	Modulation of the membrane-binding domain of tau protein: splicing regulation of exon 2. **2003**, 116, 94-105	29
1761	Gene structure and alternative splicing of glycogen synthase kinase 3 beta (GSK-3beta) in neural and non-neural tissues. **2003**, 302, 73-81	43
1760	Distinct functions of tau isoforms in Alzheimer's disease. **2003**, 1252, 347-354	
1759	Molecular pathology of transgenic tau mice. **2003**, 1252, 379-382	
1758	Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. **2003**, 73, 390-6	66
1757	Accounting for linkage in family-based tests of association with missing parental genotypes. **2003**, 73, 1016-26	84
1756	A role of P301L tau mutant in anti-apoptotic gene expression, cell cycle and apoptosis. **2003**, 24, 367-79	25
1755	Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg?. **2003**, 40, 457-60	117
1754	Two large Polish kindreds with levodopa-responsive Parkinsonism not linked to known Parkinsonian genes and loci. **2003**, 9, 193-200	2
1753	Tau and neurofilaments in a family with frontotemporal dementia unlinked to chromosome 17q21-22. **2003**, 12, 46-55	20
1752	Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies. **2003**, 14, 251-64	67
1751	beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. **2003**, 278, 40162-8	134
1750	Progressive anomia with preserved oral spelling and automatic speech. **2003**, 9, 27-43	20
1749	Human neurodegenerative disease modeling using Drosophila. **2003**, 26, 627-56	132
1748	Saitohin gene is not associated with Alzheimer's disease. **2003**, 74, 362-3	17
1747	Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. **2003**, 17, 2014-24	124
1746	Possible association of the tau H1/H1 genotype with primary progressive aphasia. **2003**, 60, 862-4	37
1745	Allele-specific silencing of dominant disease genes. **2003**, 100, 7195-200	331

1744	Neurosciences at the Postgenomic Era. **2003**,	
1743	Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. **2003**, 100, 9980-5	289
1742	The genetics of motor neuron diseases. **2003**, 4, 225-31	26
1741	Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. **2003**, 126, 814-26	94
1740	Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3beta cascade. **2003**, 17, 295-7	87
1739	Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies. **2003**, 278, 33298-304	82
1738	Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2 beta. **2003**, 278, 18997-9007	91
1737	Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. **2003**, 100, 10032-7	646
1736	Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. **2003**, 100, 9548-53	193
1735	Neurodegenerative tauopathy in the worm. **2003**, 100, 9653-5	7
1734	Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. **2003**, 62, 389-97	254
1733	Chapter 5 Clinical Aspects of Sporadic Amyotrophic Lateral Sclerosis/Motor Neuron Disease. **2003**, 111-143	5
1732	Mouse models of Alzheimer's disease: the long and filamentous road. **2003**, 25, 590-600	46
1731	Novel tau polymorphisms, tau haplotypes, and splicing in familial and sporadic frontotemporal dementia. **2003**, 60, 698-702	49
1730	Familial frontotemporal dementia: from gene discovery to clinical molecular diagnostics. **2003**, 49, 1717-25	19
1729	Tau protein in frontotemporal dementia linked to chromosome 3 (FTD-3). **2003**, 62, 878-82	30
1728	. **2003**, 16, 459-463	5
1727	Mutation screening of the MAPT and STH genes in Polish patients with clinically diagnosed frontotemporal dementia. **2003**, 16, 126-31	13

1726	Brain banking for neurodegenerative diseases. **2003**, 16, 459-63	19
1725	Pick Complex: an integrative approach to frontotemporal dementia: primary progressive aphasia, corticobasal degeneration, and progressive supranuclear palsy. **2003**, 9, 311-7	56
1724	TAU GENE MUTATIONS IN FRONTOTEMPORAL DEMENTIA AND PARKINSONISM LINKED TO CHROMOSOME 17. **2003**,	
1723	Chapter 6 Cognitive Impairment in the Motor Neuron Disorders. **2003**, 28, 145-cp1	
1722	Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. **2003**, 61, 104-7	75
1721	Molecular Genetic Diagnosis of Neurological Diseases. **2003**, 1525-1538	
1720	Alternative splicing of Cav2 genes and their functional significance. **2003**, 121, 233-40	1
1719	The neurobiology of the tauopathies. **2003**, 245-261	
1718	. **2003**,	9
1717	Molecular Mechanisms of Neurodegenerative Disorders. 377-409	
1716	Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals. **2004**, 5, 503-15	90
1715	Transgenic mouse models of neurodegenerative disease. **2004**, 533-557	
1714	Alzheimer disease: mechanistic understanding predicts novel therapies. **2004**, 140, 627-38	206
1713	Sporadic tauopathies: Pick's disease, corticobasal degeneration, progressive supranuclear palsy and argyrophilic grain disease. **2004**, 227-256	13
1712	17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and alpha-synuclein inclusions. **2004**, 61, 398-406	65
1711	Biomarker identification in neurologic diseases: improving diagnostics and therapeutics. **2004**, 4, 361-75	5
1710	Prevalence of pathogenic mutations in an Italian clinical series of patients with familial dementia. **2004**, 1, 215-8	14
1709	Tau interaction with microtubules in vivo. **2004**, 117, 6129-41	110

1708	The structure of the tau haplotype in controls and in progressive supranuclear palsy. **2004**, 13, 1267-74	102
1707	Modulation of microtubule dynamics by tau in living cells: implications for development and neurodegeneration. **2004**, 15, 2720-8	122
1706	The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. **2004**, 13 Spec No 1, R123-6	74
1705	William John Adie (1886-1935). **2004**, 75, 1111	2
1704	Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. **2004**, 75, 1107-11	80
1703	Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. **2004**, 32, 661-8	121
1702	The tau gene locus and frontotemporal dementia. **2004**, 17, 258-60	8
1701	Negative neurofilament light and tau immunostaining in frontotemporal dementia. **2004**, 17, 346-9	3
1700	Phenotypic variation in frontotemporal dementia and parkinsonism linked to chromosome 17. **2004** , 17, 261-4	16
1699	Relationship between frontotemporal dementia and corticobasal degeneration/progressive supranuclear palsy. **2004**, 17, 282-6	55
1698	Characterization of amyotrophic lateral sclerosis and frontotemporal dementia. **2004**, 17, 337-41	64
1697	A frontotemporal family bridge. **2004**, 61, 318	1
1696	Frontotemporal dementia/Pick's disease. **2004**, 61, 969-71	14
1695	Tau gene and Parkinson's disease: a case-control study and meta-analysis. **2004**, 75, 962-5	100
1694	Frontotemporal dementia: impact of P301L tau mutation on a healthy carrier. **2004**, 75, 1607-10	25
1693	Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. **2004**, 13, 3079-88	398
1692	Clinical and molecular aspects of frontotemporal dementia. **2004**, 1, 218-24	6
1691	Voxel-based morphometry in tau-positive and tau-negative frontotemporal lobar degenerations. **2004**, 1, 225-30	20

1690	Alzheimer's disease: from bench to bedside. **2004**, 18, 177-195	
1689	Animal models of tau phosphorylation and tauopathy what have they taught us?. **2004**, 16, 153-175	
1688	Familial clustering and genetic risk for dementia in a genetically isolated Dutch population. **2004**, 127, 1641-9	52
1687	Gem GTPase and tau: morphological changes induced by gem GTPase in cho cells are antagonized by tau. **2004**, 279, 27272-7	29
1686	Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind microtubules in a neuronal cortical cell model. **2004**, 279, 7893-900	41
1685	Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. **2004**, 279, 3801-6	103
1684	Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. **2004**, 279, 17957-62	148
1683	Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. **2004**, 279, 34873-81	203
1682	Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. **2004**, 24, 4657-67	147
1681	Autopsy proven sporadic frontotemporal dementia due to microvacuolar-type histology, with onset at 21 years of age. **2004**, 75, 1337-9	15
1680	Genetic aspects of Alzheimer's disease, Pick's disease, and other dementias. **2004**, 19, 219-25	4
1679	Tra2 beta, SF2/ASF and SRp30c modulate the function of an exonic splicing enhancer in exon 10 of tau pre-mRNA. **2004**, 9, 121-30	59
1678	A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10. **2004**, 90, 164-72	53
1677	Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). **2004**, 90, 352-8	131
1676	Novel isoforms of tau that lack the microtubule-binding domain. **2004**, 90, 340-51	38
1675	Identification of regulatory cis-acting elements for alternative splicing of presenilin 2 exon 5 under hypoxic stress conditions. **2004**, 91, 1191-8	24
1674	Alternative splicing in disease and therapy. **2004**, 22, 535-46	431
1673	Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. **2004**, 6, 1054-61	697

1672	Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. **2004**, 10, 1055-63	547
1671	GSK3 inhibitors: development and therapeutic potential. **2004**, 3, 479-87	609
1670	St John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. **2004**, 9, 237-51	52
1669	Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. **2004**, 9, 664-83	228
1668	PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism. **2004**, 3, 652-62	52
1667	Animal models of neurodegenerative dementing disorders other than Alzheimer's disease. **2004**, 3, 427-436	3
1666	Frontotemporal degenerative dementias. **2004**, 3, 449-460	1
1665	Effects of alpha-tocopherol on an animal model of tauopathies. **2004**, 37, 176-86	75
1664	Proteases and lipoprotein receptors in Alzheimer's disease. **2004**, 41, 139-78	4
1663	Drug discovery for Alzheimer's disease: the end of the beginning. **2004**, 24, 1-8	11
1662	Ligand-dependent inhibition and reversal of tau filament formation. **2004**, 43, 2879-87	90
1661	Microglia as a potential bridge between the amyloid beta-peptide and tau. **2004**, 1035, 85-103	104
1660	Chasing genes in Alzheimer's and Parkinson's disease. **2004**, 114, 413-38	39
1659	Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. **2004**, 108, 515-23	91
1658	Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. **2004**, 251, 1098-104	34
1657	Linkage disequilibrium and haplotype tagging polymorphisms in the Tau H1 haplotype. **2004**, 5, 147-55	22
1656	The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein. **2004**, 30, 1-18	62
1655	The cytoskeleton in neurodegenerative diseases. **2004**, 204, 438-49	123

1654	Tau exon 10, whose missplicing causes frontotemporal dementia, is regulated by an intricate interplay of cis elements and trans factors. **2004**, 88, 1078-90	82
1653	Evidence of a founder effect in families with frontotemporal dementia that harbor the tau +16 splice mutation. **2004**, 125B, 79-82	18
1652	The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. **2004**, 55, 164-73	2025
1651	Tau haplotypes regulate transcription and are associated with Parkinson's disease. **2004**, 55, 329-34	147
1650	A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. **2004**, 55, 617-26	181
1649	Novel haplotypes in 17q21 are associated with progressive supranuclear palsy. **2004**, 56, 249-58	59
1648	The role of tau (MAPT) in frontotemporal dementia and related tauopathies. **2004**, 24, 277-95	255
1647	Tau isoforms which contain the domain encoded by exon 6 and their role in neurite elongation. **2004**, 91, 880-95	20
1646	Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. **2004**, 335, 30-41	66
1645	Frontotemporal degenerative dementias. **2004**, 3, 449-449	0
1644	Animal models of neurodegenerative dementing disorders other than Alzheimer's disease. **2004**, 3, 427-427	
1643	Effects of $alpha;-tocopherol on an animal model of tauopathies. **2004**,	
1642	Assessment of Pathological Tau Proteins in Frontotemporal Dementias: Qualitative and Quantitative Approaches. **2004**, 12, 136-145	15
1641	Bedside to Bench and Back Again: Translational Neuroscience Research and Geriatric Psychiatry. **2004**, 12, 122-125	5
1640	Association of neural cell adhesion molecule 1 gene polymorphisms with bipolar affective disorder in Japanese individuals. **2004**, 55, 804-10	57
1639	Genetics of neurological disorders. **2004**, 4, 317-32	13
1638	Validation of a prefractionation method followed by two-dimensional electrophoresis - Applied to cerebrospinal fluid proteins from frontotemporal dementia patients. **2004**, 2, 7	32
1637	Heterogeneous nuclear ribonucleoprotein E2 binds to tau exon 10 and moderately activates its splicing. **2004**, 331, 107-14	20

1636	Tau gene (MAPT) sequence variation among primates. **2004**, 341, 313-22	48
1635	Genotype-phenotype correlations in FTDP-17: does form follow function?. **2004**, 187, 229-34	12
1634	More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. **2004**, 27, 129-34	152
1633	Alzheimer's disease--a sum greater than its parts?. **2004**, 25, 725-33; discussion 743-6	24
1632	Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. **2004**, 43, 321-32	670
1631	Deciphering the molecular basis of memory failure in Alzheimer's disease. **2004**, 44, 181-93	1004
1630	Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. **2004**, 44, 601-7	2228
1629	Tau protein and neurodegeneration. **2004**, 15, 45-9	114
1628	Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau. **2004**, 164, 347-53	43
1627	Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. **2004**, 165, 1643-52	147
1626	Induction of neuronal death by ER stress in Alzheimer's disease. **2004**, 28, 67-78	243
1625	Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. **2004**, 121, 95-101	18
1624	TBP, a polyglutamine tract containing protein, accumulates in Alzheimer's disease. **2004**, 125, 120-8	18
1623	Frontotemporal dementia and mitochondrial DNA transitions. **2004**, 15, 306-11	11
1622	Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. **2004**, 15, 500-9	76
1621	Microtubule-associated protein tau gene: a risk factor in human neurodegenerative diseases. **2004**, 15, 449-60	28
1620	Alterations in human tau transcripts correlate with those of neurofilament in sporadic tauopathies. **2004**, 359, 151-4	33
1619	No evidence for tau duplications in frontal temporal dementia families showing genetic linkage to the tau locus in which tau mutations have not been found. **2004**, 363, 99-101	7

1618	Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. **2004**, 22, 453-65	109
1617	Alternative splice variants encoding unstable protein domains exist in the human brain. **2004**, 343, 1207-20	17
1616	□amyloid and tau protein. **2004**, 4, S62-S69	
1615	CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. **2004**, 13, 703-14	514
1614	Role of tau protein in both physiological and pathological conditions. **2004**, 84, 361-84	641
1613	Tau phosphorylation in neuronal cell function and dysfunction. **2004**, 117, 5721-9	404
1612	PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. **2004**, 116, 671-82	275
1611	Complex genetics of amyotrophic lateral sclerosis. **2004**, 75, 933-47	91
1610	The RNA-Binding Protein Causes Aberrant Splicing of Presenilin-2 Pre-mRNA in Sporadic Alzheimer?s Disease. **2004**, 17-30	
1609	Pivotal Role of Neurofibrillary Degeneration in Alzheimer Disease and Therapeutic Targets. **2004**, 42-51	
1608	Deregulation of GSK-3β and JNK in a Mouse Model of Tauopathy: A Kinase Combination That Induces Alzheimer-Type Tau Hyperphosphorylation. **2004**, 62-70	
1607	Animal Models of Tauopathies. **2004**, 195-204	
1606	Ubiquitin-negative mini-pick-like bodies in the dentate gyrus in p301l tauopathy. **2003**, 5, 445-54	12
1605	Frontotemporal dementia: genetics and genetic counseling dilemmas. **2004**, 10, 227-34	31
1604	Frontotemporal dementia with Pick-type histology associated with Q336R mutation in the tau gene. **2004**, 127, 1415-26	73
1603	Association between tau polymorphism and male early-onset Alzheimer's disease. **2004**, 15, 175-9	18
1602	Neuropathologie de la maladie d'Alzheimer. **2004**, 1, 1-15	
1601	Non-Alzheimer's disease dementias: anatomic, clinical, and molecular correlates. **2004**, 49, 164-71	26

1600	Frontotemporal mild cognitive impairment. **2004**, 6, 1-9	57
1599	Aberrant Splicing of Tau Transcripts in Frontotemporal Dementia with Parkinsonism Linked to Chromosome 17. **2004**, 205-214	
1598	Genetics of amyotrophic lateral sclerosis. **2004**, 169-186	1
1597	Animal Models of Tauopathies. **2005**, 65-76	1
1596	Ectopic expression of Musashi-1 in Alzheimer disease and Pick disease. **2005**, 64, 675-80	18
1595	Tau alternative splicing and frontotemporal dementia. **2005**, 19 Suppl 1, S29-36	30
1594	Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. **2005**, 64, 420-8	84
1593	Frontotemporal dementia: one disease, or many?: probably one, possibly two. **2005**, 19 Suppl 1, S19-24	15
1592	Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. **2005**, 19 Suppl 1, S44-7	45
1591	Pathophysiology, pleiotrophy and paradigm shifts: genetic lessons from Parkinson's disease. **2005**, 33, 586-90	35
1590	Mechanisms of memory loss in Abeta and tau mouse models. **2005**, 33, 591-4	38
1589	Molecular genetic pathways in Parkinson's disease: a review. **2005**, 109, 355-64	30
1588	The genetic epidemiology of neurodegenerative disease. **2005**, 115, 1449-57	403
1587	Abstracts of the 19th Annual Meeting of the Japanese Psychogeriatric Society. **2005**, 5, A1-A70	
1586	Multiple pathogenesis of frontotemporal dementia. **2005**, 5, 15-17	
1585	A new family with frontotemporal dementia with intronic 10+3 splice site mutation in the tau gene: neuropathology and molecular effects. **2005**, 31, 362-73	18
1584	Untangling memory deficits. **2005**, 11, 826-7	39
1583	The molecular elements that underlie developmental evolution. **2005**, 6, 709-15	69

1582	Invertebrate models of Alzheimer's disease. **2005**, 4, 147-56	77
1581	A case for a non-transgenic animal model of Alzheimer's disease. **2005**, 4, 157-72	47
1580	Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. **2005**, 86, 173-85	41
1579	Discovery and development of biomarkers of neurological disease. **2005**, 10, 326-34	59
1578	Frontotemporal dementia. **2005**, 4, 771-80	434
1577	Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum. **2005**, 21, 664-72	49
1576	Progressive neurodegeneration in C. elegans model of tauopathy. **2005**, 20, 372-83	89
1575	Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. **2005**, 42, 93-103	80
1574	An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. **2005**, 57, 918-21	229
1573	Structural insights into Alzheimer filament assembly pathways based on site-directed mutagenesis and S-glutathionylation of three-repeat neuronal Tau protein. **2005**, 67, 156-63	24
1572	Tau is not normally degraded by the proteasome. **2005**, 80, 400-5	39
1571	Genetic testing in Parkinson's disease. **2005**, 20, 1-10	38
1570	Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting. **2005**, 20 Suppl 12, S21-8	40
1569	Tau gene mutations and their effects. **2005**, 20 Suppl 12, S45-52	90
1568	Microtubule transport defects in neurological and ciliary disease. **2005**, 62, 1556-70	34
1567	Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases. **2005**, 109, 14-24	57
1566	Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies. **2005**, 109, 25-31	80
1565	Frontotemporal dementia, motor neuron disease and tauopathy: clinical and neuropathological study in a family. **2005**, 110, 84-92	19

1564	Sporadic four-repeat tauopathy with frontotemporal degeneration, parkinsonism and motor neuron disease. **2005**, 110, 600-9	28
1563	Diagnostic investigation and multidisciplinary management in motor neuron disease. **2005**, 252, 1435-47	51
1562	Familial frontotemporal dementia associated with the novel MAPT mutation T427M. **2005**, 252, 1543-5	11
1561	Novel G335V mutation in the tau gene associated with early onset familial frontotemporal dementia. **2005**, 6, 91-5	35
1560	Microtubule-associated protein tau is a substrate of ATP/Mg(2+)-dependent proteasome protease system. **2005**, 112, 547-55	60
1559	Post-translational modifications of tau protein in Alzheimer's disease. **2005**, 112, 813-38	322
1558	Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism. **2005**, 112, 1487-502	1
1557	Understanding and treating neurodegeneration: insights from the flies. **2005**, 27, 225-39	
1556	Genetics of Atypical Parkinsonism. **2005**, 139-154	1
1555	Neuropathology of Atypical Parkinsonian Disorders. **2005**, 33-63	5
1554	. **2005**,	8
1553	Selected genetically engineered models relevant to human neurodegenerative disease. **2005**, 176-195	1
1552	A genetic outline of the pathways to cell death in Alzheimer's disease, Parkinson's disease, frontal dementias and related disorders. **2005**, 222-226	
1551	Progressive supranuclear palsy. **2005**, 663-681	5
1550	Towards a Molecular Classification of Neurodegenerative Disease. **2005**, 11-23	
1549	Racial and Ethnic Influences on the Expression of the Genotype in Neurodegenerative Diseases. **2005**, 25-36	1
1548	Apoptotic effect of caspase-3 cleaved tau in hippocampal neurons and its potentiation by tau FTDP-mutation N279K. **2005**, 7, 3-13	54
1547	. **2005**,	1

1546	Frontotemporal dementia with parkinsonism linked to Chromosome 17. **2005**, 494-511	
1545	Approach to the patient presenting with parkinsonism. **2005**, 551-560	
1544	Chromosome 17-linked Frontotemporal dementia with Ubiquitin-Positive, Tau-Negative Inclusions. **2005**, 117-137	
1543	Tau-induced neurodegeneration: a clue to its mechanism. **2005**, 8, 223-6	5
1542	Pharmacological approaches of neurofibrillary degeneration. **2005**, 2, 335-41	26
1541	Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. **2005**, 42, 837-46	189
1540	Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease. **2005**, 11, 3363-82	49
1539	Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors. **2005**, 2, 231-8	65
1538	Differential recruitment of pre-mRNA splicing factors to alternatively spliced transcripts in vivo. **2005**, 3, e374	41
1537	Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. **2005**, 102, 15659-64	47
1536	Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39. **2005**, 280, 31522-9	33
1535	Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. **2005**, 25, 3539-50	136
1534	Three- and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners. Implications for neurodegeneration. **2005**, 280, 13520-8	73
1533	Transgenic C. elegans as a model in Alzheimer's research. **2005**, 2, 37-45	66
1532	A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. **2005**, 62, 1444-50	81
1531	Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. **2005**, 14, 1385-409	51
1530	Atypical Parkinsonian Disorders. **2005**, 111-138	1
1529	Neurodegeneration in heterozygous Niemann-Pick type C1 (NPC1) mouse: implication of heterozygous NPC1 mutations being a risk for tauopathy. **2005**, 280, 27296-302	32

1528	Modeling age-related diseases in Drosophila: can this fly?. **2005**, 71, 199-223	13
1527	Tau suppression in a neurodegenerative mouse model improves memory function. **2005**, 309, 476-81	1478
1526	Atypical Parkinsonian Disorders. **2005**,	10
1525	Tau exons 2 and 10, which are misregulated in neurodegenerative diseases, are partly regulated by silencers which bind a SRp30c.SRp55 complex that either recruits or antagonizes htra2beta1. **2005**, 280, 14230-9	59
1524	The role of RNA and RNA processing in neurodegeneration. **2005**, 25, 10372-5	42
1523	Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. **2005**, 102, 227-31	328
1522	Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. **2005**, 25, 6584-93	142
1521	Identification of novel murine- and human-specific RPGRIP1 splice variants with distinct expression profiles and subcellular localization. **2005**, 46, 1882-90	28
1520	Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. **2005**, 25, 5446-54	405
1519	SNP detection using peptide nucleic acid probes and conjugated polymers: applications in neurodegenerative disease identification. **2005**, 102, 34-9	166
1518	Presymptomatic semantic impairment in a case of fronto-temporal lobar degeneration associated with the +16 mutation in MAPT. **2005**, 11, 371-83	4
1517	Dementia in first-degree relatives of patients with frontotemporal dementia. A family history study. **2005**, 19, 145-53	9
1516	Mapping the onset and progression of atrophy in familial frontotemporal lobar degeneration. **2005** , 76, 162-8	28
1515	Neurogenetics II: complex disorders. **2005**, 76, 623-31	10
1514	Molecular and cellular pathways of neurodegeneration in motor neurone disease. **2005**, 76, 1046-57	209
1513	Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). **2005**, 25, 10637-47	454
1512	Emotional reactions to predictive testing in Alzheimer's disease and other inherited dementias. **2005**, 20, 233-8	29
1511	Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. **2005**, 280, 23802-14	289

1510	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. **2005**, 14, 3281-92	144
1509	The tau gene haplotype h1 confers a susceptibility to Parkinson's disease. **2005**, 53, 15-21	40
1508	Neurotransmitter Dysfunction and Neurotransmitter Replacement Therapy as Part of Frontotemporal Dementia Treatment. **2005**, 1, 345-351	0
1507	Disruption of the MAP1B-related protein FUTSCH leads to changes in the neuronal cytoskeleton, axonal transport defects, and progressive neurodegeneration in Drosophila. **2005**, 16, 2433-42	72
1506	The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. **2005**, 18, 163-73	32
1505	TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease. **2005**, 2, 28-35	20
1504	[11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. **2005**, 128, 896-905	79
1503	Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology. **2005**, 128, 2645-53	71
1502	Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer's disease pathology. **2005**, 11, 204-11	16
1501	Proteomic analysis of in vivo phosphorylated synaptic proteins. **2005**, 280, 5972-82	266
1500	The proteomics of neurodegeneration. **2005**, 5, 259-70	29
1499	Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. **2005**, 280, 7614-23	409
1498	Residual structure in the repeat domain of tau: echoes of microtubule binding and paired helical filament formation. **2005**, 44, 1026-36	94
1497	Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. **2005**, 128, 1247-58	583
1496	Quantitative analysis of tau isoform transcripts in sporadic tauopathies. **2005**, 137, 104-9	52
1495	Tau phosphorylation in Alzheimer's disease: pathogen or protector?. **2005**, 11, 164-9	184
1494	Alzheimer's disease: Abeta, tau and synaptic dysfunction. **2005**, 11, 170-6	331
1493	Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat. **2005**, 20, 64-73	32

1492	The architecture of the tau haplotype block in different ethnicities. **2005**, 377, 81-4	11
1491	DNA sequence variations in the prolyl isomerase Pin1 gene and Alzheimer's disease. **2005**, 389, 66-70	12
1490	Transcriptional and conformational changes of the tau molecule in Alzheimer's disease. **2005**, 1739, 150-7	53
1489	Pathways of tau fibrillization. **2005**, 1739, 167-78	86
1488	Tau phosphorylation: physiological and pathological consequences. **2005**, 1739, 280-97	289
1487	Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. **2005**, 1739, 331-54	154
1486	Can tau filaments be both physiologically beneficial and toxic?. **2005**, 1739, 260-7	11
1485	Tau protein as a differential biomarker of tauopathies. **2005**, 1739, 179-97	197
1484	Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. **2005**, 1739, 268-79	133
1483	Mutations causing neurodegenerative tauopathies. **2005**, 1739, 240-50	288
1482	Regulation of tau isoform expression and dementia. **2005**, 1739, 104-15	107
1481	Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. **2005**, 1739, 91-103	189
1480	Preface. **2005**, 1739, 89-90	
1479	Tau pathology in Alzheimer disease and other tauopathies. **2005**, 1739, 198-210	608
1478	Pinning down phosphorylated tau and tauopathies. **2005**, 1739, 311-22	49
1477	Phosphorylated tau and the neurodegenerative foldopathies. **2005**, 1739, 298-310	101
1476	Mice deficient in microtubule-associated protein MAP1B show a distinct behavioral phenotype and altered retina function. **2005**, 164, 188-96	10
1475	Alternative splicing of the human Kank gene produces two types of Kank protein. **2005**, 330, 1247-53	10

1474	The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. **2005**, 122, 633-44	164
1473	Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. **2005**, 192, 274-87	86
1472	Bilateral injection of isoproterenol into hippocampus induces Alzheimer-like hyperphosphorylation of tau and spatial memory deficit in rat. **2005**, 579, 251-8	30
1471	Regulation of tau exon 10 splicing by a double stem-loop structure in mouse intron 10. **2005**, 579, 241-4	2
1470	Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation. **2005**, 579, 1399-404	22
1469	Nitration and oligomerization of tau induced by peroxynitrite inhibit its microtubule-binding activity. **2005**, 579, 2421-7	33
1468	Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. **2005**, 579, 5704-12	45
1467	Rous-Whipple Award Lecture. The Alzheimer's brain: finding out what's broken tells us how to fix it. **2005**, 167, 1183-8	16
1466	Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. **2005**, 166, 521-31	94
1465	Functional Genomics meets neurodegenerative disorders. Part II: application and data integration. **2005**, 76, 169-88	36
1464	Transgenic models of Alzheimer's disease: learning from animals. **2005**, 2, 423-37	154
1463	New prospects and strategies for drug target discovery in neurodegenerative disorders. **2005**, 2, 627-37	10
1462	Role of the protein tau in Alzheimer's disease. **2005**, 2, 395-400	1
1461	Frequency of a tau genotype in amyotrophic lateral sclerosis. **2005**, 236, 13-6	6
1460	Alzheimer: 100 Years and Beyond. **2006**,	5
1459	Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. **2006**, 314, 130-3	4289
1458	Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. **2006**, 168, 1598-607	300
1457	Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation. **2006**, 169, 1365-75	55

1456	Frontotemporale Dementie. **2006**, 31, 50-55	
1455	Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. **2006**, 129, 868-76	319
1454	Mutations in Human Genetic Disease. **2006**,	2
1453	Characterization of two VQIXXK motifs for tau fibrillization in vitro. **2006**, 45, 15692-701	126
1452	Cell-cycle markers in a transgenic mouse model of human tauopathy: increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. **2006**, 168, 878-87	31
1451	Current strategies for the treatment of Alzheimer's disease and other tauopathies. **2006**, 10, 665-76	19
1450	Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms. **2006**, 45, 4314-26	41
1449	Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: genetic and bioinformatic assessment. **2006**, 200, 82-8	42
1448	Tau phosphorylation and aggregation in Alzheimer's disease pathology. **2006**, 580, 2922-7	182
1447	Genetics of familial and sporadic amyotrophic lateral sclerosis. **2006**, 1762, 956-72	179
1446	Biochemical investigation of Tau protein phosphorylation status and its solubility properties in Drosophila. **2006**, 346, 150-9	26
1445	Aberrantly regulated proteins in frontotemporal dementia. **2006**, 348, 465-72	15
1444	Folding of the repeat domain of tau upon binding to lipid surfaces. **2006**, 362, 312-26	49
1443	LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?. **2006**, 12, 76-82	78
1442	Correlation of tau gene polymorphism with age at onset of Parkinson's disease. **2006**, 405, 202-6	8
1441	No evidence of CRHR1 gene involvement in progressive supranuclear palsy. **2006**, 409, 61-4	2
1440	The effects of APOE and tau gene variability on risk of frontotemporal dementia. **2006**, 27, 702-9	50
1439	Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. **2006**, 27, 1258-68	96

1438	A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. **2006**, 51, 549-60	116
1437	A hundred years of Alzheimer's disease research. **2006**, 52, 3-13	365
1436	ALS: a disease of motor neurons and their nonneuronal neighbors. **2006**, 52, 39-59	1124
1435	Early Alzheimer's disease genetics. **2006**, 9, 367-72	4
1434	Immunological demonstration of tau protein in neurofibrillary tangles of Alzheimer's disease. **2006**, 9, 177-85	26
1433	Tau protein, the main component of paired helical filaments. **2006**, 9, 171-5	15
1432	Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. **2006**, 9, 257-62	48
1431	Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. **2006**, 9, 219-42	68
1430	. **2006**,	19
1429	References. **2006**, 453-566	
1428	Genetic complexity of Alzheimer's disease: successes and challenges. **2006**, 9, 381-7	46
1427	Mutations in the tau gene (MAPT) in FTDP-17: the family with Multiple System Tauopathy with Presenile Dementia (MSTD). **2006**, 9, 373-80	13
1426	Alzheimer's Disease. **2006**,	
1425	Amyotrophic Lateral Sclerosis. **2006**, 137-149	
1424	Dementia: What is it All About?. **2006**, 19, 433-40	1
1423	The application of microarray technology to neuropathology: cutting edge tool with clinical diagnostics potential or too much information?. **2006**, 65, 1031-9	8
1422	Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. **2006**, 129, 3115-23	162
1421	Atypical progressive supranuclear palsy with corticospinal tract degeneration. **2006**, 65, 396-405	110

1420 Progress in clinical neurosciences: Frontotemporal dementia-pick's disease. **2006**, 33, 141-8 17

1419 Genetically Engineered Mouse Models of Neurodegenerative Disorders. **2006**, 371-408

1418 Of mice and men: more neurobiology in dementia. **2006**, 19, 555-63 21

1417 Tangle diseases and the tau haplotypes. **2006**, 20, 60-2 6

1416 Chaperone Suppression of Aggregated Protein Toxicity. **2006**, 137-164 1

1415 Demência fronto-temporal: aspectos clínicos e terapêuticos. **2006**, 28, 69-76 1

1414 GSK-3, a Key Player in Alzheimer's Disease. 105-124

1413 Animal Models with Modified Expression of GSK-3 for the Study of Its Physiology and of Its Implications in Human Pathologies. 203-219

1412 Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. **2006**, 9, 1-12 106

1411 Tau protein, the paired helical filament and Alzheimer's disease. **2006**, 9, 195-207 148

1410 Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. **2006**, 1, 6 33

1409 Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau. **2006**, 1, 7 13

1408 Bad neighbors cause dementia; a second 17q21-linked gene responsible for frontotemporal dementia. **2006**, 70, 385-387

1407 Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. **2006**, 24, 3153-62 126

1406 Tauopathy: an overview. **2006**, 26, 455-6 2

1405 Neuropathology of familial tauopathy. **2006**, 26, 471-4 11

1404 Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. **2006**, 26, 457-70 86

1403 Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. **2006**, 36, 652-60 160

1402	The relationship between Lewy body disease, Parkinson's disease, and Alzheimer's disease. **2003**, 991, 167-70	14
1401	Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?. **2006**, 98, 993-1006	104
1400	Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. **2006**, 97, 1700-25	190
1399	Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope. **2006**, 99, 154-64	61
1398	Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. **2006**, 98, 1573-84	97
1397	Disease modifying therapy for AD?. **2006**, 99, 689-707	105
1396	Pathways to primary neurodegenerative disease. **2000**, 924, 29-34	14
1395	Transgenic mouse models of Alzheimer's disease. **2000**, 908, 260-6	68
1394	Classification and description of frontotemporal dementias. **2000**, 920, 46-51	55
1393	Progress in hereditary tauopathies: a mutation in the Tau gene (G389R) causes a Pick disease-like syndrome. **2000**, 920, 52-62	24
1392	Molecular genetics of chromosome 17 tauopathies. **2000**, 920, 63-73	65
1391	Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process. **2000**, 920, 74-83	45
1390	High frequency of mutations in four different disease genes in early-onset dementia. **2000**, 920, 100-6	17
1389	Coexistent tau and amyloid pathology in hereditary frontotemporal dementia with tau mutations. **2000**, 920, 115-9	17
1388	In vivo analysis of wild-type and FTDP-17 tau transgenic mice. **2000**, 920, 126-33	17
1387	Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. **2006**, 5, 369-79	81
1386	Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. **2006**, 32, 374-87	31
1385	A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism. **2006**, 38, 999-1001	355

1384	Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. **2006**, 38, 1032-7		302
1383	Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. **2006**, 12, 856-61		441
1382	Ageing and neuronal vulnerability. **2006**, 7, 278-94		728
1381	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature*, **2006**, 442, 916-9	50.4	1549
1380	Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature*, **2006**, 442, 920-4	50.4	1212
1379	Single cell gene expression profiling in Alzheimer's disease. **2006**, 3, 302-18		67
1378	A century of Alzheimer's disease. **2006**, 314, 777-81		1478
1377	Genes and the environment in neurodegeneration. **2006**, 26, 341-67		81
1376	Hereditary diffuse leukoencephalopathy with spheroids: clinical, pathologic and genetic studies of a new kindred. **2006**, 111, 300-11		76
1375	An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. **2006**, 111, 329-40		81
1374	No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. **2006**, 112, 439-49		33
1373	Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. **2006**, 63, 1538-52		74
1372	Frontotemporal dementia. **2006**, 6, 481-9		16
1371	C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. **2006**, 41, 1007-13		143
1370	TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. **2006**, 16, 230-41		214
1369	A decade of modeling Alzheimer's disease in transgenic mice. **2006**, 22, 281-9		241
1368	Frontotemporal dementia--a brief review. **2006**, 127, 180-7		19
1367	The H2 MAPT haplotype is associated with familial frontotemporal dementia. **2006**, 22, 357-62		27

1366	A MAPT mutation in a regulatory element upstream of exon 10 causes frontotemporal dementia. **2006**, 22, 401-3	36
1365	Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. **2006**, 6, 32	6
1364	Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. **2006**, 6, 44	61
1363	Modulation of neurosteroid production in human neuroblastoma cells by Alzheimer's disease key proteins. **2006**, 66, 868-81	36
1362	Myotonic dystrophy expanded CUG repeats disturb the expression and phosphorylation of tau in PC12 cells. **2006**, 84, 841-51	13
1361	Interface between tauopathies and synucleinopathies: a tale of two proteins. **2006**, 59, 449-58	204
1360	Frontotemporal dementia, chromosome 17, and progranulin. **2006**, 60, 275-7	9
1359	HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. **2006**, 60, 314-22	174
1358	Characteristics of frontotemporal dementia patients with a Progranulin mutation. **2006**, 60, 374-80	73
1357	Early frontotemporal dementia targets neurons unique to apes and humans. **2006**, 60, 660-7	244
1356	Characterization of ubiquitinated intraneuronal inclusions in a novel Belgian frontotemporal lobar degeneration family. **2006**, 65, 289-301	37
1355	Childhood onset in familial prion disease with a novel mutation in the PRNP gene. **2006**, 63, 1016-21	18
1354	A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. **2006**, 129, 853-67	96
1353	Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. **2006**, 129, 3103-14	99
1352	A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. **2006**, 129, 841-52	82
1351	Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. **2006**, 129, 3091-102	166
1350	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. **2006**, 129, 3081-90	259
1349	Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. **2006**, 129, 3051-65	132

1348	Mutations in progranulin explain atypical phenotypes with variants in MAPT. **2006**, 129, 3124-6	85
1347	Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. **2006**, 3, 421-30	111
1346	Untangling the tau gene association with neurodegenerative disorders. **2006**, 15 Spec No 2, R188-95	90
1345	Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic target. **2006**, 2006, 31825	45
1344	Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. **2006**, 15 Spec No 2, R182-7	71
1343	Gamma-secretase as a pharmacological target in Alzheimer disease research: when, why and how?. **2006**, 12, 4313-35	13
1342	Progranulin mutations in ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. **2006**, 3, 485-91	51
1341	SRp54 (SFRS11), a regulator for tau exon 10 alternative splicing identified by an expression cloning strategy. **2006**, 26, 6739-47	53
1340	Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. **2006**, 15, 1483-96	108
1339	RBM4 interacts with an intronic element and stimulates tau exon 10 inclusion. **2006**, 281, 24479-88	42
1338	c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis. **2006**, 20, 762-4	32
1337	Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. **2006**, 103, 8864-9	147
1336	A review of genome mutation and Alzheimer's disease. **2007**, 22, 15-33	41
1335	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. **2006**, 15, 2988-3001	463
1334	Haplotype-specific expression of exon 10 at the human MAPT locus. **2006**, 15, 3529-37	110
1333	Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. **2006**, 20, 1272-4	55
1332	Stabilization of the tau exon 10 stem loop alters pre-mRNA splicing. **2006**, 281, 23302-6	66
1331	Association of tau haplotype-tagging polymorphisms with Parkinson's disease in diverse ethnic Parkinson's disease cohorts. **2006**, 3, 327-33	32

1330	HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. **2006**, 20, 753-5	135
1329	Arginine/serine-rich protein interaction domain-dependent modulation of a tau exon 10 splicing enhancer: altered interactions and mechanisms for functionally antagonistic FTDP-17 mutations Delta280K AND N279K. **2006**, 281, 2460-9	35
1328	FTDP-17 mutations compromise the ability of tau to regulate microtubule dynamics in cells. **2006**, 281, 11856-63	69
1327	The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in males. **2006**, 77, 154-8	31
1326	Therapeutic approaches to Alzheimer's disease. **2006**, 129, 2840-55	257
1325	Alternatively Spliced Genes. **2006**,	
1324	Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. **2006**, 26, 6985-96	202
1323	Impaired glutamate transport in a mouse model of tau pathology in astrocytes. **2006**, 26, 644-54	91
1322	Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. **2006**, 13, 517-27	156
1321	An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. **2006**, 103, 9673-8	180
1320	Rapamycin alleviates toxicity of different aggregate-prone proteins. **2006**, 15, 433-42	551
1319	Activation of PAR-1 kinase and stimulation of tau phosphorylation by diverse signals require the tumor suppressor protein LKB1. **2007**, 27, 574-81	65
1318	Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. **2007**, 27, 6552-62	117
1317	Tau aggregation and toxicity in a cell culture model of tauopathy. **2007**, 282, 16454-64	96
1316	Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. **2007**, 27, 3650-62	389
1315	Identification of tau stem loop RNA stabilizers. **2007**, 12, 789-99	28
1314	Handbook of Consultation-Liaison Psychiatry. **2007**,	4
1313	Frontotemporal dementia with tau pathology. **2007**, 4, 236-53	57

1312	Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation. **2007**, 69, 140-7	70
1311	A 34-year-old man with progressive behavioral and language disturbance. **2007**, 68, 68-74	4
1310	The tau N279K exon 10 splicing mutation recapitulates frontotemporal dementia and parkinsonism linked to chromosome 17 tauopathy in a mouse model. **2007**, 27, 9155-68	58
1309	A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. **2007**, 130, 1360-74	105
1308	Corticobasal syndrome associated with the A9D Progranulin mutation. **2007**, 66, 892-900	75
1307	Familial early-onset dementia with tau intron 10 + 16 mutation with clinical features similar to those of Alzheimer disease. **2007**, 64, 1535-9	30
1306	Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia. **2007**, 164, 1577-84	21
1305	Frontotemporal dementia and mania. **2007**, 164, 1811-6	28
1304	Frontotemporal lobar degeneration with ubiquitin-positive inclusions: a molecular genetic update. **2007**, 4, 227-35	20
1303	Progranulin and tau gene mutations both as cause for dementia: 17q21 finally defined. **2007**, 64, 18-9	2
1302	Fibrillogenic nuclei composed of P301L mutant tau induce elongation of P301L tau but not wild-type tau. **2007**, 282, 20309-18	57
1301	Expression, localization and tau exon 10 splicing activity of the brain RNA-binding protein TNRC4. **2007**, 16, 2760-9	16
1300	Parkinsonism-Plus Syndromes and Secondary Parkinsonian Disorders. **2007**, 233-284	
1299	Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. **2007**, 6, 1509-16	16
1298	Genetic and Environmental Factors in Neurodegenerative Diseases. **2007**, 89-114	1
1297	Genetics of Parkinson's Disease. **2007**, 663-697	3
1296	TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. **2007**, 64, 1388-94	148
1295	SUT-1 enables tau-induced neurotoxicity in C. elegans. **2007**, 16, 1959-71	53

1294	.	
1293	Chapter 5 Frontotemporal Dementia Syndromes. **2007**, 112-140	1
1292	Chapter 7 Ubiquitinopathies. **2007**, 165-185	2
1291	Structure and Function of Cellular Components. 52-101	
1290	Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease. **2007**, 30, 1-32	
1289	The pathogenesis of Alzheimer's disease and the role of Abeta42. **2007**, 12, 4-6	14
1288	Mitochondrial Medicine: The Central Role of Cellular Energetic Depression and Mitochondria in Cell Pathophysiology. 479-520	3
1287	The genetics of frontotemporal lobar degeneration. **2007**, 20, 693-8	6
1286	Pick complex--historical introduction. **2007**, 21, S5-7	5
1285	14-3-3 proteins and protein phosphatases are not reduced in tau-deficient mice. **2007**, 18, 1049-52	26
1284	Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. **2007**, 21, 1-7	47
1283	Clinical features and survival of 3R and 4R tauopathies presenting as behavioral variant frontotemporal dementia. **2007**, 21, S39-43	20
1282	Frontotemporal dementia and semantic dementia: anatomic variations on the same disease or distinctive entities?. **2007**, 21, S19-22	6
1281	Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. **2007**, 21, S14-8	173
1280	Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. **2007**, 66, 142-51	150
1279	TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. **2007**, 66, 177-83	169
1278	The DeltaK280 mutation in MAP tau favors exon 10 skipping in vivo. **2007**, 66, 17-25	40
1277	A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. **2007**, 66, 884-91	106

1276	No association of chromatin-modifying protein 2B with sporadic frontotemporal dementia. **2007**, 28, 1789-90	14
1275	Pin1 in Alzheimer's disease: multiple substrates, one regulatory mechanism?. **2007**, 1772, 422-9	63
1274	The complex aetiology of frontotemporal lobar degeneration. **2007**, 206, 1-10	25
1273	[Frontotemporal dementia]. **2007**, 36, 1477-84	2
1272	SR protein 9G8 modulates splicing of tau exon 10 via its proximal downstream intron, a clustering region for frontotemporal dementia mutations. **2007**, 34, 48-58	49
1271	Abeta, tau and ApoE4 in Alzheimer's disease: the axonal connection. **2007**, 13, 135-42	55
1270	TDP-43 gene analysis in frontotemporal lobar degeneration. **2007**, 419, 1-4	40
1269	Appearance pattern of TDP-43 in Japanese frontotemporal lobar degeneration with ubiquitin-positive inclusions. **2007**, 419, 213-8	16
1268	Phosphorylation of human microtubule-associated protein tau by protein kinases of the AGC subfamily. **2007**, 581, 2657-62	19
1267	Genetics and dementia: risk factors, diagnosis, and management. **2007**, 3, 418-27	25
1266	Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. **2007**, 171, 976-92	99
1265	Clinical genetics of Parkinson's disease and related disorders. **2007**, 13 Suppl 3, S229-32	21
1264	Parkinson's Disease. **2007**,	1
1263	Abeta Peptide and Alzheimer Disease. **2007**,	1
1262	Pharmacological Mechanisms in Alzheimer's Therapeutics. **2007**,	1
1261	Alternative ion channel splicing in mesial temporal lobe epilepsy and Alzheimer's disease. **2007**, 8, R32	28
1260	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. **2007**, 12, 229-52	20
1259	Parkinsonism and dystonia. **2007**, 84, 507-29	1

1258	Other degenerative processes. **2007**, 84, 445-57	
1257	Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. **2007**, 16, 295-306	50
1256	Frontotemporal lobar degeneration. **2007**, 25, 683-96, vi	23
1255	Parkinson-related dementias. **2007**, 25, 761-81, vii	24
1254	The genetics of frontotemporal dementia. **2007**, 25, 697-715, vi	13
1253	Chapter 4 Molecular mechanisms of motor neuron degeneration in amyotrophic lateral sclerosis. **2007**, 82, 57-87	
1252	Structural and microtubule binding properties of tau mutants of frontotemporal dementias. **2007**, 46, 2574-82	48
1251	The clinical overlap between the corticobasal degeneration syndrome and other diseases of the frontotemporal spectrum: three case reports. **2007**, 18, 159-64	10
1250	Clinical Overview and Phenomenology of Movement Disorders. **2007**, 1-42	2
1249	. **2007**,	14
1248	References. 329-360	
1247	Molecular genetics of Alzheimer's disease and other adult-onset dementias. 439-453	
1246	Overview of frontotemporal dementia. 1-24	1
1245	The genetics of frontotemporal dementia. 257-276	
1244	The histopathology of frontotemporal dementia. 161-207	1
1243	Molecular neuropathology in familial and sporadic frontotemporal dementia. 208-256	
1242	Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. **2007**, 61, 446-53	67
1241	Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. **2007**, 62, 137-44	108

1240	Progranulin null mutations in both sporadic and familial frontotemporal dementia. **2007**, 28, 846-55	143
1239	Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. **2007**, 28, 416	91
1238	S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. **2007**, 85, 1271-8	89
1237	No evidence for association between tau gene haplotypic variants and susceptibility to Creutzfeldt-Jakob disease. **2007**, 8, 77	6
1236	Progranulin mutations in Dutch familial frontotemporal lobar degeneration. **2007**, 15, 369-74	48
1235	Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease. **2007**, 12, 510-7	53
1234	A decade of tau transgenic animal models and beyond. **2007**, 17, 91-103	131
1233	Hereditary frontotemporal dementia caused by Tau gene mutations. **2007**, 17, 63-73	158
1232	Structural principles of tau and the paired helical filaments of Alzheimer's disease. **2007**, 17, 83-90	179
1231	Progressive supranuclear palsy: pathology and genetics. **2007**, 17, 74-82	193
1230	Frontotemporal lobar degeneration: current concepts in the light of recent advances. **2007**, 17, 104-14	61
1229	Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress. **2007**, 33, 2-42	66
1228	Progranulin: normal function and role in neurodegeneration. **2008**, 104, 287-97	96
1227	A novel MAPT mutation (P301T) associated with familial frontotemporal dementia. **2007**, 14, e9-10	13
1226	The tau S305S mutation causes frontotemporal dementia with parkinsonism. **2008**, 15, 156-61	20
1225	Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. **2007**, 1184, 284-94	278
1224	Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. **2008**, 12, 38-55	164
1223	Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. **2007**, 114, 34-55	38

1222	The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. **2007**, 25, 561-70	206
1221	Functional MAPT haplotypes: bridging the gap between genotype and neuropathology. **2007**, 27, 1-10	52
1220	Genetic basis of frontotemporal dementia. **2007**, 6, 840-1	4
1219	Transgenic animal models of neurodegenerative diseases and their application to treatment development. **2007**, 59, 1093-102	72
1218	A simple algorithm locates beta-strands in the amyloid fibril core of alpha-synuclein, Abeta, and tau using the amino acid sequence alone. **2007**, 16, 906-18	90
1217	RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies. **2007**, 64, 1701-14	31
1216	Tauopathies. **2007**, 64, 2219-33	226
1215	Developing pharmacological therapies for Alzheimer disease. **2007**, 64, 2234-44	36
1214	Age-related changes in tau expression in transgenic mouse model of amyotrophic lateral sclerosis. **2007**, 32, 415-21	7
1213	Brain-specific aminopeptidase: from enkephalinase to protector against neurodegeneration. **2007**, 32, 2062-71	34
1212	Plaques, tangles, and memory loss in mouse models of neurodegeneration. **2007**, 37, 79-100	113
1211	Study of tauopathies by comparing Drosophila and human tau in Drosophila. **2007**, 329, 169-78	27
1210	Biochemical and pathological characterization of frontotemporal dementia due to a Leu266Val mutation in microtubule-associated protein tau in an African American individual. **2007**, 113, 471-9	9
1209	Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. **2007**, 113, 107-17	111
1208	Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. **2007**, 113, 601-6	45
1207	The novel Tau mutation G335S: clinical, neuropathological and molecular characterization. **2007**, 113, 461-70	31
1206	Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. **2007**, 114, 243-54	18
1205	Frontotemporal lobar degeneration: clinical and pathological relationships. **2007**, 114, 31-8	244

1204	Progranulin and frontotemporal lobar degeneration. **2007**, 114, 39-47	22
1203	Frontotemporal lobar degeneration--a coming of age. **2007**, 114, 1-4	2
1202	Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. **2007**, 114, 471-9	31
1201	Tauopathy models and human neuropathology: similarities and differences. **2008**, 115, 39-53	35
1200	The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. **2007**, 8, 237-48	62
1199	The genetics of frontotemporal lobar degeneration. **2007**, 7, 434-42	36
1198	[Molecular neuropathology of Non-Alzheimer dementia]. **2008**, 29, 434-41	2
1197	Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. **2008**, 86, 1255-67	98
1196	Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. **2008**, 9, 197-205	59
1195	MAPT S305I mutation: implications for argyrophilic grain disease. **2008**, 116, 103-18	44
1194	Novel microdeletion syndromes detected by chromosome microarrays. **2008**, 124, 1-17	180
1193	Tau exon 10 alternative splicing and tauopathies. **2008**, 3, 8	177
1192	The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. **2008**, 86, 1711-20	144
1191	Progranulin gene mutation with an unusual clinical and neuropathologic presentation. **2008**, 23, 1168-73	35
1190	Mutation analyses in amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula, Japan. **2008**, 23, 2344-8	23
1189	Tau isoform regulation is region- and cell-specific in mouse brain. **2008**, 511, 788-803	114
1188	Progranulin locus deletion in frontotemporal dementia. **2008**, 29, 53-8	75
1187	Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. **2008**, 29, 512-21	61

1186	Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update. **2008**, 29, 1373-86	116
1185	TDP-43 A315T mutation in familial motor neuron disease. **2008**, 63, 535-8	497
1184	Frontotemporal dementia and related disorders: deciphering the enigma. **2008**, 64, 4-14	146
1183	Tau-based treatment strategies in neurodegenerative diseases. **2008**, 5, 443-57	109
1182	Viral Vectors: A Potent Approach to Generate Genetic Models of Parkinson's Disease. **2008**, 269-284	
1181	Conditionally inducible tau mice--designing a better mouse model of neurodegenerative diseases. **2008**, 7 Suppl 1, 12-27	13
1180	Neurogenesis and cell cycle-reactivated neuronal death during pathogenic tau aggregation. **2008**, 7 Suppl 1, 92-100	36
1179	Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2. **2008**, 275, 5748-57	25
1178	Animal models of Alzheimer's disease and frontotemporal dementia. **2008**, 9, 532-44	535
1177	13th Congress of the International Psychogeriatric Association and recent expansion of research into psychogeriatrics. **2008**, 8, 1-3	3
1176	Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. **2008**, 15, 377-85	58
1175	Parkin mediates the degradation-independent ubiquitination of Hsp70. **2008**, 105, 1806-19	81
1174	Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states. **2008**, 27, 1615-25	41
1173	Frontotemporal dementia and Parkinsonism linked to chromosome 17 in a young Australian patient with the G389R Tau mutation. **2008**, 34, 366-70	15
1172	Lentivirus Tau (P301S) expression in adult amyloid precursor protein (APP)-transgenic mice leads to tangle formation. **2008**, 34, 523-31	12
1171	A general modeling and visualization tool for comparing different members of a group: application to studying tau-mediated regulation of microtubule dynamics. **2008**, 9, 339	1
1170	Comparative analysis of sequence features involved in the recognition of tandem splice sites. **2008**, 9, 202	9
1169	Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. **2008**, 9 Suppl 2, S10	29

1168	Role of MAPT mutations and haplotype in frontotemporal lobar degeneration in Northern Finland. **2008**, 8, 48	33
1167	Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene]. **2008**, 582, 901-6	33
1166	Inflammation, genes and zinc in Alzheimer's disease. **2008**, 58, 96-105	88
1165	Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. **2008**, 7, 965-74	179
1164	Loss of progranulin function in frontotemporal lobar degeneration. **2008**, 24, 186-94	101
1163	The molecular pathology of Alzheimer□ disease. **2008**, 7, 1-5	18
1162	Etiology and pathophysiology of frontotemporal dementia, Parkinson disease and Alzheimer disease: lessons from genetic studies. **2008**, 5, 122-5	27
1161	Motor alterations are reduced in mice lacking the PARK2 gene in the presence of a human FTDP-17 mutant form of four-repeat tau. **2008**, 275, 139-44	3
1160	Mutations in progranulin gene: clinical, pathological, and ribonucleic acid expression findings. **2008**, 63, 946-52	58
1159	Genetics of Parkinson's Disease. **2008**, 9-33	0
1158	Advances in Alzheimer□ and Parkinson□ Disease. **2008**,	
1157	Protein Folding and Aggregation in in vitro Models of Parkinson's Disease. **2008**, 575-595	11
1156	Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. **2008**, 82, 834-48	379
1155	A novel deletion in progranulin gene is associated with FTDP-17 and CBS. **2008**, 29, 427-35	94
1154	Haplotype-specific expression of the N-terminal exons 2 and 3 at the human MAPT locus. **2008**, 29, 1923-9	70
1153	Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. **2008**, 60, 534-42	402
1152	[New chromosomal syndromes]. **2008**, 56, 380-7	3
1151	Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. **2008**, 85, 94-134	376

1150	Microtubule-associated protein tau in development, degeneration and protection of neurons. **2008**, 85, 148-75	295
1149	The aging brain. **2008**, 3, 41-66	425
1148	A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. **2008**, 212, 71-84	66
1147	Memory and exploratory impairment in mice that lack the Park-2 gene and that over-express the human FTDP-17 mutant Tau. **2008**, 189, 350-6	9
1146	The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. **2008**, 27, 336-49	279
1145	Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. **2008**, 89, 245-60	100
1144	Tau, a biological marker of neurodegenerative diseases. **2008**, 89, 161-72	3
1143	Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. **2008**, 172, 123-31	95
1142	Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. **2008**, 173, 762-72	49
1141	Eyes on the prize: federal Alzheimer's research effort aims to facilitate interventions. **2008**, 4, S37-47	6
1140	TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander. **2008**, 19, 299-305	61
1139	The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. **2008**, 9, 323-38	101
1138	Genetica della sclerosi laterale amiotrofica. **2008**, 8, 1-8	
1137	TDP-43 in neurodegenerative disorders. **2008**, 8, 969-78	31
1136	Progressive anomia revisited: focal degeneration associated with progranulin gene mutation. **2007**, 13, 366-77	12
1135	Genetics of progressive supranuclear palsy. **2008**, 89, 475-85	
1134	Targeting angiogenin in therapy of amyotropic lateral sclerosis. **2008**, 12, 1229-42	32
1133	Frontotemporal lobar degeneration: clinical and pathologic overview. **2008**, 89, 343-64	7

1132	Clinical aspects of hereditary frontotemporal dementia. **2008**, 89, 365-76	
1131	Epidemiological aspects of frontotemporal dementia. **2008**, 89, 331-41	5
1130	CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. **2008**, 17, 313-22	112
1129	Association, expression, pathobiology: is too much tau in PD a blueprint for genetic association?. **2008**, 71, 11-2	
1128	Distinct genetic forms of frontotemporal dementia. **2008**, 71, 1220-6	160
1127	CNV and nervous system diseases--what's new?. **2008**, 123, 54-64	31
1126	Tau isoform expression and regulation in human cortical neurons. **2008**, 22, 2357-67	29
1125	The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. **2008**, 131, 72-89	76
1124	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. **2008**, 131, 706-20	198
1123	Preliminary evidence that VEGF genetic variability confers susceptibility to frontotemporal lobar degeneration. **2008**, 11, 773-80	22
1122	Molecular genetics of Alzheimer's disease: an update. **2008**, 40, 562-83	175
1121	Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. **2008**, 283, 1744-1753	135
1120	FTDP-17 mutations in Tau alter the regulation of microtubule dynamics: an "alternative core" model for normal and pathological Tau action. **2008**, 283, 36406-15	30
1119	Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview. **2007**, 1-24	5
1118	Caenorhabditis elegans Models of Human Neurodegenerative Diseases. **2008**, 91-101	0
1117	Parkin deletion causes cerebral and systemic amyloidosis in human mutated tau over-expressing mice. **2008**, 17, 3128-43	32
1116	The genetics of frontotemporal dementia. **2008**, 89, 383-92	2
1115	Biological models in frontotemporal dementias. **2008**, 89, 449-55	

1114	Invited article: the Alzheimer disease-frontotemporal lobar degeneration spectrum. **2008**, 71, 1191-7	54
1113	Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci?. **2008**, 70, 686-94	36
1112	Biologic models of neurodegenerative disorders. **2008**, 89, 173-88	3
1111	Biological transgenic mouse models of Alzheimer's disease. **2008**, 89, 291-301	2
1110	CSF biomarkers in frontotemporal lobar degeneration with known pathology. **2008**, 70, 1827-35	165
1109	Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. **2008**, 5, 375-84	102
1108	Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases. **2008**, 17, 376-90	65
1107	Patient care and management of frontotemporal lobar degeneration. **2008**, 23, 125-31	13
1106	Neuropathology of hereditary forms of frontotemporal dementia and parkinsonism. **2008**, 89, 393-414	9
1105	Is the glass half empty or half full? Genetically determined disease in frontotemporal dementia. **2008**, 71, 1216-7	2
1104	Monitoring tau-tubulin interactions utilizing second harmonic generation in living neurons. **2008**, 13, 064039	23
1103	Clinical presentation of prodromal frontotemporal dementia. **2007**, 22, 456-67	16
1102	The quest for a message: budding yeast, a model organism to study the control of pre-mRNA splicing. **2009**, 8, 60-7	14
1101	Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. **2008**, 283, 28660-9	108
1100	New genes, new dilemmas: FTLD genetics and its implications for families. **2007**, 22, 507-15	19
1099	Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). **2008**, 65, 460-4	140
1098	Amyotrophic lateral sclerosis from bench to bedside. **2008**, 28, 205-11	28
1097	Complementary dimerization of microtubule-associated tau protein: Implications for microtubule bundling and tau-mediated pathogenesis. **2008**, 105, 7445-50	114

1096	Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. **2008**, 131, 721-31	163
1095	Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. **2008**, 131, 732-46	275
1094	Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. **2008**, 12, 1367-76	7
1093	In vivo and postmortem clinicoanatomical correlations in frontotemporal dementia and parkinsonism linked to chromosome 17. **2008**, 5, 215-7	24
1092	A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. **2008**, 105, 6439-44	317
1091	Clinical and molecular delineation of the 17q21.31 microdeletion syndrome. **2008**, 45, 710-20	156
1090	Brain magnetic resonance imaging structural changes in a pedigree of asymptomatic progranulin mutation carriers. **2008**, 11, 585-95	75
1089	Ghtique de la sclfose latfale amyotrophique. **2008**, 5, 1-8	1
1088	Role of transition metals in the pathogenesis of amyotrophic lateral sclerosis. **2008**, 36, 1322-8	23
1087	The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. **2008**, 15, 685-707	136
1086	Modeling Tauopathy in the fruit fly Drosophila melanogaster. **2008**, 15, 541-53	28
1085	Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. **2008**, 67, 280-98	71
1084	Update on recent molecular and genetic advances in frontotemporal lobar degeneration. **2008**, 67, 635-48	26
1083	White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. **2008**, 67, 963-75	95
1082	Selective functional, regional, and neuronal vulnerability in frontotemporal dementia. **2008**, 21, 701-7	166
1081	New approaches to the treatment of frontotemporal lobar degeneration. **2008**, 21, 708-16	44
1080	Genetic assessment and management of dementia. **2008**, 8, 618-21	0
1079	Tau aggregates: toxic, inert, or protective species?. **2008**, 14, 431-6	73

1078	Neurodegenerative disorders. 39-89	0
1077	Frontotemporal dementia: a topical review. **2008**, 21, 127-33	13
1076	The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. **2008**, 21, 693-700	91
1075	Park2-null/tau transgenic mice reveal a functional relationship between parkin and tau. **2008**, 13, 161-72	14
1074	Inflammation in neurodegenerative disorders: friend or foe?. **2008**, 1, 30-41	30
1073	Risk factors for dementia of Alzheimer type and aging-associated cognitive decline in a Spanish population based sample, and in brains with pathology confirmed Alzheimer's disease. **2008**, 14, 179-91	4
1072	Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly. **2008**, 14, 365-70	58
1071	[Dysfunction of axonal transport in neuropathies and motor neuron diseases]. **2008**, 24, 65-71	0
1070	An update on the toxicity of Abeta in Alzheimer's disease. **2008**, 4, 1033-42	28
1069	Differential incorporation of tau isoforms in Alzheimer's disease. **2008**, 14, 1-16	87
1068	Molecular pathogenesis of frontotemporal lobar degeneration: basic science seminar in neurology. **2008**, 65, 700-4	2
1067	Tau pathology and neurodegeneration: an obvious but misunderstood link. **2008**, 14, 437-40	14
1066	Neurogenetics of dementia. 27-44	
1065	Novel Pharmacotherapies for Alzheimer's Disease. **2009**, 52, 1059	9
1064	Exonic point mutations of human tau enhance its toxicity and cause characteristic changes in neuronal morphology, tau distribution and tau phosphorylation in the lamprey cellular model of tauopathy. **2009**, 16, 99-111	13
1063	AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. **2009**, 4, e7280	64
1062	Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. **2009**, 4, e7917	137
1061	The tau code. **2009**, 1, 1	16

1060	Neuropathology of dementia. 142-160	2
1059	Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects. **2009**, 29, 5758-67	78
1058	The molecular basis of frontotemporal dementia. **2009**, 11, e23	57
1057	Tau mutations in neurodegenerative diseases. **2009**, 284, 6021-5	124
1056	Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro. **2009**, 284, 13422-13433	35
1055	Propagation of tau misfolding from the outside to the inside of a cell. **2009**, 284, 12845-52	806
1054	Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau. **2009**, 284, 16840-16847	18
1053	Conformational diversity of wild-type Tau fibrils specified by templated conformation change. **2009**, 284, 3546-51	162
1052	Translation initiation of the human tau mRNA through an internal ribosomal entry site. **2009**, 16, 271-5	11
1051	Absence of TARDBP gene mutations in an italian series of patients with frontotemporal lobar degeneration. **2009**, 28, 239-43	8
1050	Cortical atrophy and language network reorganization associated with a novel progranulin mutation. **2009**, 19, 1751-60	42
1049	Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis. **2009**, 18, 956-65	59
1048	SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans. **2009**, 18, 1825-38	74
1047	Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing. **2009**, 18, 3266-73	43
1046	Genetic association analysis between TDP-43 polymorphisms and Alzheimer's disease in a Japanese population. **2009**, 28, 325-9	6
1045	No evidence of PGRN or MAPT gene dosage alterations in a collection of patients with frontotemporal lobar degeneration. **2009**, 28, 471-5	6
1044	Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. **2009**, 29, 10741-9	236
1043	Clinical features and diagnosis of frontotemporal dementia. **2009**, 24, 140-148	10

1042	A schizophrenia gene locus on chromosome 17q21 in a new set of families of Mexican and central american ancestry: evidence from the NIMH Genetics of schizophrenia in latino populations study. **2009**, 166, 442-9	29
1041	Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. **2009**, 132, 583-91	315
1040	Genetic screen identifies serpin5 as a regulator of the toll pathway and CHMP2B toxicity associated with frontotemporal dementia. **2009**, 106, 12168-73	66
1039	Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. **2009**, 9, 255-72	86
1038	Physiological transgene regulation and functional complementation of a neurological disease gene deficiency in neurons. **2009**, 17, 1517-26	16
1037	Autosomal dominant subcortical gliosis presenting as frontotemporal dementia. **2009**, 72, 260-7	12
1036	Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN. **2009**, 72, 813-20	108
1035	Abnormal hippocampal distribution of TDP-43 in patients with-late onset psychosis. **2009**, 43, 739-45	19
1034	Neuronal migration and neurodegeneration: 2 sides of the same coin. **2009**, 19 Suppl 1, i42-8	13
1033	Modulation of alternative splicing by long-range RNA structures in Drosophila. **2009**, 37, 4533-44	54
1032	Accumulation of tau induced in neurites by microglial proinflammatory mediators. **2009**, 23, 2502-13	103
1031	Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. **2009**, 18, 3725-38	31
1030	Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations. **2009**, 73, 1058-65	57
1029	Inhibition of autophagy induction delays neuronal cell loss caused by dysfunctional ESCRT-III in frontotemporal dementia. **2009**, 29, 8506-11	100
1028	Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. **2009**, 667, 82-97	186
1027	Resolving deconvolution ambiguity in gene alternative splicing. **2009**, 10, 237	5
1026	Chaperone signalling complexes in Alzheimer's disease. **2009**, 13, 619-30	96
1025	Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology. **2009**, 13, 2787-99	40

1024	Serum biomarker for progranulin-associated frontotemporal lobar degeneration. **2009**, 65, 603-9	185
1023	Intention tremor in essential tremor: Prevalence and association with disease duration. **2009**, 24, 626-7	86
1022	Increase in the tactile catchment area of a sensory trick for alleviating blepharospasm following pallidal DBS. **2009**, 24, 624-6	3
1021	Pseudohypoparathyroidism manifesting with paroxysmal dyskinesias and seizures. **2009**, 24, 623-4	16
1020	Hiccups associated with levodopa in Parkinson's disease. **2009**, 24, 621-22	25
1019	Recurrent hemichorea following a single infarction in the contralateral subthalamic nucleus. **2009**, 24, 617-8	14
1018	Parkinsonism and impulse control disorder: presentation of a new progranulin gene mutation. **2009** , 24, 618-9	16
1017	Drug hoarding: a case of atypical dopamine dysregulation syndrome in a RLS patient. **2009**, 24, 627-8	25
1016	Tramadol hydrochloride use and acute deterioration in Parkinson's disease tremor. **2009**, 24, 622-3	5
1015	Reported mutations in GIGYF2 are not a common cause of Parkinson's disease. **2009**, 24, 619-20	24
1014	Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation. **2009**, 10, 27-34	13
1013	Whole-genome conditional two-locus analysis identifies novel candidate genes for late-onset Parkinson's disease. **2009**, 10, 173-81	10
1012	Recent origin and spread of a common Welsh MAPT splice mutation causing frontotemporal lobar degeneration. **2009**, 10, 313-8	10
1011	Recent advances in using Drosophila to model neurodegenerative diseases. **2009**, 14, 1008-20	26
1010	Hyperphosphorylated tau aggregates in the cortex and hippocampus of transgenic mice with mutant human FTDP-17 Tau and lacking the PARK2 gene. **2009**, 117, 159-68	10
1009	Mechanisms of tau-induced neurodegeneration. **2009**, 118, 53-69	490
1008	New age of neuroproteomics in Alzheimer's disease research. **2009**, 29, 799-805	17
1007	Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein. **2009**, 37, 25-36	17

1006	Versatile somatic gene transfer for modeling neurodegenerative diseases. **2009**, 16, 329-42	10
1005	The role of tau in neurodegeneration. **2009**, 4, 13	269
1004	What have worm models told us about the mechanisms of neuronal dysfunction in human neurodegenerative diseases?. **2009**, 4, 38	52
1003	Transmission and spreading of tauopathy in transgenic mouse brain. **2009**, 11, 909-13	1196
1002	Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. **2009**, 41, 1303-7	1045
1001	Evidence for a common pathway linking neurodegenerative diseases. **2009**, 41, 1261-2	36
1000	Genetics of motor neuron disorders: new insights into pathogenic mechanisms. **2009**, 10, 769-82	226
999	Genetic testing in familial AD and FTD: mutation and phenotype spectrum in a Danish cohort. **2009**, 76, 205-9	19
998	What is 'early onset dementia'?. **2009**, 9, 67-72	21
997	Involvement of puromycin-sensitive aminopeptidase in proteolysis of tau protein in cultured cells, and attenuated proteolysis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) mutant tau. **2009**, 9, 157-66	11
996	Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies. **2009**, 108, 1167-76	61
995	The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. **2009**, 110, 1129-34	585
994	Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. **2009**, 110, 1339-51	147
993	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. **2009**, 16, 297-309	143
992	Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by novantrone (mitoxantrone). **2009**, 16, 557-66	69
991	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. **2009**, 132, 2932-46	223
990	The Hygiene Hypothesis and Darwinian Medicine. **2009**,	17
989	Protein Folding and Misfolding: Neurodegenerative Diseases. **2009**,	5

988	Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA. **2009**, 52, 6523-6	44
987	Frontotemporal lobar degeneration insights from neuropsychology and neuroimaging. **2009**, 84, 185-213	3
986	Genetic susceptibility in Parkinson's disease. **2009**, 1792, 597-603	30
985	Tau pathophysiology in neurodegeneration: a tangled issue. **2009**, 32, 150-9	243
984	Knock-out and transgenic mouse models of tauopathies. **2009**, 30, 1-13	81
983	No association of TDP-43 with sporadic frontotemporal dementia. **2009**, 30, 157-9	29
982	No association of common VCP variants with sporadic frontotemporal dementia. **2009**, 30, 333-5	3
981	Clinical and pathological features of an Alzheimer's disease patient with the MAPT Delta K280 mutation. **2009**, 30, 388-93	45
980	Prominent phenotypic variability associated with mutations in Progranulin. **2009**, 30, 739-51	150
979	Association of MAPT haplotype-tagging SNPs with sporadic Parkinson's disease. **2009**, 30, 1477-82	44
978	Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. **2009**, 30, 1825-33	36
977	Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. **2009**, 30, 656-65	29
976	From 1997 to 2007: a decade journey through the H1 haplotype on 17q21 chromosome. **2009**, 15, 2-5	13
975	Expression QTL and regulatory network analysis of microtubule-associated protein tau gene. **2009**, 15, 525-31	6
974	FTDP-17 missense mutations site-specifically inhibit as well as promote dephosphorylation of microtubule-associated protein tau by protein phosphatases of HEK-293 cell extract. **2009**, 54, 14-27	7
973	The +347 C promoter allele up-regulates MAPT expression and is associated with Alzheimer's disease among the Chinese Han. **2009**, 450, 340-3	12
972	Human microtubule-associated-protein tau regulates the number of protofilaments in microtubules: a synchrotron x-ray scattering study. **2009**, 97, 519-27	64
971	Intrafamilial clinical phenotypic heterogeneity with MAPT gene splice site IVS10+16C>T mutation. **2009**, 287, 253-6	18

970	[Parkinson disease and amyotrophic lateral sclerosis. Tauopathies, TDP-43 and SOD mutations]. **2009**, 165, 15-30	3
969	Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. **2009**, 2, 30	101
968	Drosophila models of neurodegenerative diseases. **2009**, 4, 315-42	157
967	Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. **2009**, 106, 7607-12	433
966	Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. **2009**, 194, 298-305	133
965	Inhibition of autophagy causes tau proteolysis by activating calpain in rat brain. **2009**, 16, 39-47	29
964	Ca2+/calmodulin-dependent protein kinase II mediates apoptosis of P19 cells expressing human tau during neural differentiation with retinoic acid treatment. **2009**, 24, 365-71	8
963	Progressive language impairments: Definitions, diagnoses, and prognoses. **2009**, 23, 302-326	11
962	Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. **2009**, 174, 228-38	65
961	Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration. **2009**, 175, 1598-609	48
960	Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. **2009**, 15 Suppl 3, S143-7	67
959	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. **2009**, 132, 2958-69	701
958	Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. **2009**, 10, 131-46	391
957	Neurobiology of cognitive disorders. **2009**, 22, 546-51	20
956	Frontotemporal dementia. 45-55	
955	Animal models of dementia. 131-141	
954	Early clinical features of the parkinsonian-related dementias. 197-212	2
953	The role of CHMP2B in frontotemporal dementia. **2009**, 37, 208-12	52

952	Parkinson's Disease: Genomic Perspectives. **2009**, 1233-1242	
951	Increased association between rough endoplasmic reticulum membranes and mitochondria in transgenic mice that express P301L tau. **2009**, 68, 503-14	47
950	Tau, neurodegeneration and Alzheimer's disease. **2010**, 7, 653-5	2
949	Frontotemporal degeneration. **2010**, 16, 191-211	7
948	Update on frontotemporal dementia. **2010**, 16, 16-22	40
947	Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future. **2010**, 5, 411-420	1
946	Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. **2010**, 67, 171-7	51
945	Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. **2010**, 38, 962-6	47
944	The role of MSUT-2 in tau neurotoxicity: a target for neuroprotection in tauopathy?. **2010**, 38, 973-6	11
943	Non-amyloid Approaches To Alzheimer's Disease. **2010**, 405-446	
942	Brain tau isoform mRNA and protein correlation in PSP brain. **2010**, 1,	3
941	Pathways linking Abeta and tau pathologies. **2010**, 38, 993-5	74
940	Familial Alzheimer's disease mutations in presenilins: effects on endoplasmic reticulum calcium homeostasis and correlation with clinical phenotypes. **2010**, 21, 781-93	61
939	Contemporary approaches to Alzheimer's disease and frontotemporal dementia. **2011**, 670, 1-9	7
938	Sporadic corticobasal syndrome due to FTLD-TDP. **2010**, 119, 365-74	46
937	Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. **2010**, 119, 409-19	240
936	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. **2010**, 120, 33-41	198
935	Transgenic zebrafish models of neurodegenerative diseases. **2010**, 214, 285-302	74

934	Neurodegenerative dementia and parkinsonism. **2010**, 14, 37-44	4
933	Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. **2010**, 1, 305-16	6
932	Frontotemporal dementia and primary progressive aphasia: an update. **2010**, 10, 504-11	14
931	Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. **2010**, 37, 294-306	76
930	Alzheimer's disease and tauopathy studies in flies and worms. **2010**, 40, 21-8	30
929	Neurodegenerative disorders: insights from the nematode Caenorhabditis elegans. **2010**, 40, 4-11	69
928	Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. **2010**, 39, 423-38	235
927	Genetic zebrafish models of neurodegenerative diseases. **2010**, 40, 58-65	87
926	Alzheimer's disease: insights from Drosophila melanogaster models. **2010**, 35, 228-35	88
925	Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy. **2010**, 1347, 111-24	7
924	A thorough assessment of benign genetic variability in GRN and MAPT. **2010**, 31, E1126-40	21
923	Non-apoptotic cell death in Caenorhabditis elegans. **2010**, 239, 1337-51	18
922	Current and Future Therapies for Alzheimer Disease. **2010**, 711-774	
921	Deletion of tau attenuates heat shock-induced injury in cultured cortical neurons. **2010**, 88, 102-10	17
920	Transgenic mouse and cell culture models demonstrate a lack of mechanistic connection between endoplasmic reticulum stress and tau dysfunction. **2010**, 88, 1951-61	16
919	Amyloid accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double-transgenic mouse model. **2010**, 88, 3547-54	21
918	Clinical implications of gene discovery in Parkinson's disease and parkinsonism. **2010**, 25 Suppl 1, S15-20	14
917	Association of the MAPT locus with Parkinson's disease. **2010**, 17, 483-6	41

916	Mutations in CHMP2B are not a cause of frontotemporal lobar degeneration in Finnish patients. **2010**, 17, 1393-5	11
915	Pathogenic cysteine mutations affect progranulin function and production of mature granulins. **2010**, 112, 1305-15	68
914	Hypoxic ischemia and proteasome dysfunction alter tau isoform ratio by inhibiting exon 10 splicing. **2010**, 114, 160-70	10
913	Review: Recent progress in frontotemporal lobar degeneration. **2010**, 36, 4-16	6
912	A threonine to isoleucine missense mutation in the pericentriolar material 1 gene is strongly associated with schizophrenia. **2010**, 15, 615-28	45
911	Deciphering genetic susceptibility to frontotemporal lobar dementia. **2010**, 42, 189-90	7
910	Open chromatin and diabetes risk. **2010**, 42, 190-2	9
909	Alzheimer's disease: strategies for disease modification. **2010**, 9, 387-98	808
908	Mendelian disorders and multifactorial traits: the big divide or one for all?. **2010**, 11, 380-4	60
907	H2 haplotype at chromosome 17q21.31 protects against childhood sexual abuse-associated risk for alcohol consumption and dependence. **2010**, 15, 1-11	57
906	Frontotemporal Dementia. **2010**, 428-432	
905	The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases. **2010**, 1, 15	10
904	A tangled web - tau and sporadic Parkinson's disease. **2010**, 1, 150	20
903	Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. **2010**, 6, e1001087	118
902	MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. **2010**, 5, e10551	68
901	Human stem cell-derived neurons: a system to study human tau function and dysfunction. **2010**, 5, e13947	23
900	Three repeat isoforms of tau inhibit assembly of four repeat tau filaments. **2010**, 5, e10810	68
899	[Induction and spreading of tau pathology in a mouse model of Alzheimer's disease]. **2010**, 26, 121-4	9

898	Differential effects of sumoylation on transcription and alternative splicing by transcription elongation regulator 1 (TCERG1). **2010**, 285, 15220-15233	21
897	Error in Figure in: Cellular Mechanisms of Central Nervous System Repair by Natural Autoreactive Monoclonal Antibodies. **2010**, 67, 147	
896	Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects. **2010**, 183, 3-20	16
895	Progress on progranulin. **2010**, 67, 145-7	3
894	Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies. **2010**, 19, 4399-408	53
893	Genetic causes of frontotemporal degeneration. **2010**, 23, 260-8	20
892	Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings. **2010**, 24, 303-7	23
891	Cell-mediated neuroprotection in a mouse model of human tauopathy. **2010**, 30, 9973-83	76
890	Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. **2010**, 285, 30851-60	135
889	Three- and four-repeat Tau coassemble into heterogeneous filaments: an implication for Alzheimer disease. **2010**, 285, 37920-6	51
888	Tau and neurodegenerative disorders. **2010**, 1, 131-45	3
887	Evolution of alternative splicing in primate brain transcriptomes. **2010**, 19, 2958-73	39
886	Glial fibrillary tangles and JAK/STAT-mediated glial and neuronal cell death in a Drosophila model of glial tauopathy. **2010**, 30, 16102-13	56
885	Mouse models of neurodegenerative diseases: criteria and general methodology. **2010**, 602, 323-45	18
884	TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. **2010**, 13, 509-17	65
883	Progranulin (GRN) in two siblings of a Latino family and in other patients with schizophrenia. **2010**, 16, 273-9	30
882	Reimagining Alzheimer's disease--an age-based hypothesis. **2010**, 30, 16755-62	267
881	Hsc70 rapidly engages tau after microtubule destabilization. **2010**, 285, 16798-805	61

880	The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. **2010**, 24, 4420-32	68
879	Genetics of frontotemporal lobar degeneration. **2010**, 13, S55-62	3
878	MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology. **2010**, 75, 771-8	40
877	Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. **2010**, 6, e1001026	105
876	Cancer and neurodegeneration: between the devil and the deep blue sea. **2010**, 6, e1001257	106
875	Frontotemporal dementias: Recent advances and current controversies. **2010**, 13, S74-80	12
874	Vulnerabilities in the tau network and the role of ultrasensitive points in tau pathophysiology. **2010** , 6, e1000997	12
873	Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. **2010**, 90, 465-94	325
872	Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. **2010**, 16, 2790-8	71
871	Disentangling the role of the tau gene locus in sporadic tauopathies. **2010**, 7, 726-34	35
870	Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease. **2010**, 7, 708-16	55
869	New insights into biological markers of frontotemporal lobar degeneration spectrum. **2010**, 17, 1002-9	12
868	Tau in Alzheimer disease and related tauopathies. **2010**, 7, 656-64	587
867	Tau pathology and future therapeutics. **2010**, 7, 685-96	34
866	Alterations of brain and cerebellar proteomes linked to A and tau pathology in a female triple-transgenic murine model of Alzheimer's disease. **2010**, 1, e90	41
865	Hypothermia and Alzheimer's disease neuropathogenic pathways. **2010**, 7, 717-25	25
864	Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers. **2010**, 133, 3685-98	80
863	Tau levels do not influence human ALS or motor neuron degeneration in the SOD1G93A mouse. **2010**, 74, 1687-93	16

862	Targeting tau protein in Alzheimer's disease. **2010**, 27, 351-65	60
861	Frontotemporal Dementia. **2010**, 34, 397-416	
860	Corticobasal Ganglionic Degeneration. **2010**, 375-396	1
859	Progressive Supranuclear Palsy. **2010**, 361-374	1
858	The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). **2010**, 288, 1-12	137
857	Frontotemporal lobar degeneration with motor neuron disease showing severe and circumscribed atrophy of anterior temporal lobes. **2010**, 297, 92-6	7
856	Role of epigenetics in Alzheimer's and Parkinson's disease. **2010**, 2, 671-82	84
855	Fractal growth of PAMAM dendrimer aggregates and its impact on the intrinsic emission properties. **2010**, 114, 7735-42	46
854	Human Gene Mutation: Mechanisms and Consequences. **2010**, 319-363	5
853	SJLB mice develop tauopathy-induced parkinsonism. **2010**, 473, 182-5	7
852	Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. **2010**, 17, 1025-33	112
851	Animal models reveal role for tau phosphorylation in human disease. **2010**, 1802, 860-71	63
850	In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models. **2010**, 1802, 373-88	16
849	Alzheimer's disease: old problem, new views from transgenic and viral models. **2010**, 1802, 808-18	39
848	Early behavioural markers of disease in P301S tau transgenic mice. **2010**, 208, 250-7	55
847	Acetylation of tau inhibits its degradation and contributes to tauopathy. **2010**, 67, 953-66	628
846	The pattern of human tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons. **2010**, 168, 323-34	40
845	The propagation of prion-like protein inclusions in neurodegenerative diseases. **2010**, 33, 317-25	336

844	Molecular pathways of frontotemporal lobar degeneration. **2010**, 33, 71-88	34
843	Quantitative analysis of MAP-mediated regulation of microtubule dynamic instability in vitro focus on Tau. **2010**, 95, 481-503	13
842	REVIEW: Curcumin and Alzheimer's disease. **2010**, 16, 285-97	295
841	Targeting Abeta and tau in Alzheimer's disease, an early interim report. **2010**, 223, 252-66	68
840	Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. **2010**, 223, 304-10	70
839	ASIP Outstanding Investigator Award Lecture. New approaches to the pathology and genetics of neurodegeneration. **2010**, 176, 2058-66	14
838	Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo. **2010**, 7, 99-102	25
837	Heterogeneous ribonuclear protein E2 (hnRNP E2) is associated with TDP-43-immunoreactive neurites in Semantic Dementia but not with other TDP-43 pathological subtypes of Frontotemporal Lobar Degeneration. **2017**, 5, 54	8
836	Tau Isoforms Imbalance Impairs the Axonal Transport of the Amyloid Precursor Protein in Human Neurons. **2017**, 37, 58-69	52
835	FTDP-17 with Pick body-like inclusions associated with a novel tau mutation, p.E372G. **2017**, 27, 612-626	11
834	Paclitaxel suppresses Tau-mediated microtubule bundling in a concentration-dependent manner. **2017**, 1861, 3456-3463	8
833	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. **2017**, 90, 138-148	17
832	A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. **2017**, 140, 1128-1146	62
831	The Heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort. **2018**, 61, 753-760	18
830	SIRT1 Deacetylates SC35 and Suppresses Its Function in Tau Exon 10 Inclusion. **2018**, 61, 561-570	10
829	Genetic approaches to neurodegenerative disease. 57-76	
828	Animal models of dementia. 77-93	
827	What is the evidence that tau pathology spreads through prion-like propagation?. **2017**, 5, 99	168

826	The Neurogenetics of Parkinson's Disease and Putative Links to Other Neurodegenerative Disorders. **2017**, 1-40	1
825	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside. **2017**, 7,	12
824	Targeting Splicing in the Treatment of Human Disease. **2017**, 8,	26
823	Axonal Degeneration in Tauopathies: Disease Relevance and Underlying Mechanisms. **2017**, 11, 572	56
822	Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum. **2017**, 10, 119	32
821	E3 Ubiquitin Ligases Neurobiological Mechanisms: Development to Degeneration. **2017**, 10, 151	39
820	Optimization of in vitro conditions to study the arachidonic acid induction of 4R isoforms of the microtubule-associated protein tau. **2017**, 141, 65-88	9
819	Intrafamilial phenotypic heterogeneity in a Taiwanese family with a MAPT p.R5H mutation: a case report and literature review. **2017**, 17, 186	11
818	The CNS in inbred transgenic models of 4-repeat Tauopathy develops consistent tau seeding capacity yet focal and diverse patterns of protein deposition. **2017**, 12, 72	9
817	Haplotype-specific MAPT exon 3 expression regulated by common intronic polymorphisms associated with Parkinsonian disorders. **2017**, 12, 79	9
816	Practical considerations for choosing a mouse model of Alzheimer's disease. **2017**, 12, 89	189
815	Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau. **2017**, 5, 58	26
814	Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions. **2017**, 5, 89	40
813	EuroTau: towing scientists to tau without tautology. **2017**, 5, 90	5
812	Frontotemporal Dementia. **2017**, 115-125	
811	Role of Curcumin in Treatment of Alzheimer Disease. **2017**, 04,	10
810	Recent advances in the molecular genetics of frontotemporal lobar degeneration. **2017**, 32, 7-16	26
809	Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease. **2017**, 40, 613-620	88

808	Structural magnetic resonance imaging in frontotemporal lobar dementia. **2017**, 15, 285-294	
807	Prions. **2018**,	
806	Pharmacological Inhibition of O-GlcNAcase Enhances Autophagy in Brain through an mTOR-Independent Pathway. **2018**, 9, 1366-1379	32
805	Animal Models of Pathological Aging. **2018**, 61-77	
804	Thalamic atrophy in frontotemporal dementia - Not just a problem. **2018**, 18, 675-681	28
803	Genetics of dementia in a Finnish cohort. **2018**, 26, 827-837	5
802	Frontotemporal dementia. **2018**, 148, 409-430	33
801	Progress and Challenges in Frontotemporal Dementia Research: A 20-Year Review. **2018**, 62, 1467-1480	36
800	Recent developments with tau-based drug discovery. **2018**, 13, 399-410	26
799	Autophagy induction by trehalose: Molecular mechanisms and therapeutic impacts. **2018**, 233, 6524-6543	70
798	Aberrant Cortical Event-Related Potentials During Associative Learning in Rat Models for Presymptomatic Stages of Alzheimer's Disease. **2018**, 63, 725-740	3
797	Modulation of Tau Isoforms Imbalance Precludes Tau Pathology and Cognitive Decline in a Mouse Model of Tauopathy. **2018**, 23, 709-715	34
796	Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. **2018**, 75, 860-875	56
795	Novel GRN Mutations in Alzheimer's Disease and Frontotemporal Lobar Degeneration. **2018**, 62, 1683-1689	7
794	Our Tau Tales from Normal to Pathological Behavior. **2018**, 64, S507-S516	5
793	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. **2018**, 67, 84-94	13
792	A role for tau in learning, memory and synaptic plasticity. **2018**, 8, 3184	52
791	Shedding light on aberrant interactions - a review of modern tools for studying protein aggregates. **2018**, 285, 3604-3630	9

790	Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau. **2018**, 97, 823-835.e8	80
789	Amyloids of multiple species: are they helpful in survival?. **2018**, 93, 1363-1386	6
788	Neurotransmitter deficits from frontotemporal lobar degeneration. **2018**, 141, 1263-1285	77
787	In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510. **2018**, 61, 1037-1052	41
786	Genetic Modifiers in Neurodegeneration. **2018**, 6, 11-19	8
785	Psychiatric symptoms in preclinical behavioural-variant frontotemporal dementia in mutation carriers. **2018**, 89, 449-455	23
784	The Effect of Predictive Testing in Adult-Onset Neurodegenerative Diseases on Social and Personal Life. **2018**, 27, 947-954	6
783	Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. **2018**, 293, 2408-2421	54
782	Tauopathies. **2017**, 145, 355-368	81
781	G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. **2018**, 27, 120-134	21
780	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. **2018**, 141, 521-534	84
779	Tau Imaging in Parkinsonism: What Have We Learned So Far?. **2018**, 5, 118-130	9
778	Lack of human-like extracellular sortilin neuropathology in transgenic Alzheimer's disease model mice and macaques. **2018**, 10, 40	11
777	Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family. **2018**, 10, 7	6
776	Longitudinal evaluation of Tau-P301L transgenic mice reveals no cognitive impairments at 17´months of age. **2018**, 8, e00896	10
775	Genetic risk factors in Parkinson's disease. **2018**, 373, 9-20	98
774	Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer's Disease and Frontotemporal Dementia. **2018**, 62, 913-932	31
773	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. **2018**, 66, 181.e3-181.e10	12

772	Biomarkers for Alzheimer Disease and Frontotemporal Lobar Degeneration: Imaging. **2018**, 253-277	
771	TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. **2018**, 21, 552-563	111
770	Prion-like Spreading in Tauopathies. **2018**, 83, 337-346	44
769	Amyloid Prions and the Pathobiology of Alzheimer's Disease. **2018**, 8,	44
768	Fluorine-19 magnetic resonance imaging probe for the detection of tau pathology in female rTg4510 mice. **2018**, 96, 841-851	6
767	Interplay of pathogenic forms of human tau with different autophagic pathways. **2018**, 17, e12692	89
766	Human amyloid peptide and tau co-expression impairs behavior and causes specific gene expression changes in Caenorhabditis elegans. **2018**, 109, 88-101	32
765	Neurodegeneration and the ordered assembly of synuclein. **2018**, 373, 137-148	50
764	A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations. **2018**, 38, 108-119	25
763	Frontotemporal dementia: latest evidence and clinical implications. **2018**, 8, 33-48	59
762	Untangling the tauopathies: Current concepts of tau pathology and neurodegeneration. **2018**, 46 Suppl 1, S34-S38	8
761	Atypical parkinsonian syndromes: a general neurologist's perspective. **2018**, 25, 41-58	27
760	. **2018**,	1
759	Distinct Conformers of Assembled Tau in Alzheimer's and Pick's Diseases. **2018**, 83, 163-171	31
758	Frequency of frontotemporal dementia gene variants in , , and in academic versus commercial laboratory cohorts. **2018**, 8, 23-33	3
757	Tau in neurodegenerative disease. **2018**, 6, 175	78
756	[Development of imaging-based diagnostic procedures for brain protein aging using a mouse model of tauopathy]. **2018**, 152, 4-9	
755	A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model. **2018**, 13, 59	17

754	Rbfox3/NeuN Regulates Alternative Splicing of Tau Exon 10. **2018**, 66, 1695-1704	1
753	Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response. **2018**, 12, 488	219
752	Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis. **2018**, 7, 34	52
751	Study of tau pathology in male rTg4510 mice fed with a curcumin derivative Shiga-Y5. **2018**, 13, e0208440	3
750	Intrafamilial Phenotypic Variability in the Gene Expansion: 2 Case Studies. **2018**, 9, 1615	8
749	Frontotemporal lobar degeneration: Study of a clinicopathological cohort. **2018**, 58, 172-180	5
748	Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability. **2018**, 12, 338	83
747	Delta-secretase (AEP) mediates tau-splicing imbalance and accelerates cognitive decline in tauopathies. **2018**, 215, 3038-3056	15
746	Axonal Transport, Phase-Separated Compartments, and Neuron Mechanics - A New Approach to Investigate Neurodegenerative Diseases. **2018**, 12, 358	9
745	Mutant UBQLN2 promotes toxicity by modulating intrinsic self-assembly. **2018**, 115, E10495-E10504	29
744	Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration. **2018**, 11, 276	32
743	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. **2018**, 13, e0197329	36
742	Passive Immunotherapy in Alzheimer□ Disease. **2018**,	2
741	Genotype-phenotype links in frontotemporal lobar degeneration. **2018**, 14, 363-378	42
740	Tau filaments in neurodegenerative diseases. **2018**, 592, 2383-2391	56
739	A case report of recessive myotonia congenita and early onset cognitive impairment: Is it a causal or casual link?. **2018**, 97, e10785	1
738	Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro. **2018**, 9, 1-11	9
737	High-resolution temporal and regional mapping of MAPT expression and splicing in human brain development. **2018**, 13, e0195771	29

736	Alzheimer's Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing. **2018**, 22, 505-513	24
735	Precision medicine of frontotemporal dementia: from genotype to phenotype. **2018**, 23, 1144-1165	5
734	Splice-Switching Oligonucleotides. **2018**, 445-489	
733	Tau/DDX6 interaction increases microRNA activity. **2018**, 1861, 762-772	10
732	Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy. **2018**, 13, e0195486	14
731	Antisense Oligonucleotides for Treatment of Neurological Diseases. **2018**, 389-409	1
730	Presymptomatic change in microRNAs modulates Tau pathology. **2018**, 8, 9251	5
729	Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies. **2018**, 21, 1038-1048	101
728	Generation of a human induced pluripotent stem cell-based model for tauopathies combining three microtubule-associated protein TAU mutations which displays several phenotypes linked to neurodegeneration. **2018**, 14, 1261-1280	33
727	Tau Filaments and the Development of Positron Emission Tomography Tracers. **2018**, 9, 70	21
726	Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease. **2018**, 12, 25	366
725	Phospho-Tau Bar Code: Analysis of Phosphoisotypes of Tau and Its Application to Tauopathy. **2018**, 12, 44	57
724	Vesicular Axonal Transport is Modified In Vivo by Tau Deletion or Overexpression in Drosophila. **2018**, 19,	12
723	Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models. **2018**, 19,	33
722	Role of Molecular Chaperone Network in Understanding In Vitro Proteotoxicity. **2018**, 143-164	
721	Recent Insights on Alzheimer's Disease Originating from Yeast Models. **2018**, 19,	16
720	Prion-Like Propagation of Post-Translationally Modified Tau in Alzheimer's Disease: A Hypothesis. **2018**, 65, 480-490	30
719	Untangling the Tauopathy for Alzheimer's disease and parkinsonism. **2018**, 25, 54	21

718	Near-atomic model of microtubule-tau interactions. **2018**, 360, 1242-1246	175
717	T-complex protein 1-ring complex enhances retrograde axonal transport by modulating tau phosphorylation. **2018**, 19, 840-853	12
716	An Overview on the Clinical Development of Tau-Based Therapeutics. **2018**, 19,	100
715	Transcellular Spreading of Tau in Tauopathies. **2018**, 19, 2424-2432	16
714	Living Neurons with Tau Filaments Aberrantly Expose Phosphatidylserine and Are Phagocytosed by Microglia. **2018**, 24, 1939-1948.e4	70
713	Genetically Engineered iPSC-Derived FTDP-17 MAPT Neurons Display Mutation-Specific Neurodegenerative and Neurodevelopmental Phenotypes. **2018**, 11, 363-379	25
712	Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. **2018**, 136, 69-87	16
711	Tau clearance improves astrocytic function and brain glutamate-glutamine cycle. **2018**, 391, 90-99	25
710	Single-Molecule Mechanical Folding and Unfolding of RNA Hairpins: Effects of Single A-U to A⁺C Pair Substitutions and Single Proton Binding and Implications for mRNA Structure-Induced -1 Ribosomal Frameshifting. **2018**, 140, 8172-8184	17
709	Tau Assembly into Filaments. **2018**, 1779, 447-461	2
708	The role of lysosomes and autophagosomes in frontotemporal lobar degeneration. **2019**, 45, 244-261	12
707	Feature selection for classification models via bilevel optimization. **2019**, 106, 156-168	10
706	Clinical and Genetic Study of the First Japanese FTDP-17 Patient with a Mutation of +3 in Intron 10 in the MAPT Gene. **2019**, 58, 2397-2400	2
705	RNA Secondary Structure-Based Design of Antisense Peptide Nucleic Acids for Modulating Disease-Associated Aberrant Tau Pre-mRNA Alternative Splicing. **2019**, 24,	9
704	CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. **2019**, 294, 14149-14162	6
703	Rates of lobar atrophy in asymptomatic mutation carriers. **2019**, 5, 338-346	13
702	The neuropathological diagnosis of Alzheimer's disease. **2019**, 14, 32	554
701	Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. **2019**, 39, 7428-7437	12

700	The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson's disease. **2019**, 8, 23	99
699	Gait Ignition Failure in JNPL3 Human Tau-mutant Mice. **2019**, 28, 404-413	1
698	The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications. **2019**, 13, 757	14
697	Progranulin and Frontotemporal Lobar Degeneration. **2019**, 35-69	2
696	Early Electrophysiological Disintegration of Hippocampal Neural Networks in a Novel Locus Coeruleus Tau-Seeding Mouse Model of Alzheimer's Disease. **2019**, 2019, 6981268	11
695	Novel GRN mutations in Koreans with Alzheimer disease. **2019**, 15, 345-352	3
694	The RNA encoding the microtubule-associated protein tau has extensive structure that affects its biology. **2019**, 14, e0219210	7
693	FTD spectrum: Neuroimaging across the FTD spectrum. **2019**, 165, 187-223	10
692	Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. **2019**, 28, 3255-3269	8
691	Matrix-free tomographic reconstruction for atmospheric turbulence. **2019**, 488, 395-400	
690	Intersection of pathological tau and microglia at the synapse. **2019**, 7, 109	67
689	Novel P397S MAPT variant associated with late onset and slow progressive frontotemporal dementia. **2019**, 6, 1559-1565	3
688	Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. **2019**, 142, 3636-3654	34
687	Silicon micromachining with nanometer-thin boron masking and membrane material. **2019**, 6, 116438	4
686	Intronic RNA: Ad'junk' mediator of post-transcriptional gene regulation. **2019**, 1862, 194439	5
685	Lysosomal Dysfunction at the Centre of Parkinson's Disease and Frontotemporal Dementia/Amyotrophic Lateral Sclerosis. **2019**, 42, 899-912	45
684	Tau interactome analyses in CRISPR-Cas9 engineered neuronal cells reveal ATPase-dependent binding of wild-type but not P301L Tau to non-muscle myosins. **2019**, 9, 16238	10
683	Frontrunner in Translation: Progressive Supranuclear Palsy. **2019**, 10, 1125	8

682	Loss of tau and Fyn reduces compensatory effects of MAP2 for tau and reveals a Fyn-independent effect of tau on calcium. **2019**, 97, 1393-1413	9
681	A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies. **2019**, 13, 939-955	28
680	Impaired tau-microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations. **2019**, 294, 18488-18503	11
679	Emerging Role of Genetic Alterations Affecting Exosome Biology in Neurodegenerative Diseases. **2019**, 20,	15
678	p.V363I mutation: A rare cause of corticobasal degeneration. **2019**, 5, e347	6
677	Identification of novel alternative splice variants of the human L-DOPA decarboxylase (DDC) gene in human cancer cells, using high-throughput sequencing approaches. **2019**, 719, 144075	5
676	Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer's and Pick's diseases. **2019**, 8,	173
675	Minireview - Microtubules and Tubulin Oligomers: Shape Transitions and Assembly by Intrinsically Disordered Protein Tau and Cationic Biomolecules. **2019**, 35, 15970-15978	2
674	Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer's disease. **2019**, 47, 4968-4980	9
673	Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau. **2019**, 10, 4443	25
672	Stress granules and neurodegeneration. **2019**, 20, 649-666	189
671	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. **2019**, 83, 54-62	9
670	Pathogenic Tau Impairs Axon Initial Segment Plasticity and Excitability Homeostasis. **2019**, 104, 458-470.e5	49
669	Pathological Progression Induced by the Frontotemporal Dementia-Associated R406W Tau Mutation in Patient-Derived iPSCs. **2019**, 13, 684-699	20
668	Tau Modulates VGluT1 Expression. **2019**, 431, 873-884	20
667	Tauopathy: A common mechanism for neurodegeneration and brain aging. **2019**, 178, 72-79	46
666	Human iPSC application in Alzheimer's disease and Tau-related neurodegenerative diseases. **2019**, 699, 31-40	17
665	Frontotemporal lobar degenerations: from basic science to clinical manifestations. **2019**, 45, 3-5	

664	A short perspective on the long road to effective treatments for Alzheimer's disease. **2019**, 176, 3636-3648	9
663	Modeling Alzheimer's disease with human iPS cells: advancements, lessons, and applications. **2019**, 130, 104503	13
662	Mutation dynamics of CpG dinucleotides during a recent event of vertebrate diversification. **2019**, 14, 685-707	11
661	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. **2019**, 29, 624-629	6
660	Tau local structure shields an´amyloid-forming motif and controls aggregation propensity. **2019**, 10, 2493	56
659	CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia. **2019**, 6, 863-872	4
658	The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice. **2019**, 20,	10
657	The role of APOE in transgenic mouse models of AD. **2019**, 707, 134285	14
656	Genome Wide Association Study and Next Generation Sequencing: A Glimmer of Light Toward New Possible Horizons in Frontotemporal Dementia Research. **2019**, 13, 506	15
655	Amyotrophic Lateral Sclerosis-associated GGGGCC repeat expansion promotes Tau phosphorylation and toxicity. **2019**, 130, 104493	5
654	Granulin in Frontotemporal Lobar Degeneration: Molecular Mechanisms of the Disease. **2019**, 13, 395	6
653	Decreased synthesis of ribosomal proteins in tauopathy revealed by non-canonical amino acid labelling. **2019**, 38, e101174	33
652	Elucidating Tau function and dysfunction in the era of cryo-EM. **2019**, 294, 9316-9325	24
651	Longitudinal assessment of the neuroanatomical consequences of deep brain stimulation: Application of fornical DBS in an Alzheimer's mouse model. **2019**, 1715, 213-223	6
650	Confirmation of high frequency of C9orf72 mutations in patients with frontotemporal dementia from Sweden. **2019**, 84, 241.e21-241.e25	7
649	A review on shared clinical and molecular mechanisms between bipolar disorder and frontotemporal dementia. **2019**, 93, 269-283	14
648	Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies. **2019**, 133, 473-483	25
647	Aaron Klug and the study of Alzheimer's disease. **2019**, 15, 859-861	

646	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. **2019**, 20, 1091-1107	9
645	A and tau prion-like activities decline with longevity in the Alzheimer's disease human brain. **2019**, 11,	55
644	Tau tubulin kinases in proteinopathy. **2019**, 286, 2434-2446	8
643	Mechanistic approaches to understand the prion-like propagation of aggregates of the human tau protein. **2019**, 1867, 922-932	7
642	The complexity of tau in Alzheimer's disease. **2019**, 705, 183-194	84
641	Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy. **2019**, 127, 323-338	6
640	Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau). **2019**, 7, 34	15
639	In vivo imaging reveals reduced activity of neuronal circuits in a mouse tauopathy model. **2019**, 142, 1051-1062	23
638	The Unfolded Protein Response in Cancer. **2019**,	1
637	Progranulin and Central Nervous System Disorders. **2019**,	
636	A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. **2019**, 11,	46
635	Assembly of transgenic human P301S Tau is necessary for neurodegeneration in murine spinal cord. **2019**, 7, 44	12
634	Thalamo-cortical network hyperconnectivity in preclinical progranulin mutation carriers. **2019**, 22, 101751	15
633	Precision Medicine for Frontotemporal Dementia. **2019**, 10, 75	8
632	Disease-modifying therapies for tauopathies: agents in the pipeline. **2019**, 19, 397-408	10
631	Frontotemporal Dementia: A Clinical Review. **2019**, 39, 251-263	22
630	The Effectiveness of Vitamin E Treatment in Alzheimer's Disease. **2019**, 20,	55
629	A Disease-Causing Intronic Point Mutation C19G Alters Tau Exon 10 Splicing via RNA Secondary Structure Rearrangement. **2019**, 58, 1565-1578	8

628	Amygdala subnuclei are differentially affected in the different genetic and pathological forms of frontotemporal dementia. **2019**, 11, 136-141	11
627	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. **2019**, 137, 879-899	50
626	A walk through tau therapeutic strategies. **2019**, 7, 22	133
625	MAPT mutations, tauopathy, and mechanisms of neurodegeneration. **2019**, 99, 912-928	84
624	Recent advances in the genetics of frontotemporal dementia. **2019**, 7, 41-52	22
623	Endoplasmic Reticulum Stress in Tauopathies: Contrasting Human Brain Pathology with Cellular and Animal Models. **2019**, 68, 439-458	5
622	Elevation of pS262-Tau and Demethylated PP2A in Retina Occurs Earlier than in Hippocampus During Hyperhomocysteinemia. **2019**, 68, 367-381	5
621	Heritability in frontotemporal tauopathies. **2019**, 11, 115-124	9
620	Implications of Microglia in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. **2019**, 431, 1818-1829	27
619	Secretase and its modulators: Twenty years and beyond. **2019**, 701, 162-169	26
618	rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies. **2019**, 216, 539-555	22
617	Tauopathy. **2019**,	1
616	Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain. **2019**, 11,	15
615	Role of Phosphorylated Tau and Glucose Synthase Kinase 3 Beta in Huntington's Disease Progression. **2019**, 72, S177-S191	5
614	Frontotemporal dementia. **2019**, 167, 279-299	9
613	Genetic mimics of the non-genetic atypical parkinsonian disorders - the 'atypical' atypical. **2019**, 149, 327-351	5
612	Parkinsonism in frontotemporal dementias. **2019**, 149, 249-275	15
611	Failures in Protein Clearance Partly Underlie Late Onset Neurodegenerative Diseases and Link Pathology to Genetic Risk. **2019**, 13, 1304	4

610	Neurons Expressing Pathological Tau Protein Trigger Dramatic Changes in Microglial Morphology and Dynamics. **2019**, 13, 1199	8
609	A novel C-terminal truncated mutation in hCDKL5 protein causing a severe West syndrome: Comparison with previous truncated mutations and genotype/phenotype correlation. **2019**, 72, 22-30	5
608	Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review. **2019**, 76, 101-108	105
607	Review: Molecular pathology of frontotemporal lobar degenerations. **2019**, 45, 41-57	7
606	Genetic analysis of neurodegenerative diseases in a pathology cohort. **2019**, 76, 214.e1-214.e9	14
605	FTDP-17 Mutations Alter the Aggregation and Microtubule Stabilization Propensity of Tau in an Isoform-Specific Fashion. **2019**, 58, 742-754	5
604	Differential accumulation of Tau phosphorylated at residues Thr231, Ser262 and Thr205 in hippocampal interneurons and its modulation by Tau mutations (VLW) and amyloid-peptide. **2019**, 125, 232-244	10
603	It's all about tau. **2019**, 175, 54-76	75
602	Human Genomic Variants and Inherited Disease: Molecular Mechanisms and Clinical Consequences. **2019**, 125-200	0
601	Age-related diseases as vicious cycles. **2019**, 49, 11-26	33
600	The role of monogenic genes in idiopathic Parkinson's disease. **2019**, 124, 230-239	53
599	Microtubules Deform the Nuclear Membrane and Disrupt Nucleocytoplasmic Transport in Tau-Mediated Frontotemporal Dementia. **2019**, 26, 582-593.e5	64
598	Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer's disease, Parkinson's disease. **2019**, 111, 765-777	53
597	Meta-analysis of Genetic Modifiers Reveals Candidate Dysregulated Pathways in Amyotrophic Lateral Sclerosis. **2019**, 396, A3-A20	11
596	The toxin MPTP generates similar cognitive and locomotor deficits in hTau and tau knock-out mice. **2019**, 1711, 106-114	6
595	Molecular Pathogenesis of the Tauopathies. **2019**, 14, 239-261	83
594	Review: Neuropathology of non-tau frontotemporal lobar degeneration. **2019**, 45, 19-40	57
593	Analysis of tauopathy research funding between 2006 and 2016 reveals critical gaps in research priorities. **2019**, 15, 42-54	2

592	Alzheimer's Disease and Dementia. **2019**, 25-82	0
591	Tau Abnormalities and the Potential Therapy in Alzheimer's Disease. **2019**, 67, 13-33	11
590	Minimalistic in vitro systems for investigating tau pathology. **2019**, 319, 69-76	2
589	Roles of tau pathology in the locus coeruleus (LC) in age-associated pathophysiology and Alzheimer's disease pathogenesis: Potential strategies to protect the LC against aging. **2019**, 1702, 17-28	34
588	Small molecule targeting of RNA structures in neurological disorders. **2020**, 1471, 57-71	7
587	Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. **2020**, 87, 808-818	25
586	Yeast surface display of full-length human microtubule-associated protein tau. **2020**, 36, e2920	2
585	Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. **2020**, 45, 104-120	84
584	Mechanisms of secretion and spreading of pathological tau protein. **2020**, 77, 1721-1744	82
583	A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity. **2020**, 134, 104668	10
582	Anti-GluA3 antibodies in frontotemporal dementia: effects on glutamatergic neurotransmission and synaptic failure. **2020**, 86, 143-155	16
581	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. **2020**, 16, 22-36	19
580	Two pathologically confirmed cases of novel mutations in the MAPT gene causing frontotemporal dementia. **2020**, 87, 141.e15-141.e20	2
579	Invited Review: The role of prion-like mechanisms in neurodegenerative diseases. **2020**, 46, 522-545	46
578	Integrated analysis of the aging brain transcriptome and proteome in tauopathy. **2020**, 15, 56	6
577	Microglia in Alzheimer's Disease in the Context of Tau Pathology. **2020**, 10,	22
576	Fyn Kinase Controls Tau Aggregation In Vivo. **2020**, 32, 108045	20
575	Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis. **2020**, 145, 105063	10

574	The complex relationship between genotype, pathology and phenotype in familial dementia. **2020**, 145, 105082	1
573	Identification of a pathogenic intronic KIF5A mutation in an ALS-FTD kindred. **2020**, 95, 1015-1018	9
572	Phase Separation and Neurodegenerative Diseases: A Disturbance in the Force. **2020**, 55, 45-68	70
571	Tau at the interface between neurodegeneration and neuroinflammation. **2020**, 21, 288-300	11
570	Innovative Therapeutic and Delivery Approaches Using Nanotechnology to Correct Splicing Defects Underlying Disease. **2020**, 11, 731	6
569	Fyn depletion ameliorates tau-induced neuropathology. **2020**, 8, 108	6
568	Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. **2020**, 15, 40	165
567	FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments. **2020**, 15, 39	17
566	Pharmacological Modulators of Tau Aggregation and Spreading. **2020**, 10,	7
565	Targeting Tau to Treat Clinical Features of Huntington's Disease. **2020**, 11, 580732	6
564	Dysregulated Wnt Signalling in the Alzheimer's Brain. **2020**, 10,	12
563	Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target. **2020**, 11, 590754	3
562	Role of zinc transporter ZIP12 in susceptibility-weighted brain magnetic resonance imaging (MRI) phenotypes and mitochondrial function. **2020**, 34, 10702-12725	6
561	Intrinsic Regulatory Role of RNA Structural Arrangement in Alternative Splicing Control. **2020**, 21,	8
560	Genetics of Chronic Traumatic Encephalopathy. **2020**, 40, 420-429	2
559	Pathogenic Tau Causes a Toxic Depletion of Nuclear Calcium. **2020**, 32, 107900	8
558	Modulating disease-relevant tau oligomeric strains by small molecules. **2020**, 295, 14807-14825	12
557	A novel hypomorphic splice variant in EIF2B5 gene is associated with mild ovarioleukodystrophy. **2020**, 7, 1574-1579	2

556	Tau Protein and Its Role in Blood-Brain Barrier Dysfunction. **2020**, 13, 570045	18
555	Degradation and Transmission of Tau by Autophagic-Endolysosomal Networks and Potential Therapeutic Targets for Tauopathy. **2020**, 13, 586731	18
554	Modelling frontotemporal dementia using patient-derived induced pluripotent stem cells. **2020**, 109, 103553	8
553	Precise base editing with CC context-specificity using engineered human APOBEC3G-nCas9 fusions. **2020**, 18, 111	14
552	Unclassified four-repeat tauopathy associated with familial parkinsonism and progressive respiratory failure. **2020**, 8, 148	1
551	Isolation and characterization of antibody fragments selective for human FTD brain derived TDP-43 variants. **2020**, 21, 36	2
550	Tau proteinopathies and the prion concept. **2020**, 175, 239-259	5
549	S-Adenosylmethionine Rescues Cognitive Deficits in the rTg4510 Animal Model by Stabilizing Protein Phosphatase 2A and Reducing Phosphorylated Tau. **2020**, 77, 1705-1715	3
548	Untangling the origin and function of granulovacuolar degeneration bodies in neurodegenerative proteinopathies. **2020**, 8, 153	5
547	Extensive Plasmid Library to Prepare Tau Protein Variants and Study Their Functional Biochemistry. **2020**, 11, 3117-3129	4
546	Gliosis Precedes Amyloid-Deposition and Pathological Tau Accumulation in the Neuronal Cell Cycle Re-Entry Mouse Model of Alzheimer's Disease. **2020**, 4, 243-253	5
545	P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice. **2020**, 15, 47	24
544	Insoluble Tau From Human FTDP-17 Cases Exhibit Unique Transmission Properties In Vivo. **2020**, 79, 941-949	0
543	The Q336H MAPT Mutation Linked to Pick's Disease Leads to Increased Binding of Tau to the Microtubule Network Altered Conformational and Phosphorylation Effects. **2020**, 13, 569395	2
542	Targeting Mitophagy in Alzheimer's Disease. **2020**, 78, 1273-1297	3
541	Comparison of Common and Disease-Specific Post-translational Modifications of Pathological Tau Associated With a Wide Range of Tauopathies. **2020**, 14, 581936	18
540	Coexistence of perseveration and apathy in the TDP-43 knock-in mouse model of ALS-FTD. **2020**, 10, 377	1
539	Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer's disease. **2020**, 15, 64	7

538	Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect Splicing. **2020**, 142, 8706-8727	17
537	Tau affects P53 function and cell fate during the DNA damage response. **2020**, 3, 245	18
536	MAPT haplotype-stratified GWAS reveals differential association for AD risk variants. **2020**, 16, 983-1002	11
535	Targeting tau: Clinical trials and novel therapeutic approaches. **2020**, 731, 134919	30
534	MK-8719, a Novel and Selective -GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy. **2020**, 374, 252-263	24
533	Tau Accumulation via Reduced Autophagy Mediates GGGGCC Repeat Expansion-Induced Neurodegeneration in Drosophila Model of ALS. **2020**, 36, 1414-1428	6
532	Impact of the Hereditary P301L Mutation on the Correlated Conformational Dynamics of Human Tau Protein Revealed by the Paramagnetic Relaxation Enhancement NMR Experiments. **2020**, 21,	6
531	Liquid-liquid phase separation induces pathogenic tau conformations in vitro. **2020**, 11, 2809	77
530	Tau2020 Global Conference highlights advances in tau-related neurodegenerative diseases. **2020**, 16, 939-940	
529	CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral sclerosis. **2020**, 143, 783-799	33
528	Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration. **2020**, 11, 80	6
527	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. **2020**, 16, 213-228	34
526	Optical induction of autophagy via Transcription factor EB (TFEB) reduces pathological tau in neurons. **2020**, 15, e0230026	10
525	Mechanisms of Heparin-Induced Tau Aggregation Revealed by a Single Nanopore. **2020**, 5, 1158-1167	14
524	Brain microRNAs dysregulation: Implication for missplicing and abnormal post-translational modifications of tau protein in Alzheimer's disease and related tauopathies. **2020**, 155, 104729	10
523	Cryo-EM structures of tau filaments. **2020**, 64, 17-25	61
522	Red Ginseng Inhibits Tau Aggregation and Promotes Tau Dissociation. **2020**, 2020, 7829842	7
521	Multifaceted Genes in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia. **2020**, 14, 684	10

520	FMR1 locus isoforms: potential biomarker candidates in fragile X-associated tremor/ataxia syndrome (FXTAS). **2020**, 10, 11099	3
519	Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies. **2020**, 8, 88	22
518	Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. **2020**, 9, 27	10
517	A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals. **2020**, 10, 3869	8
516	Genetic architecture of neurodegenerative dementias. **2020**, 168, 108014	3
515	Long Term Gene Expression in Human Induced Pluripotent Stem Cells and Cerebral Organoids to Model a Neurodegenerative Disease. **2020**, 14, 14	11
514	Genetic Diversity in Frontotemporal Dementia. **2020**, 54, 13-23	5
513	Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays. **2020**, 295, 4001-4013	5
512	Synergistic toxicity between tau and amyloid drives neuronal dysfunction and neurodegeneration in transgenic C. elegans. **2020**, 29, 495-505	33
511	WITHDRAWN: Genetics of Parkinson's disease. **2020**, 101471	
510	Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. **2020**, 16, 118-130	25
509	Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease. **2019**, 13, 574	14
508	Intracerebral seeding of amyloid-□and tau pathology in mice: Factors underlying prion-like spreading and comparisons with □synuclein. **2020**, 112, 1-27	17
507	Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS. **2020**, 16, 71-78	21
506	Non-coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases. **2020**, 106, 632-645	23
505	CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy. **2020**, 11, 997	15
504	Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. **2020**, 8, 13	23
503	Genetic forms of frontotemporal lobar degeneration: Current diagnostic approach and new directions in therapeutic strategies. **2020**, 176, 571-581	6

502	hnRNP A1 Regulates Alternative Splicing of Tau Exon 10 by Targeting 3' Splice Sites. **2020**, 9,	3
501	Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease. **2020**, 11, 1218-1230	12
500	Dysregulation of Exosome Cargo by Mutant Tau Expressed in Human-induced Pluripotent Stem Cell (iPSC) Neurons Revealed by Proteomics Analyses. **2020**, 19, 1017-1034	16
499	Maturation and phenotype of pathophysiological neuronal excitability of human cells in tau-related dementia. **2020**, 133,	9
498	P301 L, an FTDP-17 Mutant, Exhibits Enhanced Glycation in vitro. **2020**, 75, 61-71	
497	Phosphorylation in two discrete tau domains regulates a stepwise process leading to postsynaptic dysfunction. **2021**, 599, 2483-2498	11
496	Next-generation sequencing reveals alternative L-DOPA decarboxylase (DDC) splice variants bearing novel exons, in human hepatocellular and lung cancer cells. **2021**, 768, 145262	3
495	Genetic testing in dementia - utility and clinical strategies. **2021**, 17, 23-36	4
494	Distinct early symptoms in neuropathologically proven frontotemporal lobar degeneration. **2021**, 36, 38-45	2
493	Knockin' on heaven's door: Molecular mechanisms of neuronal tau uptake. **2021**, 156, 563-588	5
492	Tubulin modifying enzymes as target for the treatment oftau-related diseases. **2021**, 218, 107681	3
491	Amelioration of Tau pathology and memory deficits by targeting 5-HT7 receptor. **2021**, 197, 101900	4
490	The behavioural phenotype of 14-month-old female TAU58/2 transgenic mice. **2021**, 397, 112943	1
489	Brain volumetric deficits in MAPT mutation carriers: a multisite study. **2021**, 8, 95-110	4
488	Glycogen Synthase Kinase 3A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery?. **2021**, 64, 26-41	15
487	Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. **2021**, 64, 926-937	2
486	Genetics of Progressive Supranuclear Palsy: A Review. **2021**, 11, 93-105	6
485	Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes. **2021**, 29, 859-872	9

484	Lysosomal Dysfunction and Other Pathomechanisms in FTLD: Evidence from Progranulin Genetics and Biology. **2021**, 1281, 219-242	4
483	Retromer dysfunction at the nexus of tauopathies. **2021**, 28, 884-899	5
482	Comprehensive Integrative Analyses Identify TIGD5 rs75547282 as a Risk Variant for Autism Spectrum Disorder. **2021**, 14, 631-644	1
481	Hereditary Frontotemporal Dementia Linked to the Pathogenic p.L266V Variant of the MAPT Gene in Korea. **2021**, 17, 478-480	1
480	Decreased Orexin Receptor 1 mRNA Expression in the Locus Coeruleus in Both Tau Transgenic rTg4510 and Tau Knockout Mice and Accompanying Ascending Arousal System Tau Invasion in rTg4510. **2021**, 79, 693-708	3
479	Mendelian and Sporadic FTD: Disease Risk and Avenues from Genetics to Disease Pathways Through In Silico Modelling. **2021**, 1281, 283-296	1
478	Induced pluripotent stem cell derived from postmortem tissue in neurodegenerative disease research. **2021**, 221-249	0
477	Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders. **2021**, 26, 2685-2706	5
476	Clinical overview and phenomenology of movement disorders. **2021**, 1-51.e27	0
475	Clinical and Neuroimaging Aspects of Familial Frontotemporal Lobar Degeneration Associated with MAPT and GRN Mutations. **2021**, 1281, 77-92	0
474	Cholinergic neurodegeneration in Alzheimer disease mouse models. **2021**, 182, 191-209	2
473	Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies. **2021**, 16, 1	9
472	Recapitulation of Endogenous 4R Tau Expression and Formation of Insoluble Tau in Directly Reprogrammed Human Neurons.	
471	The Lys 280 -> Gln mutation mimicking disease-linked acetylation of Lys 280 in tau extends the structural core of fibrils and modulates their catalytic properties. **2021**, 30, 785-803	3
470	Splicing alterations in healthy aging and disease. **2021**, 12, e1643	4
469	Genetics of frontotemporal dementia in China. **2021**, 22, 321-335	4
468	Early anterior cingulate involvement is seen in presymptomatic MAPT P301L mutation carriers. **2021**, 13, 42	4
467	Genetic pleiotropy and the shared pathological features of corticobasal degeneration and progressive supranuclear palsy: a case report and a review of the literature. **2021**, 27, 120-128	1

466	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. **2021**, 27, 212-222	1
465	Mechanistic insights into the pathogenesis of neurodegenerative diseases: towards the development of effective therapy. **2021**, 476, 2739-2752	5
464	Mechanisms of Neurodegeneration in Various Forms of Parkinsonism-Similarities and Differences. **2021**, 10,	11
463	Mass spectrometry analysis of tau and amyloid-beta in iPSC-derived models of Alzheimer's disease and dementia. **2021**, 159, 305-317	1
462	The Role of White Matter Dysfunction and Leukoencephalopathy/Leukodystrophy Genes in the Aetiology of Frontotemporal Dementias: Implications for Novel Approaches to Therapeutics. **2021**, 22,	2
461	A Woman with Progressive Episodic Memory Loss and Personality Change. **2021**, 44-48	
460	Human tauopathy-derived tau strains determine the substrates recruited for templated amplification. **2021**, 144, 2333-2348	4
459	Emerging genetic complexity and rare genetic variants in neurodegenerative brain diseases. **2021**, 13, 59	4
458	RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays. **2021**, 26,	4
457	Transcriptome-wide Association Study in Frontotemporal Dementia Identifies New Disease Loci by In Silico Analysis. **2021**, 89, e37-e39	
456	Dysfunctional vascular smooth muscle cells mediate early and late-stage neuroinflammation and Tau hyperphosphorylation.	0
455	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. **2021**, 96, e2296-e2312	12
454	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. **2021**, 89, 825-835	3
453	Tau associated peripheral and central neurodegeneration: Identification of an early imaging marker for tauopathy. **2021**, 151, 105273	4
452	Pathogenic MAPT mutations Q336H and Q336R have isoform-dependent differences in aggregation propensity and microtubule dysfunction. **2021**, 158, 455-466	2
451	Tau strains shape disease. **2021**, 142, 57-71	13
450	Liquid-liquid phase separation of tau: From molecular biophysics to physiology and disease. **2021**, 30, 1294-1314	13
449	Structure-based Classification of Tauopathies.	9

448	Systematic characterization of short intronic splicing-regulatory elements.	0
447	Differential accumulation of tau pathology between reciprocal F1 hybrids of rTg4510 mice. **2021**, 11, 9623	1
446	A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease. **2021**, 142, 159-177	3
445	Clinical and neuropathological variability in the rare IVS10´+ 14 tau mutation. **2021**, 101, 298.e1-298.e10	0
444	Development of P301S tau seeded organotypic hippocampal slice cultures to study potential therapeutics. **2021**, 11, 10309	0
443	How an Infection of Sheep Revealed Prion Mechanisms in Alzheimer's Disease and Other Neurodegenerative Disorders. **2021**, 22,	6
442	ADP-ribose triggers neuronal ferroptosis via metabolic orchestrating.	
441	The splicing factor XAB2 interacts with ERCC1-XPF and XPG for R-loop processing. **2021**, 12, 3153	5
440	Ondine's Curse in Frontotemporal Dementia with Parkinsonism Linked to Chromosome 17 Caused by Variants. **2021**, 8, 954-958	
439	Genome-wide CRISPR screen identifies protein pathways modulating tau protein levels in neurons. **2021**, 4, 736	3
438	Oral (-)-Epicatechin Inhibits Progressive Tau Pathology in rTg4510 Mice Independent of Direct Actions at GSK3□**2021**, 15, 697319	0
437	Familial Danish dementia young Knock-in rats expressing humanized APP and human A□show impaired pre and postsynaptic glutamatergic transmission.	
436	"Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies. **2021**, 16, 37	17
435	A deep learning approach to identify gene targets of a therapeutic for human splicing disorders. **2021**, 12, 3332	3
434	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. **2021**, 12, 3452	10
433	Axonal Transport and Local Translation of mRNA in Neurodegenerative Diseases. **2021**, 14, 697973	3
432	Non-invasive and high-throughput interrogation of exon-specific isoform expression. **2021**, 23, 652-663	1
431	Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer's disease. **2021**, 9, 117	5

430	The informed road map to prevention of Alzheimer Disease: A call to arms. **2021**, 16, 49	7
429	[F]Flortaucipir PET Across Various Mutations in Presymptomatic and Symptomatic Carriers. **2021**, 97, e1017-e1030	3
428	Genetically engineered MAPT 10+16 mutation causes pathophysiological excitability of human iPSC-derived neurons related to 4R tau-induced dementia. **2021**, 12, 716	1
427	Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. **2021**, 154, 105360	27
426	Genome-wide association study and functional validation implicates JADE1 in tauopathy.	
425	FTLD Patient-Derived Fibroblasts Show Defective Mitochondrial Function and Accumulation of p62. **2021**, 58, 5438-5458	1
424	Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on Tau-Dependent and Tau-Independent Networks. **2021**, 10,	0
423	Blood CDKN2A Gene Expression in Aging and Neurodegenerative Diseases. **2021**, 82, 1737-1744	2
422	Does the Anti-Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? No. **2021**, 8, 1038-1040	2
421	High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy. **2021**, 11, 17029	1
420	Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery. **2021**, 16, 55	10
419	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. **2021**,	0
418	Deconstructing Alzheimer's Disease: How to Bridge the Gap between Experimental Models and the Human Pathology?. **2021**, 22,	7
417	Cellular and pathological heterogeneity of primary tauopathies. **2021**, 16, 57	11
416	Looking at Alzheimer's Disease Pathogenesis from the Nuclear Side. **2021**, 11,	0
415	Tau K321/K353 pseudoacetylation within KXGS motifs regulates tau-microtubule interactions and inhibits aggregation. **2021**, 11, 17069	3
414	Tau and Membranes: Interactions That Promote Folding and Condensation. **2021**, 9, 725241	1
413	Living with the enemy: from protein-misfolding pathologies we know, to those we want to know. **2021**, 70, 101391	7

412	Synaptic tau: A pathological or physiological phenomenon?. **2021**, 9, 149		5
411	Effects of altered tau expression on dentate granule cell excitability in mice. **2021**, 343, 113766		1
410	A familial Danish dementia rat shows impaired presynaptic and postsynaptic glutamatergic transmission. **2021**, 297, 101089		0
409	Current directions in tau research: Highlights from Tau 2020. **2021**,		6
408	Quantitative prediction of variant effects on alternative splicing using endogenous pre-messenger RNA structure probing.		1
407	Structure-based classification of tauopathies. *Nature*, **2021**, 598, 359-363	50.4	59
406	Editorial: Tau Pathology in Neurological Disorders. **2021**, 12, 754669		1
405	Tau and MAPT genetics in tauopathies and synucleinopathies. **2021**, 90, 142-154		3
404	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. **2021**, 11, 451		0
403	A clinical, molecular genetics and pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10G>T at the intron 9/exon 10 of the MAPT gene. **2021**, 106, 343.e1-343.e8		2
402	Frequency of frontotemporal dementia-related gene variants in Turkey. **2021**, 106, 332.e1-332.e11		
401	A role for zinc transporter gene SLC39A12 in the nervous system and beyond. **2021**, 799, 145824		0
400	Knowledge assessment and psychological impact of genetic counseling in people at risk for familial FTD. **2021**, 13, e12225		1
399	Cu, Fe, and Zn isotope ratios in murine Alzheimer's disease models suggest specific signatures of amyloidogenesis and tauopathy. **2021**, 296, 100292		8
398	Tau Protein and Frontotemporal Dementias. **2021**, 1281, 177-199		5
397	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. **2021**, 144, 2798-2811		2
396	Molecular Genetics of Frontotemporal Dementia.		2
395	Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17. 110-134		20

394	Variations of the Phenotype in Frontotemporal Dementias. **2005**, 139-152	1
393	Kognitive Störungen: Koma, Delir, Demenz. **2006**, 221-295	6
392	Familial Parkinsonism with Apathy, Depression and Central Hypoventilation (Perry's Syndrome). **2002**, 285-290	2
391	Cognitive Impairment in Transgenic Aβ and Tau Models of Alzheimer's Disease. **2007**, 77-91	1
390	Alzheimer's Disease, Parkinson's Disease, and Frontotemporal Dementias: Different Manifestations of Protein Misfolding. **2008**, 123-131	1
389	Alternative splicing in disease. **2007**, 623, 212-23	48
388	Cdk5 as a Drug Target for Alzheimer's Disease. **2008**, 283-299	1
387	Genetic Models of Parkinson's Disease. **2021**, 37-84	1
386	Tau gene mutations and tau pathology in frontotemporal dementia and parkinsonism linked to chromosome 17. **2001**, 487, 21-37	10
385	Tau pathology in neurons and glial cells of aged baboons. **2001**, 487, 59-69	9
384	Human Tau Transgenic Mice. **2001**, 71-83	6
383	Molecular Pathology of Alzheimer's Disease and Related Disorders. **1999**, 603-654	18
382	Peripheral Markers of Alzheimer's. **2000**, 191-268	1
381	Neuropathological Findings Associated with Long-Term HAART. **2009**, 29-47	2
380	The Aβ-centric Pathway of Alzheimer's Disease. **2007**, 5-36	1
379	Ursachen und Behandlungskonzepte der Demenzen. **2001**, 113-199	2
378	Alternative splicing: therapeutic target and tool. **2006**, 44, 47-64	24
377	Misregulation of tau alternative splicing in neurodegeneration and dementia. **2006**, 44, 89-107	42

376	Neurodegenerative Diseases: Insights from Drosophila and Mouse Models. **2003**, 85-103	1
375	Tau Mutations: Genetics and Pathogenetic Mechanisms. **2000**, 53-64	1
374	Tauopathies and □Synucleinopathies. **2000**, 65-86	3
373	Neurodegenerative Disorders with Tauopathies: Mad Tau Diseases?. **2000**, 105-125	1
372	Heterogeneous nuclear ribonucleoprotein particle A/B proteins and the control of alternative splicing of the mammalian heterogeneous nuclear ribonucleoprotein particle A1 pre-mRNA. **2003**, 31, 59-88	34
371	Frontallappendegenerationen und verwandte Erkrankungen. **2002**, 111-144	0
370	Demenz. **2017**, 1377-1465	1
369	Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration. **2002**, 309-19	13
368	Importance of familial Parkinson's disease and parkinsonism to the understanding of nigral degeneration in sporadic Parkinson's disease. **2000**, 101-16	5
367	Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. **2000**, 59, 213-22	32
366	Is there room for Darwinian medicine and the hygiene hypothesis in Alzheimer pathogenesis?. **2009**, 257-278	1
365	Drug Development for Neurodegenerative Diseases. **2015**, 183-216	2
364	Mark/Par-1 marking the polarity of migrating neurons. **2014**, 800, 97-111	12
363	Ordered Assembly of Tau Protein and Neurodegeneration. **2019**, 1184, 3-21	22
362	Tau Secretion. **2019**, 1184, 123-134	6
361	Structure of NFT: Biochemical Approach. **2019**, 1184, 23-34	3
360	Tau and Axonal Transport Misregulation in Tauopathies. **2019**, 1184, 81-95	27
359	Presynaptic Pathophysiology Encoded in Different Domains of Tau´- Hyper-Versus Hypoexcitability?. **2019**, 1184, 97-103	2

358	Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. **1999**, 246, II6	7
357	The Dementias. **2008**, 1855-1907	1
356	Rodent Models of Tauopathies. **2005**, 529-539	2
355	Progressive Supranuclear Palsy and Corticobasal Degeneration. **2001**, 155-171	5
354	Application of yeast to studying amyloid and prion diseases. **2020**, 105, 293-380	6
353	Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models. **2020**, 137, 104770	9
352	Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. **2021**, 64, 812-839	16
351	Astroglial contribution to tau-dependent neurodegeneration. **2019**, 476, 3493-3504	11
350	The ubiquitin□proteasome system and neurodegenerative disorders. **2005**, 41, 157-171	35
349	The physiology and pathology of microtubule-associated protein tau. **2014**, 56, 111-23	20
348	Expanding spectrum of prion diseases. **2020**, 4, 155-167	13
347	Biotin rescues mitochondrial dysfunction and neurotoxicity in a tauopathy model. **2020**, 117, 33608-33618	6
346	Clearance of intracellular tau protein from neuronal cells via VAMP8-induced secretion. **2020**, 295, 17827-17841	7
345	Genetic modifiers of tauopathy in Drosophila. **2003**, 165, 1233-42	197
344	Non-Alzheimer degenerative dementias. **1998**, 11, 417-27	26
343	Recent advances in atypical parkinsonian disorders. **1999**, 12, 441-6	31
342	Co-expression networks reveal the tissue-specific regulation of transcription and splicing.	3
341	Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson□ disease at Chr16q11.2 and on the MAPT H1 allele.	2

340	A deep learning approach to identify new gene targets of a novel therapeutic for human splicing disorders.	0
339	FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau fibers.	2
338	Gene expression imputation provides insight into the genetic architecture of frontotemporal dementia.	0
337	Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer and Pick diseases.	4
336	Highly precise base editing with CC context-specificity using engineered human APOBEC3G-nCas9 fusions.	6
335	Non-Coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases.	2
334	A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid- toxicity.	1
333	Detangling Alzheimer's disease. New insights into the biological bases of the most common cause of dementia are pointing to better diagnostics and possible therapeutics. **2003**, 2003, oa2	6
332	Galantamine in frontotemporal dementia and primary progressive aphasia. **2008**, 25, 178-85	135
331	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. **2003**, 111, 145-51	61
330	Alzheimer disease therapy: Can the amyloid cascade be halted?. **2003**, 111, 11-18	116
329	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. **2003**, 111, 145-151	152
328	The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. **2007**, 117, 648-58	459
327	A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. **2009**, 119, 1382-95	192
326	Thinking laterally about neurodegenerative proteinopathies. **2013**, 123, 1847-55	80
325	Ageing and dementia. **2008**, 1031-1152	5
324	Frontotemporal Dementias. **2016**, 22, 464-89	29
323	Frontal lobe H MR spectroscopy in asymptomatic and symptomatic mutation carriers. **2019**, 93, e758-e765	10

322	Tau interacts with src-family non-receptor tyrosine kinases. **1998**, 111, 3167-3177	309
321	Proteolytic processing and cell biological functions of the amyloid precursor protein. **2000**, 113, 1857-1870	418
320	C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. **2000**, 113, 3737-3745	219
319	Human tau filaments induce microtubule and synapse loss in an in vivo model of neurofibrillary degenerative disease. **2000**, 113, 1373-1387	53
318	The unfolded protein response protects from tau neurotoxicity in vivo. **2010**, 5, e13084	63
317	Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. **2011**, 6, e22850	73
316	Large-scale screen for modifiers of ataxin-3-derived polyglutamine-induced toxicity in Drosophila. **2012**, 7, e47452	27
315	GSK3B and MAPT polymorphisms are associated with grey matter and intracranial volume in healthy individuals. **2013**, 8, e71750	8
314	Interactions between A□and mutated Tau lead to polymorphism and induce aggregation of A□mutated tau oligomeric complexes. **2013**, 8, e73303	39
313	Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction. **2016**, 11, e0153724	8
312	Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. **2016**, 11, e0153852	17
311	DNA methylation in canine brains is related to domestication and dog-breed formation. **2020**, 15, e0240787	7
310	Familial Parkinson's disease based on the single gene defects. **2001**, 47, 53-70	1
309	[Molecular aspects of the pathogenesis and current approaches to pharmacological correction of Alzheimer's disease]. **2015**, 115, 103-114	8
308	Pathogenic Tau Protein Species: Promising Therapeutic Targets for Ocular Neurodegenerative Diseases. **2019**, 14, 491-505	8
307	Review: Alternative Splicing (AS) of Genes As An Approach for Generating Protein Complexity. **2013**, 14, 182-94	65
306	A high-throughput screening assay for determining cellular levels of total tau protein. **2013**, 10, 679-87	20
305	Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy. **2018**, 15, 655-663	11

304	Stressing Out Hsp90 in Neurotoxic Proteinopathies. **2016**, 16, 2829-38	11
303	Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. **2013**, 11, 338-78	313
302	The Role of Mitochondrial Impairment in Alzheimer's Disease Neurodegeneration: The Tau Connection. **2020**, 18, 1076-1091	6
301	Imaging of Neurotransmitter Systems in Dementia. **2016**, 271-296	9
300	Fleshing out the amyloid cascade hypothesis: the molecular biology of Alzheimer's disease. **2000**, 2, 101-10	6
299	Mechanism-based treatments for Alzheimer's disease. **2009**, 11, 159-69	13
298	Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick's disease pathology. **2013**, 26, 95-106	17
297	Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer's Disease. **2018**, 61, 195-208	19
296	Role of tau in Alzheimer's dementia and other neurodegenerative diseases. **2007**, 5, 1-12	3
295	Frontotemporal dementia parkinsonism: Clinical findings in a large Iranian family. **2015**, 4, 37	2
294	Modeling ALS and FTLD proteinopathies in yeast: An efficient approach for studying protein aggregation and toxicity. **2011**, 5, 250-257	11
293	Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention. **2013**, 2013,	25
292	Opposite changes in APP processing and human A□levels in rats carrying either a protective or a pathogenic APP mutation. **2020**, 9,	13
291	Increased Signal Delays and Unaltered Synaptic Input Pattern Recognition in Layer III Neocortical Pyramidal Neurons of the rTg4510 Mouse Model of Tauopathy: A Computer Simulation Study With Passive Membrane. **2021**, 15, 721773	
290	Tau Post-Translational Modifications: Potentiators of Selective Vulnerability in Sporadic Alzheimer's Disease. **2021**, 10,	2
289	Human Tau Isoforms and Proteolysis for Production of Toxic Tau Fragments in Neurodegeneration. **2021**, 15, 702788	1
288	Tau Pathology in Neurodegenerative Diseases. **2022**, 71-97	0
287	Frontotemporal Lobar Dementia Mutant Tau Impairs Axonal Transport through a Protein Phosphatase 1□Dependent Mechanism. **2021**, 41, 9431-9451	0

286	N-Amination Converts Amyloidogenic Tau Peptides into Soluble Antagonists of Cellular Seeding. **2021**, 12, 3928-3938	0
285	MeDUsA: A novel system for automated axon quantification to evaluate neuroaxonal degeneration.	0
284	Systems biology approaches to unravel the molecular and genetic architecture of Alzheimer's disease and related tauopathies. **2021**, 160, 105530	1
283	Distinct Tau Gene Mutations Induce Specific Dysfunctions/Toxic Properties in Tau Proteins Associated With Specific FTDP-17 Phenotypes. **2000**, 87-104	
282	Mutational Analysis of Tau in Chromosome 17-Linked Dementia. **2000**, 19-28	
281	Missense and Splice Site Mutations in Tau Associated with FTDP-17 Multiple Pathogenic Mechanisms. **2000**, 29-51	
280	Mechanism of neuron death in Alzheimer□ disease. **2001**, 201-207	
279	Tau and neurodegenerative disease: genetics and pathogenetic mechanisms. **2001**, 71-79	
278	Rearrangement of microtubule networks by tau bearing missense mutations. **2001**, 113-120	
277	Transgenic mice overexpressing the shortest human tau isoform develop a progressive tauopathy. **2001**, 61-69	
276	Epid??miologie, ??tiologie, physiopathologie, diagnostic et troubles cognitifs de la maladie de Parkinson. **2001**, 9, 1-10	
275	Molecular Genetics and Molecular Biology of Alzheimer□ Disease. **2001**, 1187-1218	
274	Tau mutations altering splicing of tau exon 10 in japanese frontotemporal dementia. **2001**, 81-84	
273	Detangling Alzheimer's disease. **2001**, 2001, oa2	1
272	Production and Analysis of Human Mutant Tau (V337M) Transgenic Mouse. **2002**, 543-548	
271	Etiology, Pathogenesis, and Genetics of Parkinson□ Disease. **2002**, 239-244	
270	Interactions of Beta-Amyloid with the Formation of Neurofibrillary Tangles in Transgenic Mice. **2002**, 139-144	
269	Grundlagen und Klinik von Alzheimer- und anderen neurodegenerativen Demenzen. **2002**, 109-126	

268 Pick's Disease and Frontotemporal Dementia. **2002**, 1-9

267 The Neuropathology of Frontotemporal Lobar Degeneration. **2002**, 523-529

266 Familial Frontotemporal Dementia and Parkinsonism (FTDP-17). **2002**, 517-522 1

265 PARK3, Ubiquitin Hydrolase-L1 and Other PD Loci. **2003**, 315-323

264 tau Genetics in Frontotemporal Lobe Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration. **2003**, 325-340

263 Die Alzheimer-Krankheit: Molekulare Grundlagen und Therapieans□ze. **2004**, 148-179

262 Frontotemporal Dementias: Genotypes and Phenotypes. **2005**, 103-115

261 Genetic Susceptibility and Animal Modeling of PSP. **2005**, 515-527

260 Mechanisms of degeneration in Parkinson□ disease. **2005**, 23-30

259 Functional genomics and pharmacogenetics in Alzheimer□ disease. **2005**, 111-124

258 □and □Synucleins: two parent proteins that display similar anti-apoptotic phenotypes but distinct responses to 6-hydroxydopamine-induced toxicity. **2005**, 103-110

257 Tauopathies. **2005**, 651-680

256 The clinical and pathological spectrum of ALS. **2006**, 31-57 0

255 Neurology and Genomic Medicine. **2007**, 19-28

254 LRRK2-Associated Parkinsonism. **2007**, 45-59

253 Delirium, Dementia, Alcohol Intoxication, and Withdrawal Syndromes. **2007**, 74-88

252 Tau Pathology as a Target in Alzheimer's Therapeutics. **2007**, 223-237

251 Protein Aggregates in Neurodegenerative Disorders. 355

250 Impact of A and Tau on Cognition in Mouse Models of Alzheimer Disease. **2009**, 1-15

249 Alzheimer Disease Related Mechanisms of Neuronal Dysfunction and Degeneration: Studies in Human Cortical Neurons. **2008**, 183-202

248 Tau Transgenic Mouse Models in Therapeutic Development. **2009**, 41-48

247 The Molecular and Genetic Basis of Neurodegenerative Diseases. **2009**, 2039-2068

246 Genetics. **2009**, 51-64

245 AD-FTLD Spectrum: New Understanding of the Neurodegenerative Process from the Study of Risk Genes. **2010**, 235-246

244 Frontotemporal Dementia-Parkinsonism. **2010**, 506-513

243 Animal Models of Frontotemporal Dementia. **2011**, 533-547

242 TAU Models. **2011**, 449-468

241 Drosophila Melanogaster as a Model Organism for Dementia. **2011**, 223-240

240 Pathological Validation of Animal Models of Dementia. **2011**, 99-141

239 The Frontotemporal Dementia Syndromes. **2010**, 348-359

238 Demenz. **2011**, 1240-1319

237 Encyclopedia of Clinical Neuropsychology. **2011**, 2471-2472

236 Introduction to the Tauopathies. 103-109 1

235 Clinical Spectrum of VCP Myopathy, Paget Disease, and fronTotemporal Dementia: Experimental Models and Potential Treatments. 219-229

234 Alzheimer-Demenz und weitere neurodegenerative Erkrankungen. **2012**, 267-279

233 Nicht-Alzheimer-Demenzen. **2012**, 209-222

232 Frontotemporal dementias. **2012**, 344-350

231 Molecular genetics. **2012**, 222-233

230 De la maladie de Pick aux d mences fronto-temporales. **2012**, 196, 431-443

229 Impaired Post-transcriptional Regulation in Alzheimer?s Disease*. **2012**, 39, 703-708

228 An Overview of Dementias. **2012**, 21, 75-84

227 Genetics. **2013**, 317-340

226 Encyclopedia of Psychopharmacology. **2013**, 1-8

225 Emerging Themes on Pulmonary Microvascular Endothelial Cell Microtubules and Microtubule Associated Proteins. **2013**,

224 Frontotemporal Lobar Degeneration: Genetics and Clinical Phenotypes. **2014**, 93-109

223 Movement Disorders in Frontotemporal Dementia. **2014**, 141-153

222 Genes that Modulate Longevity and Senescence. **1999**, 11-21 1

221 Molekulargenetik und Molekularbiologie der Alzheimer-Krankheit. **1999**, 117-165

220 Conformational Disease and RNA Disease Theory in the Context of Neurodegenerative Diseases. **2015**, 3-22

219 Pick Disease: The Evolution of Theory and Knowledge in Neurodegenerative Tauopathies. **2015**, 127-138

218 Fractal Analysis in Neurodegenerative Diseases. **2016**, 233-249 0

217 Demenz. **2016**, 1-89

216 Could Stem Cells Be Used to Treat or Model Alzheimer Disease?. **2016**, 203-225 0

215 Neuropsychological Screening and Advanced Neuropsychological Tests. **2016**, 51-90

214	Frontotemporal Dementia and Parkinsonism. **2017**,	
213	Frontotemporal Dementia. **2017**, 141-175	
212	Phos-tag SDS-PAGE analysis of complicated phosphorylation of a neurodegenerative disease protein tau. **2017**, 61, 49-52	
211	Next Generation Sequencing Data Analysis Evaluation in Patients with Parkinsonism from a Genetically Isolated Population. **2017**, 3, 44	2
210	Identification of TMEM230 mutations in familial Parkinson's disease (response to comments).	
209	Encyclopedia of Clinical Neuropsychology. **2018**, 3405-3407	
208	Prion-Like Propagation in Neurodegenerative Diseases. **2018**, 189-242	
207	Encyclopedia of Clinical Neuropsychology. **2018**, 1-3	
206	Neurodegeneration and the Ordered Assembly of Tau. **2018**, 81-98	
205	Neuropsychologische aspecten van neurodegeneratieve aandoeningen. **2018**, 423-470	
204	Autosomal Dominant Frontotemporal Lobar Degeneration: From Genotype to Phenotype. **2018**, 123-145	
203	Tau local structure shields amyloid motif and controls aggregation propensity.	1
202	Abnormal microtubule dynamics disrupt nucleocytoplasmic transport in tau-mediated frontotemporal dementia.	
201	Nuclear Tau modulates VGluT1 expression: a new function for Tau.	
200	Management of Hsp90-Dependent Protein Folding by Small Molecule Targeting the Aha1 Co-Chaperone.	
199	Amyotrophic Lateral Sclerosis. **2019**, 322-346	1
198	Autophagy in Neurodegenerative Diseases. **2019**, 197-212	
197	Assessment of Behavioral Variant Frontotemporal Dementia. **2019**, 523-542	

196 Loss of tau and Fyn reduces compensatory effects of MAP2 for tau and reveals a Fyn-independent effect of tau on glutamate-induced Ca2+ response. 1

195 La g ̃ tique de la maladie d Alzheimer. **2019**, 19, 83-90 1

194 The RNA encoding the microtubule-associated protein tau has extensive structure that affects its biology.

193 Optical induction of autophagy viaTranscription factor EB(TFEB) reduces pathological tau in neurons.

192 Yeast surface display of full-length human microtubule-associated protein tau.

191 Neurons expressing pathological Tau protein trigger dramatic changes in microglial morphology and dynamics.

190 Genetic contributions to sporadic frontotemporal dementia. **2020**, 71-88

189 Parkinson-Plus Syndromes. **2020**, 161-169

188 Integrated analysis of the aging brain transcriptome and proteome in tauopathy.

187 Genome-wide association study and functional validation implicates JADE1 in tauopathy. **2021**, 1 2

186 Clinical and pathological phenotypes in dementia. **2020**, 147-164

185 A Complex Containing HNRNPA2B1 and N6-methyladenosine Modified Transcripts Mediates Actions of Toxic Tau Oligomers.

184 Selective human tau protein expression in different clock circuits of the Drosophila brain disrupts different aspects of sleep and circadian rhythms.

183 Parkinson disease and related disorders. **2020**, 19-30 1

182 A Complex Containing HNRNPA2B1 and N 6-Methyladenosine Modified Transcripts Mediates Actions of Toxic Tau Oligomers.

181 Frontotemporal dementia. **2020**, 31-51

180 Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. **2021**, 2

179 The Splicing Factor XAB2 interacts with ERCC1-XPF and XPG for RNA-loop processing during mammalian development.

178	Neurodegenerative dementia and Parkinsonism.	
177	Neurodegenerative und verwandte Erkrankungen. **2005**, 143-175	
176	Tau Gene Mutations in FTDP-17 Syndromes. 199-213	
175	Intraneuronal A and Alzheimer's Disease. **2008**, 297-304	
174	Novel Proteins in Synucleinopathies. **2009**, 207-224	
173	Alzheimer disease therapy: can the amyloid cascade be halted?. **2003**, 111, 11-8	42
172	Vascular and Neuronal Effects of VEGF in the Nervous System. **2006**, 245-264	
171	Neurodegenerative Diseases. **2008**, 531-558	
170	Structure, Function, and Regulation of the Microtubule Associated Protein Tau. **2008**, 559-576	
169	Impact of Amyloid on the Tau Pathology in Tau Transgenic Mouse and Tissue Culture Models. **2007**, 198-215	
168	Neurobiologie psychischer Stungen. **2008**, 233-340	
167	Single cell gene expression profiling in Alzheimer's disease. **2006**, 3, 302-318	
166	Neuronal NOX4 knockdown alleviates pathological tau-related alterations in a humanized mouse model of tauopathy.	
165	The association of clinical phenotypes to known AD/FTD genetic risk loci and their inter-relationship. **2020**, 15, e0241552	1
164	Genetic neuropathology of Parkinson's disease. **2008**, 1, 217-31	63
163	Neuropathology of non-Alzheimer degenerative disorders. **2009**, 3, 1-23	63
162	Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration. **2010**, 3, 129-43	16
161	C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. **2012**, 1, 107-18	31

160	Genetic of Alzheimer's Disease: A Narrative Review Article. **2015**, 44, 892-901	9
159	Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17. **2018**, 10, 172-183	2
158	Role of caspases and apoptosis in Parkinson's disease. **2022**, 153-173	
157	Combinatorial model of amyloid and tau reveals synergy between amyloid deposits and tangle formation. **2021**,	1
156	Mitochondria Dysfunction in Frontotemporal Dementia/Amyotrophic Lateral Sclerosis: Lessons From Models.. **2021**, 15, 786076	0
155	The role of pathological tau in synaptic dysfunction in Alzheimer's diseases. **2021**, 10, 45	6
154	Human Induced Pluripotent Stem Cell Models of Frontotemporal Dementia With Tau Pathology. **2021**, 9, 766773	0
153	Tau activates microglia via the PQBP1-cGAS-STING pathway to promote brain inflammation. **2021**, 12, 6565	4
152	Targeted proteolytic products of and synuclein in neurodegeneration. **2021**,	0
151	Systematic characterization of short intronic splicing-regulatory elements in SMN2 pre-mRNA.. **2022**,	0
150	Discovery of novel carboline derivatives as selective AChE inhibitors with GSK-3 inhibitory property for the treatment of Alzheimer's disease.. **2021**, 229, 114095	3
149	Preferential Pro-GDNF Expression is Associated with Glioblastoma Cell Migration.	
148	Aberrant TDP-43 phosphorylation: a key wind gap from TDP-43 to TDP-43 proteinopathy. **2021**, 7, 119-131	
147	Pathological phase transitions in ALS-FTD impair dynamic RNA-protein granules. **2021**,	1
146	Uncovering specificity of endogenous TAU aggregation in a human iPSC-neuron TAU seeding model.. **2022**, 25, 103658	0
145	Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia.. **2022**, 16, 758182	0
144	Initial assessment of the spatial learning, reversal, and sequencing task capabilities of knock- in rats with humanizing mutations in the A coding region of App.	
143	Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective.. **2022**, 5, 27-37	0

142	Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction. **2021**,	1
141	Loss-of-function and gain-of-function studies refute the hypothesis that tau protein is causally involved in the pathogenesis of Huntington's disease.. **2022**,	0
140	Plasma Small Extracellular Vesicles with Complement Alterations in / and Sporadic Frontotemporal Lobar Degeneration.. **2022**, 11,	1
139	Classification of Diseases with Accumulation of Tau Protein.. **2022**,	1
138	Tau mRNA Metabolism in Neurodegenerative Diseases: A Tangle Journey.. **2022**, 10,	0
137	TAPPing into the potential of inducible tau/APP transgenic mice.. **2022**,	
136	Glial profiling of human tauopathy brain demonstrates enrichment of astrocytic transcripts in tau-related frontotemporal degeneration.. **2021**, 112, 55-73	1
135	Suppression of premature transcription termination leads to reduced mRNA isoform diversity and neurodegeneration.. **2022**,	2
134	Aetiology and pathophysiology of neurodegenerative disorders. **2022**, 1-16	
133	Modulation of RNA Splicing by Oligonucleotides: Mechanisms of Action and Therapeutic Implications.. **2022**,	2
132	Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimer's Disease.. **2022**, 14, 805063	
131	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis.. **2022**,	0
130	A human tau seeded neuronal cell model recapitulates molecular responses associated with Alzheimer's disease.. **2022**, 12, 2673	0
129	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.. **2022**,	24
128	A tribute to John Q. Trojanowski (1946-2022), neuropathologist extraordinaire.. **2022**, e13066	0
127	New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia.. **2022**,	2
126	Beyond Genes: Inclusion of Alternative Splicing and Alternative Polyadenylation to Assess the Genetic Architecture of Predisposition to Voluntary Alcohol Consumption in Brain of the HXB/BXH Recombinant Inbred Rat Panel.. **2022**, 13, 821026	
125	The CBI-R detects early behavioural impairment in genetic frontotemporal dementia.	

124	Tau Toxicity in Neurodegeneration.. **2022**, 1	1
123	Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy.. **2022**, 16, 801179	0
122	The Molecular Basis of Spinocerebellar Ataxia Type 7.. **2022**, 16, 818757	0
121	Alzheimer's disease - the journey of a healthy brain into organ failure.. **2022**, 17, 18	3
120	Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review.. **2022**,	2
119	Unbiased proteomic profiling reveals the IP3R modulator AHCYL1/IRBIT as a novel interactor of microtubule-associated protein tau.. **2022**, 101774	0
118	Dissecting the clinical heterogeneity of early-onset Alzheimer's disease.. **2022**,	3
117	Protein interaction network analysis reveals genetic enrichment of immune system genes in frontotemporal dementia.. **2022**, 116, 67-79	0
116	Cannabidiol (CBD) treatment improves spatial memory in 14-month-old female TAU58/2 transgenic mice.. **2022**, 425, 113812	1
115	Dysregulated coordination of MAPT exon 2 and exon 10 splicing underlies different tau pathologies in PSP and AD. **2021**, 143, 225	2
114	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations.. **2021**,	0
113	Identification of HnRNPC as a novel Tau exon 10 splicing factor using RNA antisense purification mass spectrometry.. **2021**, 1-13	0
112	Elevated 4R-tau in astrocytes from asymptomatic carriers of the MAPT 10+16 intronic mutation.. **2021**,	1
111	Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100´years.. **2022**, 1	0
110	Failure of DNA double-strand break repair by tau mediates Alzheimer's disease pathology in vitro.. **2022**, 5, 358	0
109	Tau-induced deficits in nonsense-mediated mRNA decay contribute to neurodegeneration.. **2022**,	0
108	Data_Sheet_1.DOCX. **2020**,	
107	Data_Sheet_1.PDF. **2019**,	

106	Image_1.TIF. **2019**,	
105	Image_2.TIF. **2019**,	
104	Video_1.MP4. **2019**,	
103	Video_2.MP4. **2019**,	
102	Video_3.MP4. **2019**,	
101	Video_4.MP4. **2019**,	
100	Video_5.MP4. **2019**,	
99	Video_6.MP4. **2019**,	
98	Video_7.AVI. **2019**,	
97	Prion-like strain effects in tauopathies.. **2022**, 1	0
96	The tauopathies: Neuroimaging characteristics and emerging experimental therapies.. **2022**,	
95	Tau-Induced Elevation of the Activity-Regulated Cytoskeleton Associated Protein Arc1 Causally Mediates Neurodegeneration in the Adult Drosophila Brain.. **2022**,	0
94	Ultrastructural and biochemical classification of pathogenic tau, □synuclein and TDP-43.. **2022**, 143, 613-640	1
93	Initial assessment of the spatial learning, reversal, and sequencing task capabilities of knock-in rats with humanizing mutations in the A□coding region of App.. **2022**, 17, e0263546	0
92	Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice.. **2022**, 5, 446	
91	Importin-Mediated Pathological Tau Nuclear Translocation Causes Disruption of the Nuclear Lamina, TDP-43 Mislocalization and Cell Death.. **2022**, 15, 888420	0
90	Biological basis and psychiatric symptoms in frontotemporal dementia.. **2022**,	0
89	Molecular mechanisms of amyloid formation in living systems.	3

88	Genetic architecture of primary tauopathies. **2022**,	2
87	A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?. **2022**, 438, 120294	1
86	How network-based approaches can complement gene identification studies in frontotemporal dementia. **2022**,	
85	Structures of tau and □synuclein filaments from brains of patients with neurodegenerative diseases. **2022**, 105362	0
84	Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies. 13,	0
83	Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neurons. **2022**, 29, 918-932.e8	1
82	Behavioral Variant Frontotemporal Dementia. **2022**, 28, 702-725	
81	Quantitative prediction of variant effects on alternative splicing in MAPT using endogenous pre-messenger RNA structure probing. 11,	0
80	Proteomics for comprehensive characterization of extracellular vesicles in neurodegenerative disease. **2022**, 355, 114149	0
79	Recent Updates on the Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.	0
78	Neuronal identity defines □synuclein and tau toxicity.	
77	Differences in Motor Features of C9orf72, MAPT, or GRN Variant Carriers With Familial Frontotemporal Lobar Degeneration. 10.1212/WNL.0000000000200860	0
76	Exome Sequencing of a Portuguese Cohort of Frontotemporal Dementia Patients: Looking Into the ALS-FTD Continuum. 13,	
75	Study of Alzheimer's disease- and Frontotemporal dementia- associated genes in the Cretan Aging Cohort. **2022**,	
74	Complexes of tubulin oligomers and tau form an intervening network cross-bridging microtubules into bundles.	
73	Neuronal nuclear tau and neurodegeneration. **2022**,	0
72	Alternative Splicing in Human Biology and Disease. **2022**, 1-19	
71	Neuropathology and emerging biomarkers in corticobasal syndrome. **2022**, 93, 919-929	1

70	The New Zealand Genetic Frontotemporal Dementia Study (FTDGeNZ): a longitudinal study of pre-symptomatic biomarkers. 1-21	
69	Disruption of nuclear envelope integrity as a possible initiating event in tauopathies. **2022**, 40, 111249	1
68	Atypical Alzheimer disease phenotypes with normal or borderline PET biomarker profiles.	0
67	PTK2 regulates tau-induced neurotoxicity via phosphorylation of p62 at Ser403. 1-10	
66	Differential Gene Expression in Sporadic and Genetic Forms of Alzheimer Disease and Frontotemporal Dementia in Brain Tissue and Lymphoblastoid Cell Lines.	0
65	Molecular imaging biomarkers in familial frontotemporal lobar degeneration: Progress and prospects. 13,	1
64	TMEM106B Acts as a Modifier of Cognitive and Motor Functions in Amyotrophic Lateral Sclerosis. **2022**, 23, 9276	1
63	Frequency and Longitudinal Course of Motor Signs In Genetic Frontotemporal Dementia. 10.1212/WNL.0000000000002	0
62	Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson disease at 16q11.2 and MAPT H1 loci.	0
61	Investigation of the role of prolines 232/233 in RTPPK motif in tau protein aggregation: An in vitro study. **2022**, 219, 1100-1111	0
60	Membrane estrogen receptor ER activation improves tau clearance via autophagy induction in a tauopathy cell model. **2022**, 1795, 148079	1
59	Isoform-specific patterns of tau burden and neuronal degeneration in MAPT-associated frontotemporal lobar degeneration.	1
58	Plasma Small Extracellular Vesicle Cathepsin D Dysregulation in GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration. **2022**, 23, 10693	1
57	Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum.	0
56	Populations of Tau Conformers Drive Prion-like Strain Effects in Alzheimer Disease and Related Dementias. **2022**, 11, 2997	1
55	TauLUM, an in´vivo Drosophila sensor of tau multimerization, identifies neuroprotective interventions in tauopathy. **2022**, 2, 100292	0
54	SMaRT modulation of tau isoforms rescues cognitive and motor impairments in a preclinical model of tauopathy. 10,	0
53	Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders.	8

52	The PINK1 p.Asn521Thr Variant Is Associated with Earlier Disease Onset in GRN/C9orf72 Frontotemporal Lobar Degeneration. **2022**, 23, 12847	0
51	Single-cell RNA-seq reveals alterations in peripheralCX3CR1and nonclassical monocytes in familial tauopathy.	0
50	Deterministic programming of human pluripotent stem cells into microglia facilitates studying their role in health and disease. **2022**, 119,	1
49	Elongator promotes neuritogenesis via regulation of tau stability through acly activity. 10,	0
48	Genetic overlap between cortical brain morphometry and frontotemporal dementia risk.	0
47	Posttranscriptional Regulation of Neurofilament Protein and Tau in Health and Disease. **2022**,	0
46	Phosphorylated Tau in Alzheimer Disease and Other Tauopathies. **2022**, 23, 12841	3
45	Changing perspectives on frontotemporal dementia: A review.	1
44	The central role of tau in Alzheimer disease: From neurofibrillary tangle maturation to the induction of cell death. **2022**, 190, 204-217	2
43	Quantitative live cell imaging of a tauopathy model enables the identification of a polypharmacological drug candidate that restores physiological microtubule regulation.	0
42	SUMO2 Protects Against Tau-induced Synaptic and Cognitive Dysfunction.	0
41	Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales.	0
40	A and Tau Prions Causing Alzheimer Disease. **2023**, 293-337	0
39	TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links?. **2022**, 23, 15755	0
38	Blood MAPT expression and methylation status in Alzheimer's disease. **2022**, 1,	0
37	A differential effect for tau isoforms and mutants in decreasing the stability of Arc.	0
36	Semantic and right temporal variant of FTD: Next generation sequencing genetic analysis on a single-center cohort. 14,	0
35	Identification and functional characterization of novel variants of MAPT and GRN in Chinese patients with frontotemporal dementia. **2022**,	0

34	Neurocognitive patterns across genetic levels in behavioral variant frontotemporal dementia: a multiple single cases study. **2022**, 22,	0
33	Modelling Alzheimer's Disease Using Human Brain Organoids: Current Progress and Challenges. 1-35	0
32	Genotype-phenotype correlation in the spectrum of frontotemporal dementia-parkinsonian syndromes and advanced diagnostic approaches. 1-18	0
31	Altered localization of nucleoporin 98 in primary tauopathies.	0
30	Cross-β helical filaments of Tau and TMEM106B in Gray and White Matter of Multiple System Tauopathy with presenile Dementia.	0
29	A novel human tau knock-in mouse model reveals interaction of Abeta and human tau under progressing cerebral amyloidosis in 5xFAD mice. **2023**, 15,	0
28	Direct evaluation of neuroaxonal degeneration with the causative genes of neurodegenerative diseases in Drosophila using the automated axon quantification system, MeDUsA.	0
27	MAPT genotype-dependent mitochondrial aberration and ROS production trigger dysfunction and death in cortical neurons of patients with hereditary FTLD. **2023**, 59, 102597	0
26	Inhibition and Disassembly of Tau Aggregates by Engineered Graphene Quantum Dots.	0
25	The Contribution of Transgenic Models to the Understanding of Alzheimer's Disease Progression and Therapeutic Development. **2011**, 1-14	0
24	How does precursor RNA structure influence RNA processing and gene expression?.	0
23	Network analysis reveals strain-dependent response to misfolded tau aggregates.	0
22	Protein network analysis links the NSL complex to Parkinson disease and mitochondrial biology.	0
21	Pathogenic tau decreases nuclear tension in cultured neurons. 4,	0
20	Clinical features and biomarkers of semantic variant primary progressive aphasia with MAPT mutation. **2023**, 15,	0
19	Aggregation of Disordered Proteins Associated with Neurodegeneration. **2023**, 24, 3380	1
18	Single-molecule techniques to visualize and to characterize liquid-liquid phase separation and phase transition. **2023**,	0
17	The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies. 1-12	0

16	Botulinum neurotoxin A modulates the axonal release of pathological tau in hippocampal neurons. **2023**, 228, 107110	0
15	Chaperone-mediated autophagy in neurodegenerative diseases: mechanisms and therapy.	0
14	Extended fractional-polynomial generalizations of diffusion and Fisher-KPP equations on directed networks: Modeling neurodegenerative progression.	0
13	Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases. **2023**, 12,	0
12	Moesin is an effector of tau-induced actin overstabilization, cell cycle activation, and neurotoxicity in Alzheimer's disease. **2023**, 26, 106152	0
11	The genetic basis of multiple system atrophy. **2023**, 21,	0
10	Botulinum neurotoxin A modulates the axonal release of pathological tau in hippocampal neurons.	0
9	Genetic overlap between cortical brain morphometry and frontotemporal dementia risk.	0
8	Alzheimer's disease as a synaptopathy: Evidence for dysfunction of synapses during disease progression. 15,	0
7	Friend or foe: role of pathological tau in neuronal death.	0
6	Neuronal identity defines α-synuclein and tau toxicity. **2023**,	0
5	ZCCHC17 modulates neuronal RNA splicing and supports cognitive resilience in Alzheimer's disease.	0
4	Cross-β helical filaments of Tau and TMEM106B in gray and white matter of multiple system tauopathy with presenile dementia. **2023**, 145, 707-710	0
3	Contribution of A-to-I RNA editing, M6A RNA Methylation, and Alternative Splicing to physiological brain aging and neurodegenerative diseases.. **2023**, 111807	0
2	Targeting RNA with Small Molecules. **2023**, 1-33	0
1	Troubles de la mémoire et du comportement chez un homme de 49 ans. **2023**,	0